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Abstract 
 
Obesity has become an epidemic that increases the risk of high blood pressure, 
type 2 diabetes (T2D) and atherosclerosis. One of the consequences of obesity is 
the excessive accumulation of lipids inside numerous tissues including skeletal 
muscle. This lipid oversupply contributes dramatically to accelerate and 
aggravate insulin sensitivity, leading to the development of insulin resistance 
and T2D. One of the suggested metabolic factors involved in the control of body 
weight is adaptive thermogenesis. This mechanism protects from cold exposure 
and regulates energy balance by increasing energy expenditure (EE). Brown 
adipose tissue (BAT) plays a predominant role in adaptive thermogenesis in 
small mammals, by expending excess lipids to produce heat. While human 
newborns require BAT to control their body temperature, its relevance in adults 
has previously been questioned. Recently, it has been shown that humans do 
possess active BAT that can be activated during cold exposure. Furthermore, 
CD34+ brown fat progenitor cells were identified inside human skeletal muscle 
and have a capacity to differentiate into active brown adipocytes in vitro. Our 
understanding of how BAT and skeletal muscle-derived CD34+ cell population 
are regulated in humans is limited. However, recent studies have identified 
microRNAs (miRNAs) as potential molecular mechanisms involved in mouse 
BAT development and function. miRNAs are post-transcriptional regulators 
implicated in tissue development and dysregulation under healthy and diseased 
conditions, respectively. miRNA profiling along with bio-informatics have 
become a tool to identify tissue-enriched therapeutic targets. However, little is 
known about the miRNA regulation of human BAT in comparison to mouse BAT, 
and also skeletal muscle-derived CD34+ progenitor cell differentiation into 
brown adipocytes. Furthermore the effect of cold exposure on skeletal muscle-
derived CD34+ cell population has not been investigated.  
Establishing the molecular mechanisms controlling BAT growth and 
development in humans in comparison to mouse, may help to identify potential 
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therapeutic targets to increase EE and combat obesity. The aims of the first 
study were to establish a mouse BAT enriched-miRNA profile when compared 
to skeletal muscle and white adipose tissue (WAT), and compare it to a human 
BAT miRNA profile. This study identified 35 mouse BAT-enriched miRNAs that 
were predicted to target genes potentially involved in growth and development. 
It also identified 145 miRNAs commonly expressed in mouse and human BAT, 
including 25 mouse BAT-enriched. These 25 miRNAs included miR-20a, 
predicted to target MYF5 and PPARγ, two important gene factors in brown 
adipogenesis, as well as BMP2 and BMPR2, targets involved in white 
adipogenesis. These results suggest a potential role of miR-20a in the control of 
cell fate and therefore require further investigating. For the first time, 69 
miRNAs were identified as expressed in human BAT but absent in mouse BAT, 
and 181 miRNAs were expressed in mouse BAT but not in human. These results 
establish key miRNAs that may influence differences in BAT function between 
these two species. The miRNA profiles established in this study provide a 
defined list of miRNAs to investigate as potential therapeutic targets to control 
BAT development and to increase EE.  
Increasing BAT differentiation from progenitor cells has been proposed as a 
therapeutic strategy to enhance EE. The aims of Study 2 were to establish the 
capacity of human foetal skeletal muscle-derived CD34+/31- progenitor cells, 
when compared to the CD34+/31+ cell population, to differentiate into mature 
brown adipocytes. Additionally, the miRNA and gene profiles of these CD34+ 
progenitor cells following differentiation in mature brown adipocytes was 
established and compared against the BAT-enriched miRNA profiles identified 
in Study 1. These results identified the CD34+/31- cell population as a cell type 
displaying a morphology and gene profile similar to classical brown adipocytes. 
In the differentiated CD34+/31- cell population 48 miRNAs were predicted to 
target 87 genes, potentially involved in tissue growth and development. These 
included 5 miRNAs also expressed in the list of 25 mouse BAT-enriched miRNAs 
expressed in human BAT Study 1; including miR-15a which was predicted to 
target the largest number of genes (16 of 87). These findings further support 
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human skeletal muscle-derived CD34+/CD31- cells as an in vitro model to study 
brown adipocyte differentiation. Establishing the miRNA profile of these 
differentiated cells and comparing them to the miRNA profile of mature BAT 
again identifies miRNA species that may be considered as potential therapeutic 
targets to enhance the development and function of human BAT and skeletal 
muscle-derived CD34+ brown adipocytes. The validation of these miRNA targets 
as regulators of BAT development and metabolic activity of these CD34+ brown 
adipocytes is now required.  
Recent studies have shown that cold exposure can increase BAT activity in 
human adults. The third study aimed to investigate the effect of cold exposure 
on the number of skeletal muscle CD34+ cells inside human adults in vivo, and 
the capacity of CD34+ cells to proliferate and differentiate in vitro. This study 
also identified the miRNA profile and regulation of brown fat gene markers in 
skeletal muscle following cold exposure. It was observed that 2 hours at 16°C 
was not sufficient to increase skeletal muscle CD34+ cell number or CD34 gene 
expression. This may have been due to the inter-individual variability observed 
between the human muscle biopsy samples, as well as the size of the samples 
obtained. Four of the 36 human adult CD34+ cell lines in culture proliferated but 
none fully differentiated into brown adipocytes, possibly a result of the very low 
number of cells collected from the muscle biopsies. Further studies using larger 
samples and media optimisation may increase the possibility of establishing the 
capacity of these human adult CD34+ brown fat progenitor cells to differentiate 
into brown adipocytes. Finally 4 miRNAs were up-regulated, including miR-532-
3p, a miRNA predicted to target UCP3, and highly expressed in mouse and 
human BAT as well as in CD34+ brown adipocytes. This suggests a potential role 
of miR-532-3p in BAT cold-induced thermogenesis and differentiation of brown 
adipocyte precursor cells in skeletal muscle. None of the brown fat markers, 
including PPARγ, ELOVL3, CIDEA, LHX8 and UCP1 were differentially regulated 
following cold exposure.  
For the first time, the miRNA profile of human BAT and skeletal muscle derived-
CD34+ brown fat progenitor cells have been established. The findings of this 
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thesis expand the present knowledge about miRNAs potentially regulating 
human BAT and human brown adipocyte progenitor cell growth and 
differentiation. BAT is known for its major role controlling energy balance and 
thermogenesis in rodents, hibernating animals and human newborns. Its recent 
discovery in human adults has increased the interest of identifying the 
molecular mechanisms regulating BAT development and activity. For these 
reasons, BAT may be of importance in the pursuit of therapeutic strategies to 
increase EE in obese and T2D patients.  
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Chapter I 
Review of the literature 
 
A component of this review of the literature has been published prior to the completion 
of this dissertation; Güller I and Russell AP. Journal of Physiology. 2010, 588(Pt 21): 
4075-4087. MicroRNAs in skeletal muscle: their role and regulation in development, 
disease and function. 
 
I.1. Obesity, type 2 diabetes and adaptive thermogenesis 
Obesity statistics by the World Health Organization in 2008 indicated that more 
than 1.4 billion adults (20 years and older) were overweight (body mass index 
[BMI] ≥25), of which more than 500 million were further categorised as obese 
(BMI≥30). By 2025, these numbers are expected to increase by more than half 
again [1]. In Australia, the total direct cost associated with overweight and 
obesity in 2005 was $21 billion [2]. 
Over the last century, changes in environmental and behavioural factors in 
human lifestyle have resulted in increased energy intake (EI) and decreased 
energy expenditure (EE). To compensate for this disturbed energy balance, the 
body stocks surplus energy in the form of fat droplets in a storing tissue, white 
adipose tissue (WAT). This tissue can be extended ad infinitum and 
physiologically until the body dies mainly from the consequences of this 
“lipotoxicity”. Indeed, there has been an increase in the incidence of obesity and 
secondary life-threatening diseases such as hypertension, atherosclerosis, 
cardiovascular diseases (CVD), cancer, musculoskeletal disorders and type 2 
diabetes (T2D) [3]. More specifically, the link between obesity and T2D is a state 
called insulin resistance (IR) that occurs in skeletal muscle and WAT [4]; hence 
the development of the term “diabesity” [5].  
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Excessive net positive energy gain in the human body has a major impact on 
lipid and glucose metabolism. Insulin, one of the major hormones involved in 
metabolic regulation, is released by the pancreatic β-cells in response to higher 
circulating glucose levels and amino acids [6]. Insulin facilitates glucose uptake, 
increases lipid synthesis and inhibits endogenous glucose production by the 
liver. An increase in body fat mass and particularly body fat distribution are 
important determinants of insulin resistance [7, 8]. Increased adiposity is 
positively correlated with an increase in insulin resistance and more 
specifically, visceral obesity is a risk for T2D [8]. The specific pathogenesis 
leading toward a state of IR remains undetermined [9]. An IR state appears by 
an inappropriate response of skeletal muscle and WAT to insulin. To 
compensate for this impaired insulin response and in order to maintain a 
normoglycemia, the pancreatic β-cells increase their release of insulin into the 
bloodstream, creating a state of hyperinsulinemia. A prolonged 
hyperinsulinemia can eventually lead to pancreatic β-cell failure and impaired 
insulin secretion, reaching a state of glucose intolerance and T2D requiring 
insulin therapy [10]. Similar to obesity, T2D is associated with premature 
morbidity and mortality due to secondary diseases, such as CVD, nephropathy, 
retinopathy and blindness [4, 5]. In Australia, the financial cost associated with 
T2D was estimated at $10.3 billion of which $1.1 billion was a result of obesity 
in 2006 [11].  
Despite public health campaigns to reduce energy intake, obesity is still a 
worldwide epidemic and it is therefore essential now to identify therapeutic 
targets that may enhance energy output. While physical activity alone does not 
appear to be an effective treatment for obesity [12, 13], energy dissipation 
through heat production may be a parallel approach [1]. Energy can be used to 
perform work or/and to produce heat. The latter refers to facultative 
thermogenesis and is needed to maintain body temperature following a specific 
stimuli, i.e. cold. This can be switch on and off within a short period of time [14, 
15]. Shivering thermogenesis is initially induced by muscle groups during an 
acute cold exposure but cannot be pursued over time. After a prolonged period 
in the cold, the body stops shivering but maintains a high metabolic rate mainly 
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via the brown adipose tissue (BAT). BAT is the main site for non-shivering 
adaptive thermogenesis. Understanding the molecular mechanisms underlying 
adaptive thermogenesis may identify new therapeutic targets to reduce obesity 
and insulin resistance [16]. Adaptive thermogenesis occurs in response to 
environmental chronic temperature (cold-induced thermogenesis) and under 
debate, in response to diet (diet-induced thermogenesis) in different tissues, 
such as BAT and skeletal muscle [17-19]. BAT and its role in EE via 
thermogenesis have been extensively studied in rodents when compared to 
human, as it was previously thought human adults were devoid of such tissue. 
However the recent discovery of active BAT in human adults [20-25], has 
increased the interest in this tissue as a potential therapeutic target to enhance 
energy metabolism in obesity [26-28] and assist in obesity-related diseases, 
such as insulin resistance and T2D [29]. 
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I.2. Brown adipose tissue (BAT) 
I.2.1. BAT structure and functions 
In 1551, the Swiss naturalist Konrad Gessner described for the first time BAT, 
while studying quadrupeds, as a tissue that was “neither fat, nor flesh-but 
something in between” [30]. In humans, the first description of BAT was in the 
embryo in 1902. At the time, BAT was known in hibernating animals and named 
as the interscapular or hibernating gland. Hatai compared what he observed in 
human embryos as a tissue similar to the interscapular or hibernating gland 
[31]. Indeed, BAT is mainly situated in the interscapular region in hibernating 
mammals and rodents (Figure 1). 
 
 
Figure 1: Locations of brown adipose tissue in mammals [15]. 
 
Recently, Lidell et al showed the first evidence of classical brown adipocytes in 
the interscapular BAT of newborn humans [32]. 
BAT is functionally and morphologically different from WAT (Figure 2). From a 
functional point of view, WAT is involved in the storage of excess energy and the 
mobilisation of this energy when it is required. In contrast, BAT maintains body 
temperature during prolonged cold-exposure by burning out lipids and glucose 
to produce heat [15]. This occurs via the uncoupling protein 1 (UCP1). 
Morphologically, WAT stores energy as triglycerides (TG) in large and 
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unilocular lipid droplets with a peripheral nucleus and have few mitochondria. 
On the other hand, BAT contains numerous mitochondria as well as small and 
multilocular lipid droplets with a centralised nucleus. Furthermore, BAT cells 
are highly vascularised and innervated by sympathetic nerves [33, 34]. 
 
White adipocyte Brown adipocyte  
Figure 2: Image of white and brown adipocytes.  
From T. L. Lentz, Cell Fine Structure: An Atlas of Drawings of Whole-Cell Structure, W. B. 
Saunders, 1971. 
 
BAT is present in most mammals and is the main organ for cold-induced and 
diet-induced thermogenesis (DIT). In both cases, heat is generated to adapt to 
cold or to dissipate excess energy [17-19]. However, the concept of DIT is 
controversial by some [35]. Whole-body oxygen consumption increases in rats 
fed the cafeteria diet in comparison to control, but not specifically in BAT [36]. 
This indicates that DIT is not due to BAT activity.  
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In metabolic tissues such as skeletal muscle, lipolysis is necessary for releasing 
energy in the form of adenosine tri-phospate (ATP). Lipolysis consists of the 
breakdown of TG into glycerol and free fatty acids (FA). This is followed by the 
transportation and oxidation of FA inside of the cells and as shown in Figure 3, 
can be divided into four steps: (1) FA activation by acyl-CoA synthetase inside of 
the cytoplasm, (2) β-oxidation resulting in the creation of acetyl-CoA in the 
mitochondrial matrix, (3) acetyl-CoA oxidation in the Krebs cycle or 
tricarboxylic acid cycle to release energy (ATP and guanine tri-phosphate - GTP) 
as well as reducing agents such as nicotinamide adenine dinucleotide hydrogen 
(NADH) and flavine adenine dinucleotide di-hydrogen (FADH2), (4) oxidation of 
these reducing agents by the electron transport chain (ETC) coupled to the 
phosphorylation of adenosine di-phophate (ADP), to produce some more ATP 
[37].  
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Figure 3: FA transportation and oxidation in skeletal muscle. 
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Brown adipocytes increase lipolysis, FA transportation and oxidation, partially 
occurring inside its mitochondria containing UCP1 [15]. The latter acts at the 
ETC level causing a reflux of protons that bypass the subunit V; also known as 
ATP synthase (Figure 4). As a result, oxidation of NADH and FADH2 increases, 
while phosphorylation of ADP into ATP is reduced and consequently, energy is 
dissipated as heat [38]. In contrast to skeletal muscle, β-oxidation is uncoupled 
to phosphorylation in BAT mitochondria.  
 
 
Figure 4: The role of UCP1 in uncoupled oxidation and phosphorylation. 
 
This mechanism is the result of a β-adrenergic stimulation. Indeed, 
noradrenaline stimulation acts at different important steps: (i) increases UCP1 
synthesis by acting on the protein kinase A and MAPK pathways [39]; (ii) 
activates lipolysis and releases FA that directly act as main regulators of UCP1 
[40]; (iii) inhibits the degradation pathways of UCP1 via lysosome [41, 42]. The 
actual activation of UCP1 by FA is still debated between three theories resumed 
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in [43]: (i) the flip-flop model, where FA exported by UCP1 carries a proton 
from the intermembrane space back into the inner membrane; (ii) the co-factor 
model, where negatively charged FA support UCP1 by forming a proton-
conducting channel; (iii) the functional competition model, where FA overcome 
the purine inhibition by acting as an allosteric competitor. 
Although little is known about UCP1 activation, its function has been well 
established. BAT has been a topic of scientific investigation due to its unique 
potential in the burning of excess of lipids through UCP1 [44, 45]. Transgenic 
mice without BAT become obese [46] and the ablation of Ucp1 in mice is 
sufficient to induce obesity [47]. Transgenic over-expression of Ucp1 protects 
high fat-fed mice against obesity and insulin resistance [48] and agouti yellow 
mice against genetic obesity and diabetes [49]. While many studies in mice have 
investigated BAT as an anti-obesity target, extrapolating these findings into 
humans, previously considered devoid of BAT, has been difficult. BAT is a vital 
organ in rodents and hibernating animals to control their body temperature and 
consequently their metabolism. However, as humans may no longer depend on 
active BAT to maintain body temperature, due to their development of external 
heating systems and clothing, the importance of BAT for metabolic regulation in 
humans is not known. This raises the question whether molecular observations 
made in mouse BAT are relevant to human BAT. Therefore studies are required 
to establish if the molecular profile of mouse BAT is comparable to human BAT. 
 
I.2.2. BAT origin and variations in mammals 
Initially it was believed that BAT shared a common origin with WAT. However, 
using genetic fate mapping during mouse development, it was discovered that 
cells expressing Engrailed-1 (En-1), a marker of central dermyotome, are 
directed to either dermis, muscle or BAT tissue, between embryonic day 9.5 
(E9.5) of development to E11.5 [50]. These findings were confirmed by 
microarray analysis of mouse brown and white pre-adipocytes [51]. 
Approximately 300 genes were differentially expressed between the two types 
of cells (>2 fold). Interestingly, gene ontology (GO) analysis identified an 
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enrichment of myogenic regulatory factors, previously believed to be skeletal 
muscle specific, including myogenin, myogenic differentiation 1 (MyoD) and 
myogenic factor 5 (Myf5) (Figure 5). These observations were also validated by 
real time-polymerase chain reaction (RT-PCR) [51].  
 
 
Figure 5: Origins of brown adipose tissue during embryogenesis [52].  
 
Furthermore the BAT-enriched transcriptional regulator PRD1-BF-1-RIZ1 
homologous domain protein containing protein-16 (Prdm16) was shown to 
control the switch between BAT and skeletal muscle in mouse primary and 
immortalised cell lines [53, 54]. When Prdm16 was expressed in C2C12 and 
primary myogenic cells, it induced brown adipogenesis by binding to 
peroxisome proliferator-activated receptor gamma (Pparγ), a pan-adipocyte 
specific gene [55]. Knockdown of PRDM16 in brown adipocytes expressing the 
myogenic regulatory factor Myf5, resulted in a loss of the brown adipocyte 
phenotype and enhanced the expression of myogenic genes, such as MyoD, 
myogenin and myosin heavy chain [53]. PRDM16 forms a complex with 
CCAAT/Enhancer binding protein β (C/EBPβ) to induce a complete functional 
brown adipose fate from myoblastic precursors, as well as in skin fibroblasts 
from mouse and humans [56]. 
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I.2.3. BAT in humans 
The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG 
PET) has revealed the presence of active depots of BAT in adult humans [20-25]. 
These depots contain multilocular adipocytes expressing UCP1 messenger RNA 
(mRNA) and protein. The activity of these BAT depots are enhanced by cold-
exposure (Figure 6), positively correlated with resting metabolic rate, decreased 
in obese subjects and elderly, and inversely correlated with the BMI, body fat 
content and visceral adipose tissue (VAT).  
 
 
Figure 6: BAT activity in lean and overweight subjects at thermoneutral and cold exposure 
conditions.  
Adapted from [22]. 
 
An interventional study demonstrated a defective BAT activity in obese subjects 
when compared to lean following cold exposure (Figure 6) [22]. Administration 
of the pharmacological sympathomimetic agent ephedrine (2.5mg/kg orally) 
activates BAT, to a lower degree than cold-exposure, in lean young males but 
not in an obese population [57]. This suggests a causal relationship between an 
active BAT and a healthy metabolic status. However it does not confirm that an 
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impaired BAT activation is a cause or a consequence of the development to 
obesity. 
BAT prevalence as well as BAT activity and volume in middle-aged and elderly 
females are significantly higher than in age-matched males [58, 59]. However, 
adolescent males possess a greater volume of BAT in comparison to females of 
the same age [60]. Studies in children demonstrate a positive correlation 
between greater neck and pelvis musculatures and active BAT, reinforcing the 
idea of a common developmental link between these two tissues. An increase in 
BAT presence and volume is also observed in the final two stages of puberty in 
comparison to pre-puberty, suggesting an impact of the hormonal changes 
occurring during these stages of life as observed in skeletal muscle [60, 61]. 
Seasonal variations and photoperiod influence more BAT activity rather than 
ambient temperature, with an increase of BAT activity during winter months, 
where non-shivering thermogenesis is mainly needed for the body [58]. 
Therefore it is important to consider the metabolic status, age group and sex of 
subjects as well as the time of the year when designing clinical trials looking at 
BAT presence and function in human. However, these early studies should be 
considered with care as some can be retrospective studies where ambient 
temperature, nutritional status and other parameters were not control. 
Furthermore, 18F-FDG PET cannot insure the true volume of BAT since all BAT 
may not be activated. Further studies where all these parameters will be 
controlled should be done to validate these data. 
When comparing the gene expression of human neck fat, the deepest depots are 
the most similar to the classical BAT in mouse with high expression for UCP1, 
zinc finger protein (ZIC1) and LIM homeobox 8 (LHX8) (BAT markers), while the 
subcutaneous neck depots highly express WAT markers (leptin [LEP] and 
Homeobox 9 [HOXC9]) [62]. An in-between group of fat depots expresses 
transmembrane protein 26 (TMEM26), CD137 and a number of other markers for 
the so-called brite/beige tissue (i.e. an inducible BAT from WAT), representing a 
mixed composition of human adipose tissue. Deep depots of human neck fat 
were compared to different mouse fat depots including BAT to profile the 
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expression of genes potentially involved in BAT differentiation and function. 
Human BAT has very similar gene expression patterns to classical mouse BAT 
for UCP1, peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC1α) and type II iodothyronine deiodinase (DIO2). Once differentiated in 
culture and stimulated with cyclic adenosine monophosphate (cAMP), these 
isolated adipocytes had higher expression of UCP1 and PGC1α in comparison to 
control. These results demonstrated their capacity to respond to an adrenergic 
stimulation with expression of thermogenic genes. However expression of 
PRDM16 did not change after stimulation and was not consistently expressed 
either in the deep depots in comparison to the classical mouse BAT. This 
establishes the role of PRDM16 in cell fate rather than in BAT function and 
should not be considered as a BAT marker in human. Oxygen consumption rate 
of the deepest depots in human (closest to the classical BAT) were less than half 
the value of the mouse BAT, highlighting the difference in BAT energy 
expenditure and metabolic relevance between the two species. Therapeutic 
strategies based on increasing UCP1 expression level without enhancing its 
activity are not sufficient to increase EE in BAT. But regardless of the oxidative 
capacity and UCP1 expression of this tissue, research needs to concentrate first 
on what mechanisms regulate BAT development and UCP1 activation in 
humans.  
Although these findings are consistent with the thermogenic role of BAT, most 
of these studies were performed in patients initially scanned for cancer or 
undergoing surgery and as a consequence are not representative of a healthy 
population. Furthermore, using mouse models to study BAT in human needs to 
be carefully evaluated as active human BAT is estimated at ~0.05-0.5% of total 
body mass, in comparison to ~3% in mice. Rodents and hibernating animals 
require BAT to control their metabolism and thermogenesis. As humans have 
adapted to environmental changes via the development of clothing, heating and 
shelter their reliance on BAT for maintaining body temperature and therefore 
increasing energy expenditure may have become redundant. As a consequence 
this questions the mouse model as an appropriate model for studying human 
BAT development and activity. The contribution of human BAT to energy 
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expenditure is estimated to be less than 20kcal/day during mild-cold stress [23, 
63, 64]. Therefore further investigations will need to look at the individual 
variability of UCP1 expression and activation, as well as the regulations of other 
BAT depots and the heterogeneity and plasticity of human adipose tissue, to 
confirm a potential use of BAT in future therapeutic strategies in obesity. 
 
I.3. Tissue plasticity and BAT activity during cold exposure 
I.3.1. Browning of WAT 
In addition to adipose tissue containing white adipocytes and, brown 
adipocytes, a population called brite (for “brown in white”) [65], beige [53] or 
inducible [66] adipocytes, has been identified. This latest population is capable 
of the “browning or britening” of WAT, that is represented by newly formed 
brown adipocytes into WAT, following cold exposure or β-adrenergic 
stimulation [67]. As much as this phenomenon is of great interest in the 
development of anti-obesity therapies, understanding the origins and regulation 
of brite fat has only just begun. Gene expression and lineage tracing 
experiments suggest that brite/beige adipocytes are coming from a different 
MYF5- cell precursor than the common MYF5+ cell lineage shared by brown 
adipocytes and skeletal muscle cells [53, 65, 68, 69]. The gene signature of 
brite/beige adipocytes includes CD137, TMEM26, TBX1 and CITED1 [68, 70]. 
Another hypothesis, based on the phenomenon of conversion or 
transdifferentiation, proposes that white adipocytes go through a 
transformation into brown adipocytes when stimulated by β3-adrenoceptor 
agonist or cold acclimatization [71, 72]. A recent study supports this latest 
hypothesis suggesting an actual bi-directional interconversion of brite/beige 
into white adipocytes using lineage tracing approach and transcriptional 
characterisation [73]. 
 
 15 
I.3.2. Muscle-derived progenitor cells 
Along with the discovery of brite/beige fat depot in WAT, brown fat depots 
were identified in skeletal muscle and attributed as “bruscle” (“for brown in 
muscle”) [74]. Studies have also examined the potential of brown fat progenitor 
cells inside skeletal muscle, based on the common origin of these two tissues. 
Sca1+ progenitor cells (using Sca1+/CD45-/Mac1- cell markers) reside in BAT, 
WAT and skeletal muscle of mice [66]. Sca1+ cells extracted from WAT and 
skeletal muscle differentiate into brown-like adipocytes, when stimulated in 
vitro with bone morphogenetic protein 7 (Bmp7). However, they do not derive 
from the Myf5+ lineage shared by skeletal muscle and classical BAT and are 
likely to be dedicated to an adipogenic fate. Almind et al showed that rodent 
skeletal muscle contains ectopic brown adipocytes expressing Ucp1 [75]. Ucp1 
can be up-regulated in these intermuscular brown adipocytes, in a similar 
manner to classical interscapular BAT, via stimulation with a β-adrenergic 
agonist. Consequent to these findings, the hypothesis that muscle cells and 
brown adipocytes were derived from a common origin became a subject of 
interest. Supporting these findings, mouse primary cell culture studies 
established many genes and microRNAs (miRNAs) commonly expressed 
between skeletal muscle and BAT [51, 76]. miRNAs are major post-
transcriptional regulators that will be discussed in detail further on in this 
literature review. Based on a specific endothelial surface antigen CD34, a 
population of CD34+ cells (CD34+/CD56-/CD146-/CD45-) was extracted from 
foetal human skeletal muscle using fluorescence-activated cell sorting (FACS). 
When grown in vitro in an adipogenic media, these cells displayed the unique 
capacity to differentiate into brown adipocytes. Furthermore, high levels of 
UCP1 expression and uncoupled respiration was observed, suggesting a 
reservoir of brown adipocyte progenitor cells in human skeletal muscle [77]. 
Another cell type was identified based on a similar surface antigen selection 
(CD31 used instead of CD56). These CD34+/CD31-/CD146-/CD45- cells resided 
in the outermost layer of human blood vessels and led to a lineage of 
multipotent progenitor cells in vitro [78]. Russell et al. compared the ratio of 
skeletal muscle CD34/CD31 mRNA in an obese vs lean population [79], as an 
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indirect marker of the amount of CD34 and CD31 positive cells. This ratio was 
significantly reduced in the obese vs lean subjects. Furthermore, CD34/31 
mRNA ratio was negatively correlated with BMI, fasting insulin levels and 
homeostasis model assessment (HOMA) in both lean and obese populations. 
These findings suggest a physiological association between these CD34+ cells 
and metabolic disorders. However, a limitation of this study was that only CD34 
and CD31 mRNA levels were able to be measured and this indirect measure 
cannot be assumed to represent the number of cells expressing CD34. 
Furthermore, in vitro studies are required to confirm the capacity of this more 
specific CD34+/CD31- cell population to differentiate into mature brown 
adipocytes, when compared to the CD34+/CD31+ cell population. Additionally, 
studies using FACS analysis in adult human muscle samples are required to 
determine whether CD34+ cell populations can be activated and their 
proliferation increased. Increasing the number and activation of these skeletal 
muscle-derived brown fat progenitor cells may enhance EE inside skeletal 
muscle to reduce lipid infiltration present in obese populations and restore the 
response to insulin lost in T2D [80]. 
The discovery of BAT and skeletal muscle-derived BAT progenitor cells in adult 
humans has challenged our understanding of metabolism and its dysregulation 
in disease. BAT activity appears to be dependent on season, age and metabolic 
status, highlighting a cause-to-effect relationship between these variables and 
BAT, as well as potential involvement of this tissue in human metabolism. As a 
consequence, BAT-induced adaptive adrenergic thermogenesis becomes a more 
realistic therapeutic strategy against obesity and T2D. 
 
I.3.3. Effect of cold exposure on BAT activity 
In response to cold exposure, mammals adjust their EE to maintain a 
physiological internal temperature to keep their vital organs functioning. One of 
these adjustments is to increase metabolic rate and heat production [81]. 
Thermogenesis is divided into different components, including shivering and 
non-shivering thermogenesis (NST). Shivering thermogenesis occurs in an acute 
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situation of cold-exposure, is generated by muscle groups around vital organs 
and cannot be maintained during a long period of time [15]. NST is enhanced 
during chronic cold exposure and is generated via UCP1 in BAT [82]. The two 
physiological responses occurring during cold exposure are an increase in EE, 
that enhances heat production, and/or in blood perfusion, improving heat 
transport [74]. 
Following 2h cold exposure (19°C), 18F-FDG PET scanning was able to identify 
BAT-positive and BAT-negative subjects from within a group of young healthy 
male volunteers, with comparable anthropometric parameters [83]. After cold 
exposure, EE was significantly increased by 410 ± 293 kcal/day and a positive 
correlation between BAT activity and increased EE was observed. Skin 
temperature near the supraclavicular BAT dropped significantly less in the BAT-
positive group, while no temperature difference was observed between the two 
groups in other body parts. This indicates the potential of BAT thermogenesis to 
influence whole body EE in a healthy young population. Based on the same 
design, but using a larger sample size with a broader age range (162 healthy 
subjects; age- 20-73years), the same research group observed that BAT-
negative, but not BAT-positive, subjects had an increase in adiposity-related 
parameters, such as BMI, body fat content and visceral and subcutaneous fat, 
with age. This age-dependent association between decreased BAT activity and 
gain of body fat suggests a potential protective role of BAT in fat accumulation 
in humans [84]. 
BAT requires the delivery of large amounts of oxygen to the mitochondria to 
produce heat, hence its high vascularisation. Perfusion, the process of blood 
delivery to a tissue (i.e. blood flow), corresponds with oxygen consumption [85] 
and gives an estimation of thermogenesis in BAT. In response to cold 
stimulation BAT, but not WAT, VAT or skeletal muscle, has an increase in 
glucose uptake and perfusion rate [64]. This indicates the specific BAT 
contribution to cold-induced thermogenesis. However in response to insulin 
infusion, the rate of glucose uptake, but not perfusion, increases in WAT, VAT, 
BAT and skeletal muscle. This confirms the insulin-sensitivity of these tissues. 
Additionally these results suggest that insulin may not induce a thermogenic 
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response in BAT. The highest rates of insulin stimulated glucose uptake were 
found in BAT and skeletal muscle, supporting their major contributions in 
insulin related metabolic function [64].  
Cold exposure and insulin-induced rates of glucose uptake in BAT are 
significantly higher in lean when compared to obese subjects [86]. This is also 
accompanied by a lower BAT perfusion rate in obese subjects during cold 
exposure. A five month weight loss program significantly improved whole-body 
insulin sensitivity and tended to increase cold-induced glucose uptake in BAT in 
these obese subjects. These findings were in line with an increase in BAT 
activity after bariatric surgery in morbidly obese subjects [87]. These results 
suggest that BAT activation may be dependent upon metabolic health.  
EE was measured in lean subjects during cold exposure and mitochondrial 
respiration was assessed in muscle biopsies following cold exposure [88]. When 
compared to baseline (22°C), an increased EE and a positive correlation 
between state 4 respiration and EE is observed. This suggests that by uncoupled 
respiration, skeletal muscle has the capacity for adaptive thermogenesis during 
cold exposure. Blocking the β-adrenergic receptor (mostly β2) with propranolol 
decreases EE, while mild-cold exposure increases EE, in healthy lean male 
subjects [89]. However, the increase in cold-induced EE is not affected by the β-
adrenergic inhibition suggesting that compensatory mechanisms may regulate 
cold-induced thermogenesis. BAT contains mainly β3-receptors which are less 
sensitive than β2-receptors to propranolol. Therefore, BAT may compensate for 
the propranolol-induced attenuation in skeletal muscle mitochondrial 
uncoupling during cold-exposure. Findings by Ouellet et al. support this 
possibility as they show an inverse correlation between shivering and BAT 
activity, as well as a significant increase in BAT radio density, indicating a 
decrease in TG content in the fat cells [90]. 
 
NST in BAT has been studied in rodents over many years [91] with little 
attention given to skeletal muscle. Furthermore, the effect of cold exposure on 
the regulation of human skeletal muscle-derived brown fat progenitor cells has 
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not been investigated. Before establishing possible therapies targeting BAT, the 
cellular and molecular factors that regulate differentiation and function of BAT 
and its progenitor cells, need to be elucidated. Targeting cellular bioenergetics 
has been proposed to enhance EE through 4 potential therapeutic approaches: 
1, increasing BAT differentiation from progenitor cells; 2, activating BAT-
mediated thermogenesis; 3, promoting muscle thermogenic function and 4, 
increasing general mitochondrial uncoupling [1].  
 
I.4. MicroRNAs 
I.4.1. Major transcription regulators 
miRNAs are small (a20-30 nucleotides >nt@) noncoding ribonucleic acids (RNA) 
which are highly conserved from plants to mammals (reviewed previously [92, 
93]). Presently, their known functions are to inhibit protein translation or 
enhance messenger RNA degradation [94, 95]. 
The recent identification of miRNAs has opened up a new field of investigation 
aimed at understanding the molecular processes controlling numerous disease 
states [96-99]. Dysregulation of miRNA expression can lead to the development 
of diseases, such as cancer [100] and as a consequence novel therapeutic tools 
are being developed to target these miRNAs [101-103]. Furthermore, 
establishing tissue specific or enriched miRNA and gene expression signatures 
will facilitate the identification of more specific therapeutic targets [104]. 
Therefore, it is important to understand their regulation as well as their 
downstream targets controlling cellular biogenesis, cell-type differentiation and 
fate. To date, 2578 and 1908 mature miRNAs have been discovered in human 
and rodent (mus musculus), respectively, based on the miRBase. 
 20 
 
Figure 7: Biogenesis of miRNAs.  
From [105]. 
 
As described in Figure 7, miRNAs are initially transcribed in the nucleus as long 
primary transcripts up to several kilobases long which are known as primary 
miRNAs (pri-miRNAs) [92]. The ribonuclease (RNase) III endonuclease, 
DROSHA associated to PASHA (also known as DGCR8), cleaves the pri-miRNA 
into a ~60-70 nt intermediate referred to as the miRNA precursor, or pre-
miRNA [106]. Exportin-5 (XPO5) transports the pre-miRNA from the nucleus to 
the cytoplasm [107] where a second RNase III endonuclease, DICER1, cuts the 
pre-miRNA into a ~22 nt miRNA duplex [106]. One strand is degraded while the 
other confers the mature miRNA. The latter is then incorporated into a 
ribonucleoprotein complex known as the RNA-induced silencing complex (RISC) 
[108]. This complex enables the identification and binding to the target mRNA 
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resulting in its degradation or repression of protein translation [92]. The human 
immunodeficiency virus transactivating response RNA-binding protein (TRBP) 
forms part of the RISC complex [109]. Phosphorylation of TRBP by the mitogen-
activated protein kinase ERK, increases the stability of the RISC complex and 
enhances miRNA production [110]. Individual miRNAs do not act alone nor do 
they target only a unique gene. Indeed, miRNAs have multiple gene targets and 
each target may be regulated by multiple miRNAs [111]. Because of this level of 
complexity, the emergence of bio-informatic analyses has become a time-
efficient and powerful tool allowing the prediction of miRNA:mRNA target 
interactions. Indeed, several prediction databases such as TargetScan, TarBase 
and PicTar have been created, basing their specificity on sequence 
characteristics required for miRNA:mRNA target binding [112-114]. Among 
these characteristics, seed sequence match, conservation of the miRNA binding 
sequence, free energy of miRNA:mRNA duplex and multiple binding sites are the 
most used [115]. These various prediction databases actually overlap very little, 
complementing each other’s. As a consequence, miRNA array technologies have 
emerged that allow the identification of miRNA profiling of tissues and/or 
specific conditions. Bio-informatic platforms such as Ingenuity® (Ingenuity® 
Systems, www.ingenuity.com) cross miRNA results with gene array data from 
the same samples based on different characteristics. Combined results can 
highlight signalling pathways essential to a specific tissue development or 
dysregulated in disease, using gene ontology analysis and KEGG pathways 
(Kyoto Encyclopedia of Genes and Genomes). This is a very important tool when 
looking at a novel emerging field such as human BAT development and function. 
 
I.4.2. MicroRNA regulation in obesity and type 2 diabetes 
The involvement of miRNAs in obesity and T2D has recently been reviewed 
with a focus on insulin-related tissues and more particularly pancreas, adipose 
tissue and liver [97, 116-118]. Dysregulation of some miRNAs, including miR-
103, miR-107, miR-143, miR-125, miR-181, miR-375 and miR-802, suggest their 
roles in insulin regulation [119-124]. However, while miRNAs play important 
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roles in the regulation of glucose and lipid metabolisms through the control of 
pancreatic islet cell function, adipocyte proliferation and differentiation and 
cholesterol biosynthesis, their role in skeletal muscle function in obesity and 
T2D is not well established. Furthermore, the recent discovery of BAT and its 
potential contribution to a healthy metabolic status [86, 87] opens up a new 
field of investigation in obesity and T2D. 
Few studies have looked at the consequences of insulin resistance on miRNA 
expression in skeletal muscle [125-129]. miRNA expression profiles, analysed 
and compared from skeletal muscle of Goto-Kakizaki (GK) and control rats, 
revealed the differential expression of 15 miRNAs (4 up- and 11 down-
regulated; fold change ≥1.5) [125]. Three out of the four up-regulated miRNAs 
were paralogs of the miR-29 family. Northern blot analyses confirmed the 
increase in their expression in three insulin-dependent tissues (i.e. skeletal 
muscle, liver and fat) from diabetic GK rats, suggesting an association between 
this miRNA family and insulin sensitivity [125]. A similar study determined the 
regulation of miRNA expression in GK rats but observed slightly different 
results [126]. In this study, nine miRNAs were differentially expressed (2 up- 
and 7 down-regulated; fold change ≥2.0), with only miR-24 and miR-126 down-
regulation confirmed by Northern blot analysis. Disparity in these results may 
have been due to different miRNA extraction methods, probe preparation and 
software used to identify the regulated miRNAs in the microarrays. 
Furthermore, small sample sizes, lack of replication/validation and rigorous 
statistics may also add in to the difference in these results. It should also be 
noted that Huang et al also observed a 3-fold increase in p38 mitogen-activated 
protein kinase (Mapk) protein levels, part of the MAPK pathway [126], involved 
in cell differentiation. p38 Mapk is known to be a direct target of miR-24 [130]. 
miRNA profiling of adipose, liver and muscle tissues was used for three inbred 
rat strains differing in diabetes susceptibility (GK rats compared to 
normoglycaemic genetically related Wistar Kyoto [WKY] rats and Brown 
Norway [BN] genetically distant rats) [129]. Results revealed the presence of 
112 commons miRNAs expressed in the 3 tissues, as well as tissue-specific 
miRNAs when compared to the two others (i.e. myomiR-1, -133 and -206 in 
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skeletal muscle). When comparing the three bred for a linear relationship 
between miRNA levels and strain-specific glycaemic phenotype, miR-10b 
appeared to have a lower expression in GK rats vs WKY and in WKY vs BN. 
These results strongly suggest a role of this miRNA in the skeletal muscle 
dysregulation that occurs in T2D. To observe the impact of insulin on skeletal 
muscle miRNA levels, vastus lateralis muscle biopsies were taken from healthy 
subjects before and after a three hour (hr) euglycemic-hyperinsulinemic clamp 
[128]. miRNA expression profiling showed that 39 miRNAs were down-
regulated by insulin, including the muscle enriched miRNAs (known as 
myomiRs) miR-1, miR-133a and miR-206. Additionally, miR-29a and miR-29c, 
miRNAs enriched in insulin-sensitive tissues were also down-regulated. Insulin 
down-regulates miR-1 and miR-133a, via the activation of sterol regulatory 
element binding protein 1c (SREBP-1c), a key mediator of insulin 
transcriptional action, and its inhibition of MEF2C, in human muscle cells in 
vitro [128]. Furthermore, the expression levels of miR-1 and miR-133a are 
increased in an insulin deficient mouse model induced by streptozotocin 
injection [128]. In human skeletal muscle the basal expression levels of miR-1 
and miR-133a were not different when compared between five healthy control 
and five insulin-resistant type 2 diabetic subjects [128]. However, insulin 
reduced miR-1 and miR-133a expression in the healthy, but not in the T2D 
subjects. This response was also associated with the inability of insulin to 
reduce MEF2C expression in the diabetic patients. Along similar lines, the 
expression levels of miR-1 was not different when compared between ten T2D 
patients, ten impaired glucose tolerance patients (IGT) and ten healthy controls 
[127]. However, this study did observe a decrease in miR-133a and miR-206 in 
the T2D patients when compared with the IGT patients and healthy subjects. Of 
clinical interest was the significant positive correlation between miR-133a and 
fasting glucose levels and 2hr glucose tolerance, when all 30 subjects were 
analysed. While a discrepancy with respect to the regulation of miR-133a 
between these studies is evident, the reason for this is not clear and highlights 
the need for further research in this area. 
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The role of miRNAs in obesity and diabetes has only started to be explored and 
future investigation will unravel their roles in metabolism and EE [131]. Indeed, 
the discovery of active BAT in adult humans enlarges the field of research on the 
possible role of miRNAs in BAT development and function, and then using them 
as therapeutic target in obesity and T2D.  
 
I.4.3. The role of microRNA in skeletal muscle and BAT 
Skeletal muscle is enriched with the myomiRs miR-1, miR-133a, miR-133b, miR-
206, miR-208, miR-208b, miR-486 and miR-499 [132-136]. Several of these 
miRNAs are organized under bicistronic clusters on the same chromosome (i.e. 
miR-1-1/133a-2, miR-1-2/133a-1 and miR-206/133b) and are transcribed 
together [137, 138]. Regulation of these myomiRs is controlled by key myogenic 
regulatory factors (MRF), including myogenic differentiation 1 (MyoD), 
myogenin [139, 140], myocyte enhancer factor 2 (Mef2) [141], serum response 
factor (Srf) [142] and myocardin-related transcription factor-a (Mrtf-a) [134]. 
MyomiRs influence multiple facets of muscle development and function through 
their regulation of key genes controlling myogenesis [139, 142, 143]. miR-1 and 
miR-133a also regulate Srf and Mef2 demonstrating the existence of negative 
feed-back loops [142]. A recent profiling combining miRNA and gene data in 
human myoblasts and human biopsies of skeletal muscle identified 60 miRNAs 
and 6,616 genes regulated during myogenesis [144]. This miRNA and gene 
profiling predicted new targets involved in myogenesis as well as a better 
understanding of their potential roles this process. Aberrant regulation of some 
of these muscle-enriched miRNAs can disrupt intracellular signalling networks 
[134, 145] which may result in pathological conditions [146]. Therefore this 
highlights the relevance of miRNA and gene profiling in cell differentiation and 
tissue development to identify and manipulate potential therapeutic targets. 
Our knowledge of mouse BAT-enriched miRNA is limited and almost non-
existent in humans due to the difficulty in accessing human BAT. Walden et al 
identified several muscle-enriched miRNAs (miR-1, miR-133a and miR-206) in 
both mouse brown pre-adipocytes and in brown mature adipocytes, but not in 
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WAT [76]. Although the levels of these miRNAs were similar in both proliferated 
and differentiated brown adipocytes, their expression levels were ~10-2000-
fold lower in comparison to proliferated and differentiated murine C2C12 
muscle cells. This suggests that these myomiRs might be involved in cell lineage 
specification, rather than brown fat cell development. miR-143 is highly 
expressed in both BAT and WAT during proliferation and differentiation, 
suggesting the role of this miRNA in adipogenesis. The higher expression level 
of miR-143 in white adipocytes, when compared with brown adipocytes, 
especially during differentiation, suggests a functional role in energy storage. 
miR-455, a miRNA highly expressed in skeletal muscle, is also expressed in 
white and brown adipocytes. Overall, miR-455 expression level is enhanced in 
mature adipocytes as compared with pre-adipocytes. But interestingly, mature 
brown adipocytes have a higher miR-455 expression level that positively 
correlates with an enhanced expression level of Ucp1, following treatment with 
noradrenaline (α- and β-adrenergic agonist) and rosiglitazone (PPARγ agonist). 
This suggests a potential role of miR-455 in enhancing a catabolic phenotype 
[76]. A similar study comparing mature BAT, WAT and skeletal muscle tissues in 
mice revealed the presence of 91 miRNAs expressed differentially between the 
three tissues [147]. Bio-informatic analyses were done on miR-193b-365, a 
BAT-enriched miRNA cluster. Interestingly, predicted targets of miR-193b-365 
included Runx1T1, a brown adipogenesis inhibitor. Manipulation of miR-193b 
and/or miR-365 confirmed the role of these miRNAs in repressing myogenesis 
and inducing brown adipogenesis in C2C12 myoblasts as well as in primary 
human myoblasts. Prdm16 up-regulates miR-193-365, partially via Pparα and 
as a consequence, miR-193b contributes to the regulation of brown 
adipogenesis. At present, this is the only miRNA profiling study comparing BAT, 
WAT and skeletal muscle in mice. However the use of oligonucleotide microchip 
technology only allowed for the screening of ~350miRNAs [148] and is not as 
sensitive as quantitative RT-PCR array technology to detect miRNA expression. 
Therefore, future studies will need to validate and expand on these results by 
investigating a broader number of targets and using more sensitive qPCR-array 
methods. Muscle-enriched miR-133 is down-regulated in mouse BAT after cold 
exposure [149]. In mouse adipogenic primary cell culture, miR-133 directly 
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targets and downregulates Prdm16 mRNA. This confirms the central role of 
miR-133 in brown adipogenesis in response to cold exposure. miR-133 also 
controls a switch between a myogenic and an adipogenic fate in skeletal muscle 
satellite cells, reinforcing the common origin between these tissues [150]. Cold 
exposure of mice or knockdown of miR-133 in mouse tibialis anterior muscle 
leads to the induction of brown adipocytes within the muscles fibers. After 
extraction of these muscles and comparison with controls, all the metabolic 
characteristics of classical brown adipocytes were observed, including 
uncoupled respiration and elevated glucose uptake. These data established 
skeletal muscle-derived brown adipocytes as an important niche of active 
brown adipocytes.  
The role of miRNAs in the “browning” of WAT has been investigated. miR-155 
and its target C/EBPβ form a double-negative feedback loop in brown 
adipogenesis in vivo and white fat browning in vitro [151]. In brown adipocytes, 
miR-155 directly targets C/EBPβ, a transcription factor known to form a 
complex with Prdm16 that induces brown adipogenesis [56]. But more 
interestingly, the miR-155 promoter contains a transcription factor-binding site 
for C/EBPβ and as a consequence, is regulated by its own target to control 
brown adipogenesis as well as the browning of white adipocytes. Finally, miR-
196a is able to recruit brown adipocytes in WAT of mice via targeting Homeobox 
8 (Hoxc8), a repressor of C/EBPβ [152].  
In conclusion, miRNAs play a role essential in cell fate, BAT differentiation and 
function. BAT-enriched and conserved miRNAs in mouse and human BAT still 
need to be compared in order to confirm the use of mouse as a model in BAT 
studies. Furthermore, it is important to establish what miRNAs are regulated 
during the development of human skeletal muscle-derived CD34+ cells into 
brown adipocytes in vitro, as well as under cold exposure, in order to 
understand how to manipulate them for therapeutic prospective. 
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I.5. Summary and significance of research 
With the growing prevalence of obesity and T2D, the need for developing new 
therapeutic strategies is required to reduce the social and financial costs that 
these diseases place on society. The discovery of BAT in adult humans and 
skeletal muscle-derived BAT progenitor cells identifies new potential targets for 
therapeutic manipulation. The emergence of the miRNA field provides an 
exciting opportunity to further understand the molecular factors that control 
the development and function of BAT and skeletal muscle-derived BAT 
progenitor cells. While BAT regulation and function is well understood in 
rodents, only little is known about the regulation of human BAT. Therefore this 
thesis will focus on profiling the miRNA species highly enriched in mouse and 
human BAT, as well as in differentiated human skeletal muscle-derived BAT 
progenitor cells. Bio-informatics will be used to identify the BAT-enriched 
miRNAs and their predicted gene targets that potentially regulate human BAT 
and skeletal muscle-derived BAT progenitor cell differentiation, growth and 
function. A cold exposure intervention in humans will be performed to 
determine if skeletal muscle-derived BAT progenitor cell number and BAT-
enriched miRNAs and genes are increased in skeletal muscle. These 
investigations will provide insights into the molecular similarities between 
mouse and human BAT and identify potential miRNAs and gene targets that 
may control human BAT differentiation and growth. 
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I.6. Aims and hypotheses 
The specific aims of this thesis are: 
1. To identify BAT-enriched miRNAs in mouse, by comparing miRNA 
expression in BAT, skeletal muscle tissue and WAT, and predict their 
target genes involved in growth and development. Additionally, this 
mouse BAT-enriched miRNA profile will be compared with human BAT 
miRNA profile to establish the consistently expressed miRNAs between 
the two species. 
2. To establish the enhanced capacity of the human foetal skeletal muscle-
derived CD34+/31- cells to differentiate into mature brown adipocytes in 
vitro, when compared to the CD34+/31+ cell population. Additionally, the 
miRNA and gene profiles of the differentiated-CD34+ cells will be 
established and compared with the human BAT miRNA profile. 
3. To establish if mild cold exposure increases the number of skeletal 
muscle-derived CD34+/31- cells in human adults in vivo. Additionally, the 
capacity of these human adult CD34+/31- cells to proliferate and 
differentiate into mature brown-adipocytes in vitro will be established, 
as well as the effect of cold exposure on skeletal muscle miRNA profile 
and brown fat gene markers. 
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It is hypothesised that: 
1. Mouse BAT will have an enriched set of miRNAs, that are either not 
expressed or lowly expressed in skeletal muscle and WAT, and that are 
predicted to target genes involved in BAT growth and development. 
These miRNAs will be consistently expressed in human BAT. 
2. The human foetal skeletal muscle-derived CD34+/31- cells will have an 
enhanced capacity to differentiate into mature brown adipocytes in vitro, 
when compared to the CD34+/31+ cells. These CD34+/31- cells, when 
differentiated into brown adipocytes, will present a gene and miRNA 
profiles similar to human BAT. 
3. Mild cold exposure will increase the number of CD34+ cells in adult 
human skeletal muscle in vivo. These cells will proliferate and 
differentiate into mature brown adipocytes in vitro and cold exposure 
will increase expression of BAT-enriched miRNAs and brown fat gene 
markers. 
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Chapter II 
Study I: Comparative analysis of microRNA 
expression in BAT, WAT and skeletal muscle. 
 
II.1. Introduction 
Obesity is a world-wide epidemic that negatively affects public health and 
increasing the risk of cardiovascular disorders, certain cancers and T2D [3]. 
Obesity results from an energy imbalance whereby EI exceeds EE. Initial 
strategies to decrease obesity have been orientated towards a reduction in EI, 
unfortunately without success. Consequently new therapeutic strategies are 
aimed at targeting the other side of the balance, EE. In mammals EE is mainly 
controlled by skeletal muscle and brown adipose tissue (BAT), through several 
mechanisms such as basal metabolism, physical activity and adaptive 
thermogenesis [153]. Skeletal muscle uses energy for contraction to enable 
movement and to maintain posture, whereas BAT expends energy to produce 
heat in situations of chronic cold exposure (non-shivering cold-induced 
thermogenesis) or excessive food intake (diet-induced thermogenesis) [17-19]. 
Discovery of active human BAT has renewed interest in the possibility that it 
may regulate metabolism and EE in humans [26-28]. 
Several lines of evidence demonstrate that skeletal muscle and BAT share a 
common lineage. During development in mice between E9.5 to E11.5, cells 
expressing En-1, a marker of central dermyotome, are directed to either dermis, 
muscle or BAT tissue [50]. Additionally, microarray screenings of mouse BAT 
and WAT pre-adipocytes revealed an enriched myogenic transcriptional 
signature in BAT as indicated by the expression of muscle-enriched genes 
including myogenin, MyoD and Myf5 [51]. PRDM16, an abundant protein in BAT, 
was identified as a switch controlling the differentiation between BAT and 
skeletal muscle by forming a transcriptional complex with C/EBPβ [53, 54, 56]. 
Understanding the mechanisms that control BAT differentiation may identify 
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potential therapeutic targets to enhance BAT-controlled metabolism and to 
increase EE. 
miRNAs are short non-coding RNAs that regulate gene expression [94, 95]. 
miRNA screenings have become effective in identifying large scale miRNA 
expression in tissues and diseases. The combination of bio-informatic analyses 
has also enabled a snapshot of potential gene targets and biological functions 
controlled by certain miRNAs. The muscle-enriched miRNAs (myomiRs), 
including miR-1, -133a/b, -206, -208, -208b, -486 and -499, are key regulators 
of myogenesis [132-136]. Interestingly, some of these myomiRs, such as miR-1, -
133a and -206, are also expressed in murine brown pre and mature adipocytes, 
but not in white adipocytes [76], reaffirming the common origin between BAT 
and skeletal muscle. However, it is important to note that although these 
myomiRs were expressed in both developmental stages of BAT, their expression 
levels were ~10-2000-fold lower in comparison to a murine muscle cell line, 
C2C12. At present, only one study has compared the miRNA expression patterns 
between BAT, WAT and skeletal muscle in mouse tissues. Sun et al. observed 91 
differentially expressed miRNAs between BAT, WAT and skeletal muscle [147]. 
However, the oligonucleotide microchip technology used in this study allowed 
for the screening of only ~350 miRNAs and is not as sensitive as quantitative 
RT-PCR array technology to detect miRNA expression [148]. Validation and 
investigation of a broader number of BAT miRNA targets using qPCR-array 
methods will enhance our understanding of the potential factors regulating BAT 
development and function. Presently several miRNAs controlling brown 
adipocyte development and function have been identified, including miR-133, -
155, -193b-365 and miR-196 [147, 149-152]. miR-133 directly targets the 3’-
UTR of Prdm16 [149] and controls the differentiation of satellite cells within 
skeletal muscle toward an adipogenic or myogenic phenotype [150], while the 
cluster miR-193-365 is up-regulated by Prdm16, partially through Pparγ [147]. 
While most of these studies have identified several miRNAs controlling rodent 
brown adipocyte development, it is unknown if these miRNAs are expressed in 
human BAT. 
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BAT plays a critical role in the regulation of energy balance and temperature in 
rodents and newborns. Brown fat deficient mice develop obesity and in the long 
term hyperphagia [46]. Premature infants possess an incompletely developed 
BAT [154] and therefore require an incubator for their survival and 
development [155]. However, BAT is no longer essential to maintain body 
temperature in humans, due to the presence of clothing and heating systems 
and therefore its role in human adult metabolism remains unknown. 
Consequently, the relevance of molecular findings in mouse BAT to human BAT 
can be questioned and further investigations comparing the molecular profile of 
BAT in both species are required. 
Therefore the primary aims of this study were to: 
1. Identify the BAT-enriched miRNAs in mouse by comparing BAT, skeletal 
muscle tissues and WAT, and predict their target genes involved in 
growth, proliferation and development. 
2. Compare the BAT-enriched miRNAs found in mice with those in human 
BAT. 
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II.2. Material and methods 
II.2.1. Tissue collection 
Interscapular BAT, gastrocnemius and visceral WAT from 8 week old male 
C57BL/6J mice were kindly donated by Professor Matthew Watt from Monash 
University, Clayton, Australia.  
BAT from newborn human aged between 10.6+4.3 days were kindly donated by 
Dr. Shingo Kajimura, from UCSF Diabetes Center and Department of Cell and 
Tissue Biology, San Francisco, USA. The samples were surgically removed from 
the subcutaneous supraclavicular/supracervical area, intra-abdominal area or 
retroperitoneal area during post-mortem examination 24hrs after death [70]. 
All tissue samples were snapped frozen in liquid nitrogen and kept at -80°C 
until required for RNA extraction. 
II.2.2. RNA extractions  
Mouse tissues 
Approximately 20 mg of BAT and gastrocnemius and 100 mg of WAT were 
homogenised in 500 μL of Tri-Reagent® Solution (Life Technologies, CA, USA), 
using the MagNA Lyser (Roche, Basel, Switzerland) for 20sec at a speed setting 
of 5500 revolutions per minute (rpm). After transferring the homogenate into a 
fresh tube, RNA extraction was completed according to the manufacturer’s 
protocol. RNA quality was assessed using an Agilent 2100 Bioanalyzer (Agilent 
Technologies, CA, USA). The RNA concentration was assessed using a Nanodrop 
1000 Spectrophotometer (Thermo Fisher Scientific, MA, USA). 
Human tissues 
Approximately 20 mg of BAT were homogenised in 300 μL of the denaturation 
solution from the TōTALLY RNA kit™ (Life Technologies, CA, USA), using the 
MagNA Lyser (Roche, Basel, Switzerland) for 20sec at a speed setting of 
5500rpm. After transferring the homogenate into a fresh tube, RNA extraction 
was completed according to the manufacturer’s protocol. RNA quality was 
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assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA). 
The RNA concentration was assessed using a Nanodrop 1000 
Spectrophotometer (Thermo Fisher Scientific, MA, USA). 
II.2.3. Megaplex reverse transcription and miRNA arrays 
Mouse and human tissues 
Rodent Megaplex™ Primer Pools and TaqMan® Array miRNA Cards A version 
2.0 and B version 3.0 (Life Technologies, CA, USA) were used to reverse 
transcribe and amplify ~750 miRNAs according to the manufacturer’s protocol. 
This was performed on 4 BAT, 4 gastrocnemius and 4 WAT samples. Human 
Megaplex™ Primer Pools and TaqMan® Array miRNA Cards A version 2.1 and B 
version 3.0 (Life Technologies, CA, USA) were used to reverse transcribe and 
amplify ~750 miRNAs according to the manufacturer’s protocol. This was 
performed on human tissues from 5 different individuals. All cards were run on 
the 7900HT Fast Real-Time PCR System machine at Monash Institute of Medical 
Research (MIMR, Clayton, VIC, Australia). Results were analysed using 
ExpressionSuite software v1.0.1 (Life Technologies, CA, USA). Global 
normalisation was used for this study [156]. 
Statistics 
For the mouse samples, miRNAs were considered expressed in a given tissue 
when a minimum of 3 out of the 4 samples analysed had CT values below 32, as 
suggested in the manufacturer’s protocol. miRNAs expressed in 2 tissues only 
were compared using an unpaired t-test following log transformation of their 
expression values. For the miRNAs expressed in the 3 tissues (BAT, 
gastrocnemius and WAT), statistical analysis was performed using STATA data 
analysis and statistical software using a Kruskal–Wallis test. When a significant 
difference was detected a two-sample Wilcoxon-rank sum test was used to 
locate the differences. A p-value of <0.05 was considered as significant for all 
analyses. 
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For the human samples, miRNAs were considered expressed in a given tissue 
when a minimum of 3 samples (out of 5) had CT values below 32, as mentioned 
in the manufacturer’s protocol. 
II.2.4. Bio-informatics 
Bio-informatic analyses were performed on specific lists of miRNAs to 
determine their predicted gene targets. Data were analysed through the use of 
IPA (Ingenuity®Systems, www.ingenuity.com) and more specifically, the 
microRNA Target filter tool. Filters were used to refine the analysis based on 
experimentally observed and high predicted gene targets only in the column 
“confidence”, as well as gene involved in cellular growth, proliferation and 
development pathways only. 
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II.3. Results 
II.3.1. Mouse BAT, WAT and skeletal muscle tissues 
miRNA array analysis on mouse tissues 
To define miRNAs enriched in mouse BAT, comparisons were made between 
BAT gastrocnemius (muscle) and WAT as described in the flowchart (Figure 8).  
 
 
Figure 8: Flow chart of the miRNA array analysis from mouse tissues.  
 
From the 750 miRNAs measured 433 miRNAs were expressed at least in one 
tissue. The Venn diagram represents the tissue distribution of these 433 
miRNAs. Six miRNAs were exclusively expressed in BAT. Nineteen miRNAs 
(circled) were expressed only in BAT and WAT, with 4 of these significantly 
higher in BAT tissue (p<0.05). Three miRNAs were expressed only in BAT and 
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muscle, but none were significantly elevated in BAT. There were 298 miRNAs 
(circled) commonly expressed in the 3 tissues, of which 54 were significantly 
higher in BAT compared to WAT and muscle (p<0.05). When adding all the 
exclusively and highly expressed miRNAs found in BAT, 64 BAT-enriched 
miRNAs were obtained as shown in the heat map below (Figure 9).  
 
 
Figure 9: Heat map of the 64 miRNAs specifically and highly expressed in mouse BAT as 
compared with muscle and WAT. 
1 and 12 represent the lowest and highest values, respectively. White values represent non-
expressed miRNAs. 
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Eleven miRNAs were exclusively expressed in muscle, 67 miRNAs were 
exclusively expressed in WAT, while another 29 of miRNAs were expressed in 
both muscle and WAT only (Appendix 1). A more detailed explanation of this 
analysis can be found in Appendix 2. 
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Bio-informatic analyses on mouse BAT-enriched miRNAs  
To identify miRNAs potentially involved in BAT development a microRNA target 
filter was performed using IPA software (Ingenuity®Systems, 
www.ingenuity.com). The predicted gene targets of the 64 BAT-enriched 
miRNAs potentially involved in cellular growth, proliferation and development 
pathways were identified. 859 genes involved in these pathways were targeted 
by 35 out of the 64 miRNAs (Appendix 3). Table 1 represents these miRNAs as 
well as the number of predicted genes targeted by each miRNA. miR-15a was 
predicted to target the most genes involved in cellular growth, proliferation and 
development pathways. 
 
Table 1: A list of the 35 miRNAs highly expressed in mouse BAT and the number of predicted 
gene targets involved in cellular growth, proliferation and development.  
miRNA ID Number of targeted genes miRNA ID 
Number of 
targeted genes 
miR-15a 184 miR-140 48 
miR-20a 149 miR-150 45 
miR-19a 141 miR-193 39 
miR-30b 139 miR-328 39 
miR-182 135 miR-542-3p 39 
let-7g 133 miR-491 38 
miR-203 112 miR-18a 37 
miR-351 108 miR-455 33 
miR-26b 106 miR-484 11 
miR-25 100 miR-451 10 
miR-320 97 miR-129-3p 9 
miR-107 92 miR-126-3p 6 
miR-374-5p 89 miR-450a-5p 3 
miR-155 82 miR-671-3p 3 
miR-132 75 miR-345-3p 2 
miR-423-5p 58 miR-582-3p 2 
miR-142-3p 55 miR-338-5P 1 
miR-365 49 
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II.3.2. Comparison of miRNA expressed in human and mouse BAT 
To establish if human and mouse BAT express similar BAT-enriched miRNAs, 
miRNA array analysis was performed on 5 human and 4 mouse BAT samples.  
Data were analysed as described in the flowchart (Figure 10).  
 
 
Figure 10: Flow chart of the miRNA array analysis for the comparisons of human and mouse 
BAT.  
 
Of the 750 miRNAs measured 214 miRNAs and 326 miRNAs were expressed in a 
minimum of 3 human BAT samples and 3 mouse BAT samples, respectively. Of 
these miRNAs, 145 were expressed in both human and mouse BAT (Appendix 
4), including 23 miRNAs that had the same name but their sequences differed by 
few nucleotides between the species (i.e. miR-155, miR-193b, miR-455). Thus, 
69 miRNAs were expressed in human BAT but not mouse BAT, while 181 
miRNAs were expressed in mouse BAT but not human BAT.  
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As shown in the flowchart in Figure 11 a comparison was also made between 
the 145 miRNAs common to both human and mouse BAT and with the 35 BAT-
enriched miRNAs identified from the bio-informatic analyses in Table 2. 
 
 
Figure 11: Flow chart of the miRNA analysis for the comparisons between human and mouse 
BAT-enriched miRNAs.  
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Twenty five of the 35 mouse BAT-enriched miRNAs were expressed in human 
BAT (table 2) and predicted to regulate 788 genes involved growth, 
proliferation and development pathways (Appendix 5). Ten miRNAs enriched in 
mouse BAT were not expressed in human BAT. 
 
Table 2: The 25 miRNAs highly expressed in mouse and human BAT and the number of 
predicted gene targets involved in cellular growth, proliferation and development.  
miRNA ID Number of targeted genes miRNA ID 
Number of 
targeted genes 
miR-15a 184 miR-365 49 
miR-20a 149 miR-140 48 
miR-19a 141 miR-150 45 
miR-30b 139 miR-193 39 
let-7g 133 miR-328 39 
miR-203 112 miR-491 38 
miR-26b 106 miR-18a 37 
miR-25 100 miR-455 33 
miR-320 97 miR-484 11 
miR-155 82 miR-451 10 
miR-132 75 miR-126-3p 6 
miR-423-5p 58 miR-338-5P 1 
miR-142-3p 55 
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Figure 12 represents 10 of these 25 BAT-enriched miRNAs commonly expressed 
in human and mouse BAT, with their predicted gene targets described in the 
literature as involved in brown adipogenesis. 
 
 
Figure 12: Selected miRNAs common to human and mouse BAT and their gene targets known 
to be involved in brown adipogenesis.  
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BMP2 and BMP7 are predicted to be targeted by miR-20a,-140 and miR-25, -
30b, respectively. Bone morphogenetic protein receptor 2 (BMPR2) is known to 
be targeted by miR-19a, -20a and miR-25 [157] and predicted to be targeted by 
miR-455. Homeobox C9 (HOXC9) is predicted to be targeted by miR-193, 150 
and -26b. Finally, PPARγ is known to be targeted by miR-20a [158] and MYF5 is 
predicted to be targeted by miR-20a. 
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II.4. Discussion 
The recent discovery of active BAT in human adults [20-25] has opened a new 
field of investigation for the treatment of obesity [26-28]. Therefore, 
understanding the molecular mechanisms, regulating human BAT development 
may identify novel therapeutic strategies to increase energy expenditure. 
miRNAs are important molecular switches that display high levels of tissue 
enrichment and can control cell differentiation and tissue growth and 
development. Few studies have investigated miRNAs in mouse BAT [76, 147, 
149-152], however their expression levels have not been validated in human 
BAT. The present study measured and compared the expression of miRNAs 
highly enriched in mouse and human BAT, as well as predicting their gene 
targets potentially involved in BAT growth and development. Several novel 
observations were made. Firstly, 64 miRNAs were exclusively or highly 
expressed in mouse BAT in comparison to mouse skeletal muscle and WAT. 
Secondly, of these 64 BAT-enriched miRNAs, 35 potentially regulate genes 
involved in cellular growth, proliferation and development. Thirdly, 145 
miRNAs were found to be commonly expressed in human and mouse BAT. 
Finally, 25 of these 145 miRNAs are common with the 35 mouse BAT-enriched 
miRNAs potentially involved in cellular growth, proliferation and development. 
Identifying the molecular mechanisms (i.e. miRNAs) controlling BAT 
development has become a priority to develop therapeutic strategies in the fight 
against obesity. While BAT shares a common origin with skeletal muscle [50, 
51], studies on mouse WAT recently discovered a phenomenon called 
“browning” that consists of the new formation of brown adipocytes in WAT 
after cold exposure or β-adrenergic stimulation [67]. Therefore it was of 
interest to compare these three mouse tissues in order to identify the BAT-
enriched miRNAs. In the present study, qPCR-based miRNA screening of ~750 
miRNAs identified 64 miRNAs exclusively or highly expressed in mouse BAT in 
comparison to skeletal muscle and WAT. Consistent with a similar study [147], 
~22% of the miRNAs commonly expressed between the three tissues were 
significantly higher in BAT. Using a less sensitive technology based on 
oligonucleotide microchip, Sun et al found 20 miRNAs highly expressed in 
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mouse BAT in comparison to skeletal muscle and WAT. Fifteen of these 20 
miRNAs were also listed as BAT-enriched miRNAs in the present study, 
excluding miR-106b, -29a, -30a, -17 and -29b. 
miRNAs regulate various component of cellular networks and maintain cellular 
homeostasis [159]. Therefore it was of interest to select BAT-enriched miRNAs 
that were predicted to target genes involved specifically in cellular growth, 
proliferation and development, in order to identify potential therapeutic targets 
controlling BAT development. Thirty-five of the 64 miRNAs were predicted to 
target 859 genes involved in growth and development pathways. When 
comparing mouse primary pre-adipocytes with differentiated mature brown 
adipocytes in vitro, 16 and 12 miRNAs were up- and down-regulated 
respectively, using global deep sequencing [151]. Of these, miR-142-3p, -19a, -
30c and -30e were also up-regulated in the present list of 35 BAT-enriched 
miRNAs targeting genes involved in growth and differentiation. This highlights 
the potential role of these miRNAs during BAT development in mice. However, 
miR- 155 and -328, miRNAs down-regulated in mature brown adipocytes when 
compared to pre-adipocytes, were identified in the list of 35 BAT-enriched 
miRNAs. These discrepancies may be indicative of the differences between 
mature brown adipocytes in vitro and mature BAT. 
Most studies have used mice as a model to study BAT development and 
function, due to the previously held view that humans did not possess BAT as 
well as the present difficulties in accessing human BAT. As such, no study has 
looked at the miRNA profile of human BAT. It was therefore of interest to 
compare miRNA profiles of mouse and human BAT to establish the potential 
molecular similarities and differences between the two species. These 
comparisons also provide a snapshot of the potential to translate these 
molecular observations in mice to human. For the first time, a miRNA screening 
revealed the presence of 214 miRNAs expressed in human BAT including 145 
commonly expressed in mouse BAT. This screening also showed that 69 
miRNAs expressed in human BAT were not expressed in mouse BAT and 
therefore were not taken into consideration when comparisons were made with 
the mouse model. Further investigations of these 69 miRNAs will be required to 
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identify their potential unique role in human BAT. In contrast, 181 miRNAs in 
mouse BAT were not present in human BAT and as a consequence these 
findings indicate that translating results from mouse to human BAT should be 
considered carefully.  
Of the 145 miRNAs common to both mouse and human BAT, 25 were identified 
in the list of 35 mouse BAT-enriched miRNAs potentially targeting genes 
involved in cellular growth, proliferation and development. 788 genes involved 
in these pathways were predicted to be targeted by these 25 miRNAs. In this 
present study, miR-20a was the only miRNA predicted to target MYF5 and 
PPARγ (a previously experimentally observed target [158]), two important 
factors directing cell fate toward a brown fat phenotype [53]. In contrast, miR-
20a is predicted to also target BMP2 and BMPR2, a growth factor and receptor 
increased in white fat differentiation [160]. These findings suggest that miR-20a 
may have the capacity to control cell fate toward a brown or white fat 
phenotype. Furthermore, miR-20a was the second miRNA targeting the most 
genes (149) involved in growth and development, highlighting its importance in 
these pathways. To date, miR-20a has not been studied in relation to BAT 
growth and development and therefore requires further investigations. miR-
155, highly expressed in brown pre- adipocytes when compared to 
differentiated mature brown adipocytes inhibits brown adipogenesis by 
targeting C/EBPβ [151], a transcription factor forming a complex with PRDM16 
during brown adipogenesis [56]. In contrast to these observations, miR-155 was 
identified as a highly enriched miRNA in human BAT and mouse BAT. This 
observation suggests that human BAT may be comprised of a mixed 
composition of cells with different stages of cell maturation. However, the 
presence of miR-20a, -25 and -30b, predicted to inhibit expression of genes 
involved in brown fat development, may prevent the development of a 
“classical” brown fat phenotype in human BAT. Previous studies developing a 
gene signature in human BAT identified a signature that closely resembled a 
brite/beige phenotype [68, 70], while others established a mixed composition 
from WAT to the classical BAT depending on the depth of the BAT from the most 
superficial to the deepest, respectively [62]. Of these 25 miRNAs, the miR-193b-
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365 cluster and miR-455 have been shown to regulate brown fat development 
supporting our findings. Inhibition of miR-193a/b and/or -365 in mouse 
primary brown pre-adipocytes impairs brown adipogenesis [147]. miR-455 
expression level is increased in mature murine brown adipocytes and positively 
correlates with UCP1 levels suggesting a potential metabolic role in brown 
adipocytes [76]. miR-19a, -140, -150 and -26b are predicted to target white fat-
related genes (BMP2 or BMPR2 or HOXC9) [68, 160] and therefore may have a 
role in selecting cell fate toward brown adipogenesis.  
In summary, this study has identified 64 miRNAs enriched in mouse BAT when 
compared to skeletal muscle and WAT, including 35 miRNAs specifically 
involved in cellular growth, proliferation and development. Furthermore, for 
the first time a comparison between human and mouse BAT revealed the 
presence of 145 commonly expressed miRNAs in BAT from both species. These 
included 25 miRNAs specifically expressed in mouse BAT and involved in 
cellular growth, proliferation and development. The discovery of specific BAT-
enriched miRNAs, highly-enriched in both mouse and human BAT such as miR-
20a may help to identify BAT phenotype and improve our understanding of its 
molecular regulation in humans. These novel findings provide guidelines for 
further studies using mouse model to understand human BAT development, as 
well as examining the role of specific miRs in order to develop therapeutic 
targets to manipulate BAT differentiation and function. 
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Chapter III 
Study II: Establishing the microRNA profile of 
human skeletal muscle-derived CD34+ cells 
following their differentiation into brown 
adipocytes. 
 
III.1. Introduction 
BAT and skeletal muscle share a common cell lineage that positively expresses 
the MYF5 gene [50, 53]. Their fate towards an adipogenic or a myogenic 
phenotype is controlled by PRDM16, a zinc-finger transcription factor that acts 
as a switch during their development [53, 54]. PRDM16 binds to C/EBPβ 
forming a transcriptional complex, sufficient to induce a complete brown fat 
program from myoblastic precursors [56]. 
The increasing interest in regenerative therapies has assisted with the 
identification of multi-lineage stem cells within different organs, including 
muscle-derived stem cells (MDSCs) [161]. Subsets of MDSCs exclusively 
expressing endothelial surface markers such as CD34, or co-expressing 
endothelial and myogenic markers such as CD56 have been identified [162]. 
These MDSCs, sorted from human skeletal muscle, did not lose their ability to 
regenerate when cultured for several weeks. When injected into injured skeletal 
muscle of immunodeficient mice, these cells promoted muscle fibre 
regeneration [162]. Using FACS, Crisan et al. discovered a dormant cell 
population within foetal skeletal muscle that were positive for the cell surface 
marker CD34, negative for CD56, CD146, CD45 and hence referred to as CD34+ 
cells [77]. These CD34+ cells were able to differentiate in vitro into brown 
adipocytes and were characterized by the expression of UCP1 and uncoupled 
respiration. A similar population of cells defined by CD34+/CD31-/CD146-
/CD45- in the outermost layer of human adult blood vessels was shown to give 
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rise to a lineage of multipotent progenitor cells [78]. Based on this result, the 
ratio of CD34/31 mRNA was used as an indirect measure of the amount of CD34 
and CD31 positive cells in muscle of lean and obese subjects [163]. A significant 
decrease in the ratio of CD34/31 mRNA was observed in obese skeletal muscle 
when compared to the lean control muscle. This ratio was negatively correlated 
with BMI, fasting insulin levels and HOMA for lean and obese subjects, 
suggesting a physiological interconnection between the CD34+ cell population 
and metabolic disorders. However the enhanced capacity of the CD34+/CD31- 
cell population to differentiate into brown adipocytes when compared to the 
CD34+/CD31+ cell population has not been investigated. These skeletal muscle-
derived brown adipocyte cells may therefore be potential therapeutic targets to 
enhance EE, however the molecular factors regulating their differentiation are 
not known. 
Skeletal muscle-enriched miRNAs are expressed in mouse BAT (i.e. miR-1, -
133a, -206 and -455), further confirming the common origin of these tissues 
[76]. Several miRNAs are suggested to regulate BAT development, including 
miR-133, miR-155, miR-193b-365 and miR-196a [147, 150-152]. Inhibition of 
miR-133 increases Prdm16 [149] and can direct mouse skeletal muscle satellite 
cells towards a brown adipogenic phenotype [150]. Interestingly, Prdm16 up-
regulates the miR-193b-365 cluster, partially through Pparγ, and promotes 
brown adipogenesis by targeting Runx1T1, an adipogenic inhibitor [147]. miR-
155 directly down-regulates C/EBPβ in brown and white pre-adipocytes and 
consequently inhibits brown or brite/beige adipogenesis [151]. In contrast, 
miR-196a targets Hoxc8, a repressor of C/ EBPβ and can induce browning in 
WAT [152]. Presently the miRNA profile of CD34+ cells following their 
differentiation into brown adipocytes has not been established. Also 
comparative miRNA expression profiling between CD34+ differentiated brown 
adipocytes and mature BAT has not been performed. Study I identified 64 
miRNAs enriched in mouse BAT of which, 35 miRNAs were predicted to target 
genes involved in growth and developmental pathways. Additionally, 25 of 
these 35 BAT-enriched miRNAs were also highly expressed in human BAT 
suggesting that they may be important for the development of BAT. Establishing 
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the miRNA and gene target profiles of CD34+ cells following their differentiation 
into brown adipocytes, as well as establishing how close the miRNA profile of 
these cells represent mature BAT, may identify important miRNAs potentially 
involved in human BAT development.  
Therefore the aims of this study were to: 
1. Establish if the human foetal CD34+/31- cells have an enhanced capacity 
to differentiate into brown adipocytes when compared to CD34+/31+ 
cells. 
2. Establish the miRNA and gene profiles of CD34+ brown adipocytes when 
compared to CD34+ proliferating cells. 
3. Compare the miRNA profiles of CD34+ brown adipocytes and human 
BAT. 
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III.2. Material and methods 
III.2.1. Cell collection 
CD31+ cells (CD34+, CD31+, CD56-, CD146-, CD45-) and CD34+ cells (CD34+, 
CD31-, CD56-, CD146-, CD45-) were kindly donated by Dr. Mihaela Crisan at the 
Erasmus Stem Cell Institute for Regenerative Medicine, Netherlands. These cell 
types were extracted from human foetal skeletal muscle and sorted using FACS 
techniques following the protocol published previously [77]. For each cell types, 
two cell lines were created (#310- CD31+ cells, #314- CD31+ cells, #310- CD34+ 
cells and #314- CD34+ cells). 
III.2.2. Cell culture 
Cells were seeded at 1.3x104 cells per cm2 in 0.2% gelatin-coated 50mm dishes 
(n=3) and cultured until confluence (4–6 days) at 37°C in EGM™-2 Bulletkit™ 
medium (Lonza, MD, USA). Differentiation (8–12 days) was induced by treating 
cells with an adipogenic medium consisting of Dulbecco’s Modified Eagle’s 
Medium (DMEM)-Ham’s F-12 medium (Life Technologies, CA, USA) containing 
0.86 μM insulin, 10 μg/ml transferrin, 0.2 nM triiodo-L-thyronine (Sigma-
Aldrich, MO, USA), 1 μM rosiglitazone (Cayman Chemical, MI, USA), 100 μM 3-
isobutyl-1-methylxanthine, 1 μM dexamethasone, isoproterenol (Sigma-Aldrich, 
MO, USA) and 1% penicillin/streptomycin (Life Technologies, CA, USA). Media 
was changed every 2-3days. Images were captured using an Olympus IX51 
microscope and AnalySIS getIT software (Olympus Corporation, Tokyo, Japan). 
Cells were washed twice with 1X phosphate buffered saline (PBS) (Life 
Technologies, CA, USA) prior to RNA extraction. 
III.2.3. Tissue collection 
Human BAT were collected as described in Chapter II.2.1. 
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III.2.4. RNA extraction 
Cell culture 
Total RNA was extracted from the CD31+ and CD34+ cells before and after their 
differentiation into brown adipocytes using 1mL of Tri-Reagent® Solution (Life 
Technologies, CA, USA) according to the manufacturer’s protocol. RNA quality 
was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, CA, 
USA). The RNA concentration was assessed using a Nanodrop 1000 
Spectrophotometer (Thermo Fisher Scientific, MA, USA). 
Human tissues 
This procedure has been described in Chapter II.2.2. 
III.2.5. Reverse transcription and RT-PCR for gene expression on cell 
culture experiment 
CD31+ and CD34+ cells 
One μg of total RNA was DNase treated for 15 minutes (mins) at room 
temperature using Sigma DNase treatment kit (Sigma-Aldrich, MO, USA). The 
reaction was inactivated for 10mins at 70°C. First strand cDNA was generated 
using the High Capacity RNA-to-cDNA kit (Life Technologies, CA, USA) according 
to the manufacturer’s instructions. All synthesised cDNA samples were RNase 
treated for 20mins at 37°C using RNase H (Sigma-Aldrich, MO, USA). The cDNA 
was diluted 1:20 in nuclease free water and stored at -20°C until further 
analyses. Gene markers were used to confirm the differentiation of the cells into 
a brown adipogenic phenotype. These markers were MYF5, PPARγ, UCP1, 
elongation of very long chain fatty acid 3 (ELOVL3), cell death-inducing DNA 
fragmentation factor α subunit like effector a (CIDEA) and LHX8. Specific primer 
pairs (Table 3) were designed using Primer Express 3.0 software (Life 
Technologies, CA, USA) and sequence specificity confirmed using Basic Local 
Alignment Search Tool (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi). Primers 
were purchased from Geneworks (Geneworks, SA, Australia).  
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Real-Time PCR was performed using a Stratagene Mx3000P QPCR System and 
the MxPro QPCR software (Stratagene, CA, USA). Cycling conditions for the real 
time PCR consisted of one denaturing cycle at 95°C for 10mins, followed by 40 
to 45 cycles of denaturing at 95°C for 30 sec and annealing at 55 to 60°C for 20 
sec and elongation at 72°C for 60 sec A dissociation curve was generated to 
show that only one product was amplified during the PCR. Each 20 μL reaction 
contained Power SYBR Green QPCR master mix (Life Technologies, CA, USA), 25 
ng of cDNA, and the forward and reverse primers for the gene of interest. All 
samples were measured in triplicate. Data were normalised to cDNA input as 
quantified using Oligreen (Life Technologies, CA, USA) according to 
manufacturer’s instructions. 
 
Table 3: Sequences of human primers used for RT-PCR analyses.  
Gene 
GenBank 
Accession No. 
Forward primer (5’ – 3’) Reverse primer (5’ – 3’) 
MYF5 NM_005593.1 TTCTACGACGGCTCCTGCA CCACTCGCGGCACAAACT 
PPARγ NM_005037 AGGCGAGGGCGATCTTG CCATCATTAAGGAATTCATGTCAT 
UCP1 NM_021833.4 TGCCCAACTGTGCAATGAA TCGCAAGAAGGAAGGTACCAA 
ELOVL3 NM_152310.1 TTCGAGGAGTATTGGGCA GAAGATTGCAAGGCAGAAGG 
CIDEA NM_001279 TGAACCCCAAGGACTTCAT AGAAACTGTCCCGTCACCTG 
LHX8 NM_001001933.1 ACAACCCAGATGCACAGAC TGGCGTGCTCTACAATTCTG 
 
III.2.6. Gene arrays 
CD34+ cells 
Two cell lines were used for this experiment: #310-CD34+ and #314-CD34+. 
gene arrays were done on CD34+ proliferating cells (n=3) and CD34+ brown 
adipocytes (n=3) for both cell lines. Cell culture and RNA extraction were 
performed as described in Chapters III.2.2. and III.2.4., respectively. 
3μg of total RNA were sent to the Australian Genome Research Facility (AGRF, 
Parkville, VIC, Australia) to be analysed using Illumina gene chip technology. 
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III.2.7. Megaplex reverse transcription and miRNA arrays 
CD34+ cells 
Samples used were the same samples as for the gene arrays. Megaplex reverse 
transcription and miRNA arrays were performed as described in Chapter II.2.3. 
using primers and arrays for human samples. 
Results were analysed using the RQ Manager 1.2 (Life Technologies, CA, USA). 
Normalisation was done against small RNA U6 for both cards A and B and 
threshold was manually set to 0.2, as suggested in the manufacturer’s protocol. 
Human tissues 
Microarrays were carried out on 5 human tissues and analysed as described in 
Chapter II.2.3. 
III.2.8. Statistics 
CD31+ and CD34+ cells RT-PCR 
A two-way ANOVA was performed using GraphPad Prism 6. The level of 
significance was set as p<0.05. When a significance difference was detected, 
Tukey’s multiple comparison test was undertake to identify the differences. 
CD34+ cell gene array 
Analysis was completed by comparing #310-CD34+ proliferating cells vs #310-
CD34+ brown adipocytes and same for #314. Comparisons were also carried out 
between #310-CD34+ proliferating cells vs #314-CD34+ proliferating cells as 
well as #310-CD34+ brown adipocytes vs #314-CD34+ brown adipocytes. 
ANOVA analysis of normalized probe intensities values was performed in 
Partek® Genomic SuiteTM software, version 6.6 build 6.12.0420 (Copyright © 
2003-20012 Partek Inc., St. Louis, MO, USA). ANOVA was used to calculate 
significance of variation in normalized expression values between sample 
groups and fold change of gene expression was calculated as mean ratio. Probes 
with an unadjusted p-value of 0.05 or less (no False Discovery Rate correction 
was applied) and an absolute fold change of 1.5 or more were defined as 
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differentially expressed. Only the genes expressed differentially between 
proliferation and differentiation in both cells lines were analysed.  
CD34+ cell miRNA array 
Cell lines were first analysed separately. miRNAs were considered expressed in 
a cell line when a minimum of 2 replicates in at least one developmental stage 
(proliferating or differentiated cells) had CT values below 32, as suggested by 
the manufacturer’s protocol. Once the dataset of both cell lines were pooled 
together, only the miRNAs commonly expressed within the same development 
stage between the two cell lines were included in the statistical analysis. 
Therefore four lists of miRNAs (#310-CD34+ proliferating cells and #310-CD34+ 
brown adipocytes and #314-CD34+ proliferating cells and #314-CD34+ brown 
adipocytes) were obtained. Statistical analysis was performed by STATA data 
analysis and statistical software using a two-sample Wilcoxon-rank sum (Mann-
Whitney U) test. Analysis compared miRNA expression levels between 
proliferating and differentiated cells within a same cell line. A p-value of <0.05 
was considered as significant. miRNAs found significantly different in both cell 
lines were kept for further analyses. 
III.2.9. Bio-informatics 
Bio-informatic analyses were performed on specific list of miRNAs and on the 
gene array data. Datasets were analysed through the use of IPA 
(Ingenuity®Systems, www.ingenuity.com) and more specifically, the microRNA 
Target filter tool and Core analyses (Function analysis and Canonical Pathways 
analysis). For the Core analysis, a p-value calculation was based on the Fisher’s 
Exact test with a Benjamini-Hochberg methods of multiple testing correction on 
this p-value that allowed to calculate the false discovery rate vs noise into our 
dataset. A p-value of <0.05 was considered as significant for all analyses. For the 
microRNA Target filter tool, filters were used to refine the analysis based on 
experimentally observed and high predicted gene targets, as well as genes 
involved in cellular growth, proliferation and development pathways only. 
Expression pairing between miRNAs and mRNAs selected only these following 
combinations: miRNA up/mRNA down and miRNA down/mRNA up. 
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III.3. Results 
III.3.1. Characterisation of the skeletal muscle-derived CD34+ cells 
Cell culture 
When the CD31+ and CD34+ cells reached 95% confluence, media was changed 
to differentiation. After 2-3 days, CD34+ cells started to become more circular 
while CD31+ cells formed a heterogeneous shape with circular and longitudinal 
cells. CD31+ cells had a high rate of mortality, hence the disparity of the cells in 
Figure 13. Following 4-6 days of differentiation, both cell types started to 
accumulate small lipid droplets. By 10-12 days of differentiation, the CD34+ cells 
appeared fully differentiated into brown adipocytes. At the same stage, the 
CD31+ cells had accumulated small lipid droplets but this occurred in only 30% 
of cells. 
 
 
Figure 13: Photos of CD31+ cells and CD34+ cells during proliferation at day 5 and differentiated 
at day 12 (x100).  
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RT-PCR 
Brown fat markers were measured in the proliferating CD31+ and CD34+ cells 
and fully differentiated the CD31+ and CD34+ cells (Figure 14). MYF5, a 
myogenic regulator expressed in brown precursor cells [51], was expressed in 
both cell lines during proliferation, with a decreased expression following 
differentiation. Overall a higher expression was observed in the CD31+ cells 
compared to CD34+ cells. PPARγ, a nuclear receptor involved in brown 
adipogenesis [53], was significantly increased during differentiation in the 
CD34+ cells only (p<0.001). UCP1, ELOVL3, CIDEA and LHX8 expression was 
measured to confirm the brown fat phenotype in the differentiated cells [45, 51, 
164, 165]. Expression of UCP1 and ELOVL3 was significantly higher in the 
differentiated when compared to the proliferating CD34+ cells (p<0.01 and 
p<0.0001, respectively) and also the differentiated CD31+ cells (p<0.01 and 
p<0.001, respectively). CIDEA expression was significantly increased in the 
differentiated CD34+ cells when compared to the proliferating CD34+ cells 
(p<0.05). LHX8 expression was higher in the proliferating CD34+ cells and 
further increased following differentiation (p<0.01).  
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Figure 14: Expression of brown fat markers in CD31+ (black bar) and CD34+ (grey bar) cells 
during proliferation and differentiation.  
(A) MYF5, (B) PPARγ, (C) UCP1, (D) ELOVL3, (E) CIDEA and (F) LHX8 gene expression. N=6 per 
group for each cell line. Values represent the mean ± standard error of the mean (SEM). 
Significant differences between proliferation and differentiation within a cell line; *, p<0.05, **, 
p<0.01, ***, p<0.001, ****, p<0.0001. Significance differences between CD31+ and CD34+ cells in 
differentiation; ##, p<0.01, ###, p<0.001. 
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Based on the morphological results shown in Figure 13 and the gene data above, 
the CD34+ cells were selected for further investigation. Following 
differentiation, the CD34+ cells will be referred to as CD34+ brown adipocytes 
throughout the remainder of the thesis.  
III.3.2. Gene and miRNA profiles during differentiation skeletal 
muscle-derived CD34+ cells 
Gene array analysis and bio-informatics 
To establish the genes regulated during differentiation of the CD34+ brown 
adipocytes, gene arrays were performed on two separate cell lines (#310 and 
#314), with 3 replicates for each development stage (CD34+ proliferating cells 
and CD34+ brown adipocytes) as described in the flowchart (Figure 15). 
 
 
Figure 15: Flow chart of the gene array analysis from CD34+ cells.  
 
3200 and 3962 genes were differentially expressed following differentiation of 
the CD34+ proliferating cells to CD34+ brown adipocytes, in #310 and #314 cell 
lines, respectively. 2375 genes were identified in both cells lines to be 
differentially expressed following differentiation. This included 1183 genes that 
were up-regulated and 1192 genes that were down-regulated. To identify the 
main pathways involving these selected genes, bio-informatic analyses were 
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performed using two different tools through Core analysis in IPA software 
(Ingenuity®Systems, www.ingenuity.com). A Function analysis (Figure 16) was 
first performed, that related these genes to known biological functions. 
Following this, a Canonical Pathway analysis (Figure 17) was performed that 
displayed these genes within well-established metabolic pathways based on 
their level of regulation following differentiation into CD34+ brown adipocytes. 
For both analyses, the ten most significant pathways are presented below with a 
significant threshold set at p<0.05. All significant Function and Canonical 
Pathway analyses can be found in Appendices 6 and 7, respectively. 
 
 
Figure 16: Ten most significant biological function pathways involving the 2375 genes 
regulated in CD34+ brown adipocytes vs CD34+ proliferating cells.  
Threshold set at 0.05.  
 
The 2375 genes differentially regulated following differentiation into CD34+ 
brown adipocytes were mainly related to cell growth, development and 
organisation (Figure 16). However, energy production, lipid metabolism and 
small molecule biochemistry functions were also significantly represented. 
These three biological functions also include oxidation, concentration, 
accumulation and metabolism of lipids, carbohydrates, amino acids and ATP. 
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A Canonical analysis was performed based on fold change values obtained by 
the gene arrays in CD34+ brown adipocytes vs CD34+ proliferating cells, to 
identify the potential metabolic pathways regulated by these genes (Figure 17). 
 
 
Figure 17: Ten most significant metabolic pathways involving the 2375 genes regulated in 
CD34+ brown adipocytes vs CD34+ proliferating cells.  
Y axis represents the percentage of genes from the dataset involved in a particular pathway. 
Bold number on the right of each bar represents the number of genes involved in this particular 
pathway based on Ingenuity database. 
 
Fatty acid β-oxidation was the most significant metabolic pathway displaying 
up-regulated genes only following differentiation into CD34+ brown adipocytes. 
Other metabolic pathways identified included lipid metabolism, endocrine 
system development and function and cellular growth and proliferation, 
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displaying mainly up-regulated genes following differentiation into CD34+ 
brown adipocytes. 
miRNA array analysis and bio-informatics 
To establish the miRNAs regulated during differentiation of the CD34+ 
proliferating cells into CD34+ brown adipocytes, miRNA array analysis were 
performed on two separate CD34+ cell lines (#310 and #314), with 3 replicates 
for each development stage (CD34+ proliferating cells and CD34+ brown 
adipocytes) as described in the flowchart (Figure 18). 
 
 
Figure 18: Flow chart of the miRNA array analysis from CD34+ cells. 
 
Of the 750 miRNAs measured, 220 miRNAs and 196 miRNAs were expressed in 
proliferation or differentiation in a minimum of 2 replicates in #310 and #314 
cell lines, respectively. Statistical comparison of the datasets from both cell lines 
identified 108 common miRNAs that were differentially regulated following 
differentiation into CD34+ brown adipocytes, including 88 that were up-
regulated and 20 that were down-regulated (Appendix 8). 
 
 
 66 
Expression pairing between gene and miRNA datasets 
To determine the potential miRNA:mRNA interactions involved in the 
differentiation of CD34+ brown adipocytes, the miRNA and gene datasets were 
paired using the microRNA Target filter tool in the IPA software 
(Ingenuity®Systems, www.ingenuity.com) (Figure 19). This pairing was based 
on three filters: 1. prediction software selecting experimentally observed or 
highly predicted targets only; 2. genes involved in cellular growth, proliferation 
and development pathways only; 3. expression level pairing miRNA up/mRNA 
down regulated and miRNA down/mRNA up regulated. 
 
 
Figure 19: Flow chart of the miRNA:mRNA expression pairing analysis in CD34+ cells during 
differentiation.  
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Expression pairing of the 2375 genes and 108 miRNAs differentially expressed 
following differentiation into CD34+ brown adipocytes identified 48 miRNAs 
predicted to target 87 genes involved in cellular growth, proliferation and 
development pathways. This list of miRNAs and the number of their predicted 
targets is presented in Table 4. 
 
Table 4: A list of the 48 miRNAs and the number of predicted gene targets differentially 
expressed during CD34+ cell differentiation, involved in cellular growth, proliferation and 
development.  
miRNAs annotated with * are down-regulated in CD34+ brown adipocytes. 
miRNA ID 
Number of 
targeted 
genes 
miRNA ID 
Number of 
targeted 
genes 
miRNA ID 
Number of 
targeted 
genes 
miR-15a 16 miR-374a 5 miR-342-3p 2 
miR-30d 13 miR-455-5p 5 miR-376a* 2 
let-7g 11 miR-143 4 miR-455-3p 2 
miR-103 11 miR-196b 4 miR-491-5p 2 
miR-320 11 miR-335 4 miR-708 2 
miR-145 9 miR-10b 3 miR-769-5p 2 
miR-26a 9 miR-125a-5p 3 miR-1247 1 
miR-365 9 miR-1260 3 miR-191 1 
miR-101 8 miR-1275* 3 miR-193a-5p 1 
miR-301a 8 miR-140-5p 3 miR-30e-3p 1 
miR-148a 8 miR-193b 3 miR-328 1 
miR-543* 8 miR-21 3 miR-339-3p 1 
miR-186 7 miR-324-5p 3 miR-485-3p* 1 
miR-204 7 miR-361-5p 3 miR-532-3p 1 
miR-22 6 miR-431* 3 miR-532-5p 1 
miR-224* 6 miR-324-3p 2 miR-660 1 
 
The full list of genes predicted to be targeted by these miRNAs can be found in 
Appendix 9. 
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III.3.3. Comparison of the miRNA profiles established for the CD34+ 
brown adipocytes and human BAT 
To establish if the CD34+ brown adipocytes and the human BAT express 
similarly highly enriched miRNAs, comparison of the up-regulated miRNAs in 
the CD34+ brown adipocytes and the miRNAs expressed in human BAT was 
performed (Figure 20). 
 
 
Figure 20: Flow chart of the miRNA analysis comparing the CD34+ brown adipocytes and the 
human BAT.  
 
Of the 88 up-regulated miRNAs in the CD34+ brown adipocytes and the 214 
miRNAs expressed in human BAT, 80 were commonly expressed between both 
human cells and BAT (Appendix 10). Eight miRNAs were highly expressed in the 
CD34+ brown adipocytes but not in the human BAT, while 134 miRNAs were 
expressed in human BAT but not in the CD34+ brown adipocytes. 
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As shown in the flowchart in Figure 21, a comparison was also made between 
the 42 up-regulated miRNAs of the final 48 regulated in the CD34+ brown 
adipocytes (Table 4) and the 25 mouse BAT-enriched miRNAs expressed in 
human BAT as identified in Study I. 
 
 
Figure 21: Flow chart of the miRNA analysis comparing the CD34+ brown adipocytes and the 
mouse BAT-enriched miRNAs expressed in human BAT.  
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5 of the 25 mouse BAT-enriched miRNAs expressed in human BAT were up-
regulated in the CD34+ brown adipocytes and predicted to target 389 genes 
involved in growth, proliferation and development pathways, including 38 
down-regulated in the gene array data (Figure 22). These 5 miRNAs were let-7g, 
miR-15a, -320, -328 and -365. 
 
 
Figure 22: The 5 mouse BAT-enriched miRNAs expressed in both human BAT and CD34+ brown 
adipocytes, with their mRNA targets.  
Red and green represent the highest and lowest values, respectively.  
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III.4. Discussion 
During embryogenesis, BAT and skeletal muscle descend from a common cell 
ancestor [50, 53]. A niche of BAT progenitor cells was discovered inside of foetal 
skeletal muscle and subsequently referred to as skeletal muscle CD34+ cells 
[77]. These human BAT progenitor cells had the ability to differentiate into 
mature metabolically active brown adipocytes in vitro and may therefore be 
potential therapeutic targets to enhance EE. However the molecular factors 
regulating their differentiation are currently unknown. Experiments examining 
the role of miRNAs in regulating mouse BAT have identified several potential 
therapeutic targets [147, 150-152], however there are no published studies 
investigating miRNAs in human BAT. Study I established 25 mouse BAT-
enriched miRNAs present in human BAT. However miRNA regulation of CD34+ 
cells inside of skeletal muscle has not to date been examined. The present study 
compared the capacity of CD31+ and CD34+ cell populations to differentiate into 
mature brown adipocytes in order to select the most adipogenic population. 
Additionally, the miRNAs and gene targets regulated during their differentiation 
into brown adipocytes were established. A final comparison with findings from 
Study I was made. Several novel observations were made. Firstly, CD34+ cells 
had the most enhanced capacity to differentiate morphologically and genetically 
into mature brown adipocytes. Secondly, 2375 genes differentially expressed 
during CD34+ brown adipocyte differentiation are related to cell growth, 
development and organisation, as well as fatty acid β-oxidation pathways. 
Thirdly, 48 of 108 miRNAs differentially expressed during differentiation were 
predicted or known to target 87 genes of the 2375 regulated in CD34+ 
differentiation. Finally 80 miRNAs were common between CD34+ brown 
adipocytes and human BAT, including 5 miRNAs of the 25 mouse BAT-enriched 
miRNAs established in Study I. 
Increasing BAT differentiation from progenitor cells and promoting muscle 
thermogenic function has been proposed as potential therapeutic strategies to 
enhance EE [1]. Identifying brown fat progenitor cells inside of skeletal muscle, 
able to differentiate into mature brown adipocytes, could be an initial step 
toward this anti-obesity approach. The present study identified CD34+ cells, 
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when compared to CD31+ cells, as a cell type displaying a morphology and gene 
profile more representatives of classical brown adipocytes. Differentiated 
CD34+ cells contained the typical brown fat multilocular lipids droplets [33, 34] 
and expressed brown fat markers such as UCP1, CIDEA, LHX8 and ELOVL3 [45, 
51, 164, 165]. Both proliferating CD31+ and CD34+ cells expressed the myogenic 
regulator MYF5 [51] supporting their common origin within skeletal muscle. 
CD34+ cells, when compared with CD31+ cells, had lower MYF5 mRNA and 
higher PPARγ levels following differentiation, suggesting their shift from 
myogenic to an adipogenic signature. Indeed PPARγ is a key transcription factor 
indispensable for adipogenesis (reviewed in [55]). Therefore, based on these 
results, CD34+ cells were selected for further molecular investigations. While 
this CD34+ population has a morphology and gene profile very close to classical 
brown adipocytes, further studies will be required to confirm their metabolic 
activity such as uncoupled respiration and their answer to β-adrenergic 
activation. 
Establishing the molecular factors regulated during differentiation of the CD34+ 
brown adipocytes may identify potential therapeutic targets to manipulate cell 
proliferation and function. Gene array analysis identified that 1183 genes were 
up- and 1192 genes were down-regulated in the CD34+ brown adipocytes, 
compared to the proliferating CD34+ cells. Bio-informatic analyses identified 
that the main pathways involving these regulated genes were included cell 
growth, development and organisation, as well as energy production and lipid 
metabolism. Detailed metabolic bio-informatic analyses confirmed their 
implication in lipolysis with the fatty acid β-oxidation pathway being the most 
significant pathway represented exclusively by the up-regulated genes. Along 
with acetyl-CoA biosynthesis and mitochondrial L-carnitine shuttle pathways, 
these results represent the classical lipid breakdown undertaken by FA in a 
oxidative tissue such as skeletal muscle [37]. Stimulation of lipolysis in brown 
adipocytes induces thermogenesis, the main function of an active BAT [15]. 
Therefore, these results suggest an active metabolism in these CD34+ brown 
adipocytes towards lipolysis and thermogenesis. This however requires to be 
experimentally validated. 
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miRNAs are tissue-enriched regulators that can be the cause of diseases when 
deregulated [100]. Therefore, it was of interest to identify the miRNA profile of 
these CD34+ brown adipocytes and select the mRNA:miRNA pairs potentially 
involved in growth, proliferation and development pathways. In the present 
study expression pairing of miRNAs and genes identified 42 up and 6 down-
regulated miRNAs that were predicted to target 87 genes involved on growth, 
proliferation and development in the CD34+ brown adipocytes. Included in 
these 48 miRNAs, miR-193b-365 cluster and -455 are involved in brown fat 
development and activity [76, 147]. Indeed, miR-193b-365 is up-regulated by 
Prdm16 partially via Pparγ, and as a consequence targets a brown fat inhibitor, 
Runx1T1 in mouse BAT [147]. miR-455 is positively correlated to an increased 
Ucp1 expression level in murine brown adipocytes, following treatments with 
an α-adrenergic or Pparγ agonist [76]. Finally, 5 miRNAs were commonly 
expressed between the 42 up-regulated miRNAs and the 25 mouse BAT-
enriched miRNAs expressed that were also enriched in human BAT tissues 
identified in Study I. Of these, let-7g, miR-15a and -365 are enriched in mouse 
BAT when compared with epididymal WAT and skeletal muscle [147]. While 
miR-365 is a known factor in brown adipogenesis [147], the roles of BAT-
enriched let-7g and miR-15a have not been established. Finally, miR-15a, 
present in mouse and human BAT as well as the CD34+ brown adipocytes, was 
predicted to target the largest gene set involved in cellular growth, proliferation 
and development. To date, expression of miR-15a in plasma and vastus lateralis 
muscle is associated with human T2D [127, 166], suggesting its role in human 
metabolism. However miR-15a has not been studied in relation to BAT or CD34+ 
brown adipocyte development and requires further investigations. 
In summary, this study has established that the differentiated CD34+ cell 
population has a morphology and gene profile similar to BAT. Furthermore, 
gene bio-informatic analyses predicted the involvement of these CD34+ brown 
adipocytes in lipolysis, suggesting a potential role in thermogenesis. 48 miRNAs 
were predicted to target 87 genes differentially expressed during CD34+ cell 
differentiation and potentially involved in growth and metabolism. Additionally 
80 miRNAs were commonly expressed between the CD34+ brown adipocytes 
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and human BAT, including 5 miRNAs enriched in both mouse and expressed in 
human BAT. Finally, miR-15a, a target systematically expressed in mouse and 
human BAT as well as the CD34+ brown adipocytes, was predicted to regulate 
the largest gene set involved cellular growth, proliferation and development. 
This study has identified a novel miRNA profile in CD34+ brown adipocytes that 
has similar characteristics to BAT, and predicted potential genes targeting 
human BAT development. These novel findings have opened a new avenue for 
experimental investigations to study the potential of skeletal muscle-derived 
brown adipocyte cells as potential therapeutic targets to regulate human BAT 
development and enhance EE. 
 
 75 
Chapter IV 
Study III: Effect of cold exposure on human 
skeletal muscle regulation of the CD34+ cell 
population and microRNA profile. 
 
IV.1. Introduction 
BAT has been broadly studied in rodents and hibernating animals for its role in 
cold- and diet-induced thermogenesis [17-19]. While humans were believed to 
have lost BAT during childhood, recent studies using 18F-FDG PET on healthy 
people and those with cancer revealed the presence and function of BAT in 
human adults [20-25]. This observation has increased the interest in BAT as an 
anti-obesity target. The amount and function of human BAT depend on sex, with 
greater BAT amounts in young males compared to young females and the 
opposite being observed in middle-aged populations; age, with more BAT in 
young compared with elderly subjects; ambient temperature, as BAT is more 
active in winter than in summer; and adiposity-related parameters, with BAT 
more active in healthy lean subjects when compared with obese subjects [20-25, 
58, 60]. However, these early studies should be consider with care as some can 
be retrospective studies where ambient temperature, nutritional status and 
other parameters were not control. Furthermore, 18F-FDG PET cannot insure 
the true volume of BAT since all BAT may not be activated. Further studies 
where all these parameters will be controlled should be done to validate these 
data. 
Cold exposure stimulates human BAT activity. Correlations between an 
increased BAT activity and an increased EE [83] and also between a decreased 
BAT activity and an increased BMI, body fat content, visceral and subcutaneous 
fat with age [84] have been observed. Following cold exposure, an increase in 
glucose uptake and blood delivery (perfusion) in BAT is significantly higher in 
lean subjects in comparison to obese subjects [64, 86]. These results support a 
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role of BAT in human metabolism and suggest that BAT activity may depend on 
metabolic health. Furthermore, following cold exposure in healthy subjects a 
positive correlation between total daily EE and skeletal muscle uncoupled 
respiration is observed [88, 89]. At the molecular level cold exposure down-
regulates the muscle-enriched miR-133 in mouse BAT [149], and in mouse 
skeletal muscle, resulting in the induction of differentiation into brown 
adipocytes within the muscle fibres [150]. These results imply a role for 
miRNAs in cell fate and the regulation of EE in BAT. 
Skeletal muscle-derived CD34+ brown fat progenitor cells differentiate into 
mature active brown adipocytes in vitro [77]. Additionally, the CD34/31 mRNA 
ratio is significantly decreased in obese subjects when compared with lean 
subjects [79]. These findings suggest a negative association between CD34+ 
progenitor cell expression and metabolic disorders. Study II established the 
CD34+/31- cell population as a highly adipogenic cell population expressing 80 
common miRNAs with human BAT, including 5 mouse BAT-enriched miRNAs 
and several BAT gene markers such as UCP1, CIDEA and LHX8. These 
observations support the notion that CD34+/31- cells may be a therapeutic 
target to increase EE [1]. Cold stimulates thermogenesis indirectly via the 
central nervous system and sympathetic nervous system (SNS). The SNS 
releases NE that activates the thermogenic gene program in brown adipocytes 
via β-adrenergic receptors [15]. However, a recent study showed that cool 
temperatures could directly activate white and beige adipocytes in a cell-
autonomous manner and independently of the classical signalling pathway of 
the β-adrenergic receptors [167]. The cold exposure activation of the SNS may 
also regulate the human muscle-derived CD34+ cell population as well as 
skeletal muscle miRNAs, however this has not been investigated. 
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Therefore the aims of this study were to: 
1. Establish if cold exposure increases the number of skeletal muscle-
derived CD34+ cells in human adults.  
2. Establish the capacity of the CD34+ cells, collected from human adult 
muscle biopsies, to proliferate and differentiate in vitro. 
3. Establish the effect of cold exposure on the miRNA profile and expression 
levels of BAT markers in human skeletal muscle, and compare these 
findings with the miRNA lists of Study 1 and Study 2 
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IV.2. Material and methods 
IV.2.1. Clinical trial 
Ethics application (2010-252) was approved by the Deakin University Research 
Ethics Committee. 
Ten healthy male subjects (table 5) were recruited to undertake a randomised 
cross-over design study following completion of a medical questionnaire and 
approval by a medical practitioner. Subjects were required to come twice to the 
Deakin University Clinical Research Facility (Burwood campus, VIC, Australia), 
with a minimum of a week apart. This study was completed during the winter 
season. 
 
Table 5: Anthropometric characteristics of the 10 subjects. 
Values represent the mean ± SEM.  
Subjects 
Criteria Mean ± SEM 
Age 24.9 ±1.07 
Weight (kg) 74.0 ±2.75 
Height (cm) 173.0 ±2.20 
Fat mass (kg) 13.2 ±1.85 
Lean mass (kg) 57.5 ±2.52 
 
A standardised meal including durum wheat pasta and a stir through sauce was 
provided to all subjects for their evening meal prior to both trial days (20% fat, 
14% protein and 66% carbohydrate). Subjects arrived in a fasted state at the 
Clinical Research Facilities on the morning of both trial days. Body composition 
was assessed using a Dual Energy X-ray Absorptiometry scanner (GE Luna 
Prodigy, GE Healthcare, WI, USA) in total body mode. Following this, the 
subjects remained in a climate chamber. Randomly distributed, participants 
spent either 3hrs at 22°C (control trial) then a week later 1hr at 22°C followed 
by 2 hrs at 16°C (cold exposure trial) (van Marken Lichtenbelt, Vanhommerig et 
al. 2009), or vice versa. Muscle biopsies were taken before and immediately 
after the 3hrs intervention. Muscle temperature was measured by a type T 
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flexible thermocouple probe (Physitemp Instruments, NJ, USA) inserted into the 
first biopsy incision. Core temperature was measured throughout the trial using 
a VitalSense® Jonah™ telemetric core body temperature capsule (Mini Mitter, 
OR, USA) that the subject had swallowed 30mins before the start of the trial. 
Skin temperature was measured using a VitalSense® skin temperature patch 
(Mini Mitter, OR, USA) placed on one thigh. Both temperature data were 
detected and recorded in real-time by a VitalSense® monitor (Mini Mitter, OR, 
USA). Insulative vasomotor response is a physiological adjustment of the body 
exposed to cold [168]. To assess this, a gradient was calculated between core 
and skin temperatures (core/skin) as measured previously [22]. EE was 
assessed every 30mins by measuring VO2 and VCO2 using the Parvo Medics' 
TrueOne® 2400 (ParvoMedics, UT, USA). Total EE was expressed as the mean 
value over the last two hours of each trial. 
IV.2.2. Muscle biopsies 
Skeletal muscle samples were obtained under local anaesthesia (1% Xylocaine) 
from the belly of the vastus lateralis muscle using a percutaneous needle biopsy 
technique [169] modified to include suction [170]. A small incision was made 
through the skin in preparation for the muscle biopsies. Muscle samples were 
removed from the biopsy needle and either snapped frozen and stored in -80°C 
until RNA extraction or stored in DMEM high glucose, 50% horse serum and 1% 
PS (Life Technologies, CA, USA) at 4°C for 24 to 96 hrs until processing for FACS 
analysis. 
IV.2.3. Fluorescent Activating Cell Sorting 
FACS was done on samples collected from 9 subjects. Fresh adult muscle was 
cut into small pieces with scissors in DMEM high-glucose media containing 20% 
FBS, 1% PS (Life Technologies, CA, USA). After being transferred to a tube, the 
tissue was digested by collagenases IA-S, II-S, and IV-S (0.5 mg/ml) (Sigma-
Aldrich, MO, USA) at 37°C for 75mins with constant stirring (100rpm). Final cell 
dissociation was achieved between ground-glass slides. Cells were then washed 
with PBS (Lonza, MD, USA) containing 10% FBS and 1% PS (Life Technologies, 
CA, USA) and centrifuged for 5mins at 1200rpm and 4°C. They were 
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resuspended in 1X 0.8% ammonium chloride (Sigma-Aldrich, MO, USA) acting 
as a red blood cell lysing buffer and incubated for 10mins at room temperature 
under constant stirring (100rpm). After incubation, cells were centrifuged for 
5mins at 1200rpm and 4°C and the pellet was resuspend in 100-200 μL of 
media. 5 μL of this suspension were diluted in 200 μL of media for the 
“unstained tube”. Propidium iodide (PI) (BD Biosciences, NJ, USA) was added to 
this tube to determine cell viability. The remaining cells were stained with the 
following directly coupled mouse anti-human antibodies: CD31-FITC (1/10), 
CD45-v450 (1/20), CD56-APC (1/50), CD34-PECy7 (1/20), and CD146-PE 
(1/50) (BD Biosciences, NJ, USA) at 4°C for 30-45mins (Crisan et al. 2008). 
Compensating tubes were used for CD31-FITC, CD34-PECy7, and CD146-PE 
with BD™ CompBeads (BD Biosciences, NJ, USA). After washing and 
centrifugation, samples were run on a MoFlo XDP flow cytometer (Beckman 
Coulter, FL, USA) at Monash Medical Centre (Monash Medical Centre, VIC, 
Australia). Cell viability was assessed by adding PI (BD Biosciences, NJ, USA) to 
the unstained tube. Firstly, CD45+, CD146+ and CD56+cells were gated out. The 
sort was then based on the CD34+ and CD31+ cells, represented in Figure 23. 
Each red dot is a cell detected by the machine and it is situated on the graph 
based on the fluorescent-coupled antibodies it carried.  
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Therefore the CD34+/31- cell population was situated at the bottom of the Y axis 
and on the right of the X axis (Figure 23A and B - black circle). The number of 
CD34+ cells was expressed as a percentage of total live cells in each sample.  
 
 
Figure 23: FACS graphs.  
(A) Pre-treatment sample (B) Post-treatment sample (same subject).Black circles represent the 
CD34+/CD31-/CD146-/CD45-/CD56- cells gated for counting and collection.  
 
Following this, each sample of CD34+ cells was collected in a tube containing 
EGM™-2 Bulletkit™ medium (Lonza, MD, USA) and then plated for cell culture. 
IV.2.4. Cell culture 
CD34+ cells were cultured from samples collected from 9 subjects at 4 time 
points each (pre and post; control and cold exposure); a total of 36 cultures. 
CD34+ cells were plated in one well of a 0.2% gelatin-coated 96well plate 
(growth surface of 0.32cm2/well). They were left in their media for one week 
with fresh media added on top every 2-4 days. Then media was changed every 
3-4 days. Differentiation media was prepared as described in Chapter III.2.2. 
Media was changed every 2-3days. Images were captured using Olympus IX51 
and AnalySIS getIT software (Olympus Corporation, Tokyo, Japan).  
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IV.2.5. RNA extraction 
Muscle biopsies 
RNA extraction and quality check was performed as described in Chapter II.2.2. 
for the human tissues. 
IV.2.6. Megaplex reverse transcription and microRNA arrays 
Muscle biopsies 
miRNA arrays were run on samples collected from the 10 subjects. Megaplex 
reverse transcription, miRNA arrays and normalisation where performed as 
described in Chapter II.2.3. using primers and arrays for human samples.  
IV.2.7. Reverse transcription and RT-PCR for gene expression 
Muscle biopsies 
RT-PCR were run samples collected from the 10 subjects. Reverse transcription, 
primer design and RT-PCR were performed as described in Chapter II.2.2 and 
III.2.5 (Table 6). Different genes were measured: CD34, PGC1α, PPARγ, ELOVL3, 
CIDEA, LHX8, UCP1, UCP3 short (UCP3S) and long (UCP3L) isoforms as well as 
total UCP3 (UCP3T); the latter being the sum of UCP3S and UCP3L.  
 
Table 6: Sequences of human primers used for RT-PCR analyses.  
Gene 
GenBank 
Accession No. 
Forward primer (5’ – 3’) Reverse primer (5’ – 3’) 
CD34 NM_001773.2 TGAAATTGACTCAGGGCATCT CCTCTCCCCTGTCCTTCTTAA
PGC1α NM_013261.3 TCAGTCCTCACTGGTGGACA TGCTTCGTCGTCAAAAACAG 
UCP3S NM_022803.2 ATGGACGCCTACAGAACCAT TCACCGCTACATCCCAGGTT 
UCP3L NM_003356.3 ATGGACGCCTACAGAACCAT TACGAACATCACCACGT 
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IV.2.8. Statistics 
A two way ANOVA with repeated measures was used to determine the 
interaction between time (pre and post treatment) and treatment (ambient 
temperature and cold exposure). T-tests were used for post-hoc analysis with a 
Bonferroni adjustment. A p-value of <0.05 was considered as significant for all 
analyses. 
Muscle biopsy miRNA array 
Four lists of miRNAs were created: pre-control, post-control, pre-cold exposure 
and post-cold exposure. miRNAs were considered expressed within a list when 
a minimum of 6 subjects (out of 10) had CT values below 32, as suggested by the 
manufacturer’s protocol. miRNAs were kept for statistical analysis when they 
were expressed in at least one of the four lists. Statistics were performed as 
mentioned above.  
IV.2.9. Bio-informatics 
Bio-informatic analyses were performed on a specific list of miRNAs. Datasets 
were analysed through the use of IPA (Ingenuity®Systems, 
www.ingenuity.com) and more specifically, the microRNA Target filter tool.  
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IV.3. Results 
IV.1.1. Effect of cold exposure on physiological parameters and 
human adult skeletal muscle CD34+ cell number 
Energy expenditure and skin, muscle and core temperatures 
Skin and core temperatures were measured every 30mins during both trials 
(Figure 24). During the control trial, skin temperature increased after 30mins 
(p<0.01) and remained constant until the end of the trial. During cold exposure, 
skin temperature was not different from 0-90mins, but was at 120mins 
(p<0.01) and remained constant until 180mins. Skin temperature was lower 
following 120-180mins of cold exposure when compared to the control trial 
(p<0.01). Core temperature did not change in treatment or over time. A 
temperature gradient between skin and core temperatures was established as a 
measure of insulation [22]. There was an interaction between treatment and 
time (p<0.0001). In the control group, the core/skin temperature gradient did 
not significantly change over the 3hr period. During cold exposure, the 
core/skin temperature gradient steadily increased. The core/skin temperature 
gradient was greater during the final hour of cold exposure when compared 
with the control group. 
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Figure 24: Skin and core temperatures and temperature gradient during the control and cold 
exposure trials.  
Values represent the mean ± SEM. Control and cold exposure trials are represented by circle and 
square, respectively. Temperature was changed from 22°C to 16°C at T60 (blue frame) during 
the cold exposure trial. (A) Skin temperature; ** p<0.01, all different from T0 in the control 
group; #, p<0.01, different from T0 to T90 in the cold group and at the same time points in the 
control group. (B) Core temperature. (C) Temperature gradient. #, p<0.0001, different from T90 
to T180 in the cold exposure trial; **, p<0.001, different from T120 to T180 in the cold exposure 
trial; %, p<0.001, different from T150 to T180 in the cold exposure trial; ***, p<0.0001, different 
at the same time points when compared with cold exposure. N=10 subjects. 
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Muscle temperature was measured every 30mins to ensure that 16°C was 
sufficient to reduce the temperature significantly inside the site of the biopsy, 
when compared to the control trial (Figure 25). Muscle temperature was 
siginficantly lower following T120 to T180 of cold exposure when compared to 
the first 90mins of cold exposure. Additionally, muscle temperature was 
siginficantly lower at T180 of cold exposure when compared to control group at 
the same time point. Muscle temperature did not change in the control group. 
Total resting energy expenditure was compared over the last two hours of the 
control and cold exposure trials. No change was observed. 
 
 
Figure 25: Muscle temperature during the control and cold exposure trials and total resting 
energy expenditure over the last two hours of both trials. 
Values represent the mean ± SEM. Control and cold exposure trials are represented by circle-
black bar and square-grey bar, respectively. Temperature was changed from 22°C to 16°C at T60 
(blue frame) during the cold exposure trial. (A) Muscle temperature; ** p<0.01, T120 to T180 
are different from T0 to T90 in the cold exposure trial; #, p<0.01, different at T180 between the 
control and cold exposure trials. (B) Resting energy expenditure over the last two hours of both 
trials. N=10 subjects. 
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Cell number 
To establish the effect of cold exposure on the number of human adult CD34+ 
cells inside skeletal muscle, FACS analyses were done on digested and stained 
muscle biopsies before and after the control and cold exposure trial days 
(Figure 26).  
 
 
Figure 26: Percentage of human adult CD34+ cells before and after the control and cold 
exposure trials for each subject.  
Cells are expressed as a percentage of total live cells in each sample. SEM for T0 and for T180 
are represented at the left and right of each graph, respectively. N=9.  
 
There was no significant difference in the number of CD34+ cells between the 
control and cold exposure trials. A large inter-individual variability was 
observed in the number of cells as well as in response to treatment.  
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IV.1.2. Capacity of human adult CD34+ cells to proliferate and 
differentiate 
To establish the capacity of human adult CD34+ cells to proliferate and 
differentiate in vitro, cells were collected in growth media after FACS analyses 
and plated in one well of a 96well plate (surface of 0.32cm2/well).  
 
Table 7: Biopsy weights and number of CD34+ cells collected for cell culture.  
Muscle biopsy weight in mg (wet weight). 
Control Cold exposure 
T0 T180 T0 T180 
Subject #1 Biopsy weight (mg) 100 100 160 110 
CD34 cell number 78 23 124 49 
Subject #2 Biopsy weight (mg) 165 N/A 125.50 168 
CD34 cell number 87 114 145 520 
Subject #3 Biopsy weight (mg) 162 113.8 136 147 
CD34 cell number 92 171 192 195 
Subject #4 Biopsy weight (mg) 114 131.7 85.5 76.5 
CD34 cell number 1109 583 2210 2390 
Subject #5 Biopsy weight (mg) 114 121 118 110 
CD34 cell number 826 921 1020 545 
Subject #6 Biopsy weight (mg) 91 123 129 N/A 
CD34 cell number 332 364 2940 5410 
Subject #7 Biopsy weight (mg) 114 119 113 143 
CD34 cell number 558 1750 748 776 
Subject #8 Biopsy weight (mg) 118 114 105 108 
CD34 cell number 263 878 1050 419 
Subject #9 Biopsy weight (mg) 97 123.6 118 160 
CD34 cell number 1010 710 184 1060 
 
Thirty-six CD34+ cell lines were grown from 9 subjects (samples from before 
and after the control and cold exposure trials) with a starting number of cells 
varying between 23 until 5410 cells (Table 7). Therefore the ratio between 
number of cells and surface of culture varied from approximately 70 to 17x103 
cells/cm2. 
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Figure 27: Photos of human adult CD34+ cells during proliferation at passages 1 and 3 and 
differentiated at day 12 of passage 3 (x100).  
 
Four of the 36 cell lines proliferated until passage 3 (Figure 27). One cell line 
died after passage 1. Two cell lines spontaneously accumulated small lipid 
droplets from passage 2 and stopped proliferating after passage 3. One cell line 
was place in differentiation media at passage 3 as proliferation slowed down 
dramatically. Twenty per cent of the cells accumulated small lipid droplets after 
in differentiation media. The number of cells was not enough to obtain a 
sufficient amount of RNA for gene expression measurements. The 32 other cell 
lines did not proliferate. 
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IV.1.3. Effect of cold exposure on the miRNA profile and the 
expression level of BAT gene markers in human skeletal 
muscle. 
miRNA array analysis on muscle biopsies 
To establish the miRNAs regulated during cold exposure, miRNA arrays were 
performed on 10 subjects, before and after both trial days (Figure 28). 
 
 
Figure 28: Flow chart of the miRNA array analysis before and after control and cold exposure 
trial days in human skeletal muscles.  
N=10.  
 
Of the 750 miRNAs measured, 238, 230, 226 and 224 miRNAs were expressed in 
pre-control, post-control, pre-cold exposure and post-cold exposure samples, 
respectively. Statistical comparison of the datasets identified 4 miRNAs 
significantly up-regulated after cold exposure: miR -28-5p, -517, -532-3p and -
1208. 
These 4 miRNAs were compared with the previous lists of miRNAs identified in 
mouse and human BAT (Chapter II - Study 1) and in the CD34+ brown 
adipocytes (Chapter III – Study 2). miR-532-5p was the only one expressed also 
in the list of 145 miRNAs commonly expressed in human and mouse BAT, as 
well as in the list of 48 miRNAs differentially expressed in the CD34+ brown 
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adipocytes predicted to target genes involved in growth, proliferation and 
development (up-regulated in the CD34+ brown adipocytes vs CD34+ 
proliferating cells). 
Bio-informatics 
To identify the predicted gene targets of these 4 miRNAs, bio-informatic 
analyses were performed. miR-28-5p, -532-3p, -517 and -1208 were predicted 
to target 302, 203, 50 and 25 mRNAs, respectively (Table 8). 
 
Table 8: The 4 miRNAs up-regulated following cold exposure in human skeletal muscle and the 
number of predicted gene targets.  
miRNA ID Number of targeted genes 
miR-28-5p 302 
miR-532-3p 203 
miR-517 50 
miR-1208 25 
 
The full list of genes predicted to be targeted by these 4 miRNAs can be found in 
Appendix 10. miR-28-5p was predicted to target CD34 gene expression. miR-
532-3p was predicted to target UCP3 mRNA; potentially resulting in its decrease 
it following cold exposure. 
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RT-PCR 
RT-PCR was performed to identify the effect of cold exposure on CD34 gene 
expression, PGC1α and other brown fat markers including, PPARγ, ELOVL3, 
CIDEA, LHX8 and UCP1 in the skeletal muscle biopsies (Figure 29). No significant 
changes were observed either in time (pre and post) or treatment (control and 
cold exposure) in any of the genes measured. UCP1 gene expression was not 
detected in the samples.  
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Figure 29: Gene expression of CD34 cell surface marker and brown fat markers in muscle 
biopsies before (T0) and after (T180) 3hrs a 22°C (control) or 1hr at 22°C and 2hrs at 16°C (cold 
exposure).  
Values represent the mean ± SEM. (A) CD34, (B) PGC1α, (C) PPARγ, (D) ELOVL3, (E) CIDEA and 
(F) LHX8 gene expression. N=10.  
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UCP3S, UCP3L and UCP3T were measured as well (Figure 30), considering the 
increased expression of miR-532-3p, a miRNA predicted to target UCP3 mRNA. 
UCP3S, UCP3L and UCP3T mRNAs were measured and did not differ between 
groups. 
 
 
Figure 30: Gene expression of UCP3S, UCP3L and UCP3T in muscle biopsies before (T0) and 
after (T180) 3hrs a 22°C (control) or 1hr at 22°C and 2hrs at 16°C (cold exposure).  
Values represent the mean ± SEM. (A) UCP3S, (B) UCP3L, (C) UCP3T gene expression. N=10.  
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IV.4. Discussion 
BAT in mammals is a key organ controlling EE through cold- or diet-induced 
thermogenesis [17-19]. Recently discovered in human adults [20-25], 
attenuated BAT activity during cold exposure is negatively associated with an 
increase in adiposity-related parameters with age [84]. Therefore, BAT 
activation is proposed as a potential therapeutic strategy in obesity and T2D 
[26-29]. Skeletal muscle-derived CD34+ progenitor cells can differentiate into 
active brown adipocytes in vitro with uncoupled respiration [77]. A decrease in 
CD34/31 mRNA ratio in adult obese vs lean subjects [79] suggests a reduction in 
the amount of these cells in metabolic disorders. Study 2 established that the 
CD34+/31- cell population had an enhanced capacity to differentiate into brown 
adipocytes and identified miRNAs that may regulate the differentiation of these 
cells. However, the effect of cold exposure on the human adult CD34+ cell 
population and the regulation of miRNAs inside skeletal muscle have not been 
investigated. The present study compared the effect of 2hrs of cold exposure 
(16°C) on the number of human adult CD34+ cells, their capacity to proliferate 
and differentiate in vitro and the regulation of specific miRNAs and gene 
expression in human skeletal muscle. A comparison was also made with the 
BAT-enriched miRNAs and CD34+ brown adipocyte-enriched miRNAs found in 
Study 1 and 2, respectively. Firstly, 2hrs at 16°C had no effect on the number of 
CD34+ cells inside human adult skeletal muscle biopsy samples. Secondly, only 
four samples of the human adult CD34+ cells successfully proliferated in vitro 
but none fully differentiated into mature brown adipocytes. Thirdly, 4 miRNAs 
were up-regulated during cold exposure in skeletal muscle, including miR-532-
3p, a target up-regulated in mouse and human BAT, and in the foetal CD34+ 
brown adipocytes. Finally, cold exposure had no effect on CD34 gene expression 
or classical markers of BAT in skeletal muscle. 
During cold exposure, an increased BAT activity is positively correlated with 
increased EE in human adults [83], suggesting a conserved role in cold-induced 
thermogenesis. Establishing if cold exposure can increase the number of brown 
fat progenitor CD34+ cells inside human adult skeletal muscle may support a 
brown fat-like sensitivity, activation and role of these CD34+ cells in response to 
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cold stimulation. The present study showed no changes in the number of CD34+ 
cells in skeletal muscle biopsy samples following 1hr at 22°C and 2hrs at 16°C, 
when compared to 3hrs at 22°C. In a similar study (2hrs at 17°C), cold exposure 
had no effect on glucose uptake and extraction, and blood flow in human 
skeletal muscle [86]. Combined, these results suggest that 2hrs of mild-cold 
exposure might not be sufficient to stimulate skeletal muscle metabolism, and as 
a consequence stimulate an increase in CD34+ progenitor cells. However, muscle 
systematic nerve activity measurement should be used in future studies to 
insure its activation in comparison to control, as well as level of noradrenaline 
in plasma. It is important to note that the large variability in the number of 
CD34+ cells extracted from each subject may have contributed to this 
observation. This variability may have been due to the differences in skeletal 
muscle biopsy sizes as well as the inherent variability in sample preparation for 
FACS. Inter-individual variability in tissue sampling has previously been 
observed when studying human neck fat phenotypes, including neck BAT [62]. 
Muscle-derived CD34+ progenitor cells and BAT represent small proportions of 
cells and tissue mass when compared to the rest of the body. Therefore 
variability between individuals should be considered when sampling muscle-
derived BAT progenitor cells or BAT in humans. In the present study no effect of 
mild cold exposure on EE was observed. This is in contradiction to several 
previous studies [22, 90, 171, 172]. Difference between studies might be due to 
the use of a stringent randomized cross-over trial design in this present study 
compared to non cross-over trial design in others, such as van Marken et al. and 
Ouellet et al. [22, 90]. Also, some of these studies recruited males as well as 
females without considering their menstrual cycle [171, 172]. Daily EE 
increases of 8-16% during the post ovulatory phases of the menstrual cycles 
[173]. Therefore it is important to measure EE in females at the exact same 
period of their menstrual cycle to avoid variations between subjects within a 
same study. Subjects have also been exposed to the cold for a longer period of 
time (3hrs) [90] and also to greater variations in temperatures (delta of 9.5°C) 
[172]. Therefore, trial design and specific methodologies in BAT studies should 
be established to allow consistency when comparing similar studies. 
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Human foetal CD34+ cells described in Crisan et al. [77] and the CD34+/31- 
progenitor cells from Study 1 have the capacity to develop into mature brown 
adipocytes. Therefore it was of interest to determine if human adult CD34+ 
progenitor cells could proliferate and differentiate into CD34+ brown 
adipocytes. Only four of the 36 CD34+ cell lines proliferated. This may have been 
due to extraction of too few cells and a large variability of the cell numbers 
extracted from the small biopsy samples. Indeed the ratio between the starting 
number of CD34+ cells (from 23 to 5410 cells) and growth surface of one well of 
a 96well plate was between 70 to 17x103 cells/cm2, while the foetal CD34+ 
progenitor cells require a minimum of 13x103 cells/cm2. This may have affected 
the cells capacity to interact with each other and release enough growth factors 
into the media to stimulate their proliferation as necessary for various cell 
culture models [174, 175]. Further studies using larger samples of tissues 
(potentially surgical wastes) may provide a better chance to obtain sufficient 
cell numbers to investigate the capacity of these human adult CD34+ cells to 
differentiate into mature active brown adipocytes. Increasing the sensitivity of 
the methods to select the CD34+ cells from small muscle samples as well as 
testing different growth and differentiation media may allow the sorting of a 
more optimal number of cells and permit a more thorough in vitro investigation 
of these cells. 
Recent studies have investigated the role of miRNAs in BAT development and 
function [76, 147, 149-152]. MyomiR-133 is down-regulated in mouse BAT after 
cold exposure and is known to directly target Prdm16 mRNA [149], confirming 
the role of miRNAs in brown adipogenesis during cold exposure. Four miRNAs 
were up-regulated during cold exposure when compared to the control trial. Of 
these miRNAs, miR-532-3p was observed in Study 1 to be expressed in human 
and mouse BAT, and in Study 2 to be up-regulated in CD34+ brown adipocytes 
and predicted to target genes involved in growth, proliferation and 
development. Using bio-informatic analysis, miR-532-3p was predicted to target 
UCP3, however there was no change in UCP3 mRNA levels. In a study using 
longer cold exposure (60hrs at 16°C), UCP3 short (p=0.07) and long (p=0.1) 
isoforms and total (p=0.07) expression had a tendency to decrease in human 
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skeletal muscle biopsies, although the increased protein content was positively 
correlated with the EE [176]. Combined, this may indicate a delay between the 
increased miRNA levels and the inhibition of their specific targets. miR-28-5p 
was predicted to target CD34 mRNA. However no change was observed in CD34 
gene expression. None of the predicted gene targets for miR-517 and -1208 
were related to growth, proliferation, development or metabolism. 
PGC1α, PPARγ, ELOVL3, CIDEA, LHX8 and UCP1 gene expression were measured 
to establish if cold exposure would increase the expression of brown fat 
markers in skeletal muscle. Furthermore Pgc1α mRNA is known to be increased 
in mouse skeletal muscle following cold exposure (4°C for 12hrs) [153]. 
However, PGC1α gene expression did not change during cold exposure in the 
present study. The differences between studies could be due to disparities in 
protocol designs with a shorter and warmer intervention in the present study, 
or it could indicate a difference in the response to cold exposure between 
skeletal muscles of these two species. However, the increase of Pgc1α following 
12hrs at 4°C might be a reflection of the shivering alone that the mouse would 
experience at this temperature without being previously adapted. PGC1α gene 
expression might not have been a relevant brown fat marker in this study as it is 
more likely that it represents a muscle response rather than browning. None of 
the other brown fat markers (PPARγ, ELOVL3, CIDEA, LHX8 and UCP1) were 
differentially expressed after cold exposure. This suggests that this protocol is 
not sufficient in duration or in temperature to regulate BAT-related genes. 
However, considering the limited amount of classical BAT present in its usual 
known sites in human (i.e. neck), it is probably questionable that there would be 
many brown adipocytes in skeletal muscle. Finally, it is important to note that 
skeletal muscle temperature significantly dropped by an average of 2.1°C ± 0.42 
by the end of the 2hrs at 16°C. However, muscle temperature also had a 
tendency to drop by an average of 0.69 °C ± 0.33 during the control trial. Future 
trials might look at a prolonged cold exposure to accentuate the difference in 
muscle temperature between control and cold conditions. This will determine if 
skeletal muscle-derived CD34+ cells respond to cold exposure in a similar way 
to BAT. 
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In summary, this study showed that 2hrs at 16°C has no effect on human adult 
CD34+ progenitor cell numbers or on the gene expression of CD34 and other 
brown fat markers, when compared to control temperature. Furthermore, this 
study observed considerable variability in the extraction of human adult CD34+ 
progenitor cell numbers and their capacity to proliferate. While this may be due 
to inter-individual variability, further investigations using larger muscle 
samples and longer cold exposure periods may be required. The protocol of 
2hrs at 16°C increased the expression of 4 miRNAs, including miR-532-3p; a 
miRNA highly expressed in mouse and human BAT and human foetal CD34+ 
brown adipocytes. This underlying result may indicate a role of miR-532-3p in 
cold-induced thermogenesis and requires further investigation.  
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Chapter V  
Conclusion and future directions 
 
V.1. Summary of major findings 
The overall aims of this PhD were to establish the BAT enriched-miRNA profiles 
in mouse and human BAT as well as in skeletal muscle-derived CD34+ brown 
adipocytes, and identify miRNAs predicted to target genes potentially involved 
in BAT and/or CD34+ cell growth and development. Additionally, the effect of 
cold exposure on the number of CD34+ cells inside human adult skeletal muscle, 
the skeletal muscle miRNA profile and brown fat gene expression were 
established in vivo, along with the capacity of the human adult CD34+ cells to 
proliferate and differentiate in vitro. The present findings established a mouse 
BAT-enriched miRNA profile conserved in human BAT and predicted to target 
genes potentially involved in growth and development. The present results also 
identified a human skeletal muscle-derived CD34+ cell population with the 
capacity to differentiate into brown adipocytes in vitro. These CD34+ brown 
adipocytes expressed common miRNAs to mouse and human BAT. Finally these 
findings show an up-regulation of 4 miRNAs in human adult skeletal muscle 
following cold exposure. These 4 miRNAs were also present in mouse and 
human BAT as well as in CD34+ brown adipocytes. 
In Chapter 2, 35 miRNAs were identified to be enriched in mouse BAT in 
comparison to skeletal muscle and WAT. These miRNAs were also predicted to 
target genes involved in cellular growth, proliferation and development 
indicating a potential role for these miRNAs in regulating BAT development. For 
the first time, miRNA profiling identified the expression of 214 miRNAs in 
human BAT. When compared to the 35 mouse BAT-enriched miRNAs, 25 
miRNAs were commonly expressed between the two species. Specifically, miR-
20a was predicted to target MYF5 and PPARγ, two important factors regulating 
brown adipogenesis, suggesting a role of this miRNA in cell fate. For the first 
time, a miRNA screening of human BAT was established and compared to 
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mouse BAT, identifying potential molecular mechanisms involved in BAT 
development and function. However, these results also identified a large 
number of miRNAs that were not commonly expressed in mouse and human 
BAT. These may be key miRNAs that influence the differences between mouse 
and human BAT function. The expression level of these human BAT-enriched 
miRNAs may have increased overtime as a reflection of the way humans have 
altered their control of body temperature. Therefore these BAT species-
enriched miRNAs should be considered carefully when translating results from 
mice to humans. 
In Chapter 3, human foetal CD34+/31- cells were established for the first time to 
have an enhanced capacity to differentiate into brown adipocytes in vitro when 
compared to the CD34+/31+ cells. The CD34+/31- cells were also observed to 
have a gene signature strongly indicating their capacity for brown fat-like 
activity. Forty-eight miRNAs were expression paired with 87 genes expressed in 
the CD34+ brown adipocytes and involved in cellular growth, proliferation and 
development. Five of these 48 miRNAs were enriched in mouse as well as 
human BAT, including miR-15a that was predicted to target the largest number 
of genes (16) present in the CD34+ brown adipocyte gene dataset. These results 
identify new targets for investigating the development and function of human 
BAT and skeletal muscle-derived CD34+ brown adipocytes as well as 
establishing the potential of these CD34+ brown adipocytes to increase EE in 
obese and T2D patients. 
In Chapter 4, cold exposure was shown for the first time to up-regulate 4 
miRNAs in skeletal muscle when compared to control. However, 2hrs at 16°C 
was not sufficient to increase the number of CD34+ cells in human adult skeletal 
muscle. Among these 4 miRNAs, miR-532-3p was the only one also commonly 
expressed in mouse and human BAT as well as in CD34+ brown adipocytes. 
These results indicate that miR-532-3p is predicted to target UCP3 mRNA, a 
gene known to be decreased during cold exposure. Furthermore these results 
suggest a role of miR-532-3p in adaptive thermogenesis. Adult CD34+ cells 
proliferated during early passages but did not fully differentiate in brown fat-
like cells. Further studies are required to confirm the capacity of these adult 
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CD34+ cells to differentiate into mature brown adipocytes and to validate the 
miRNAs that control their differentiation. 
 
V.2. Future directions 
Future studies need to focus more on the possibility of using miRNAs as a 
therapeutic tool, via gain and loss of function experiments in brown adipocytes 
and muscle cell models, as well as in rodents in vivo. As with all models of 
genetic manipulation, issues such as target and tissue specificity will be a major 
issue. Nevertheless, the potential of miRNA-based therapies offers an exciting 
and powerful alternative to attenuate and hopefully cure these devastating 
metabolic diseases. 
V.2.1. miRNA profiling of BAT-positive and BAT-negative 
human adults 
Rationale 
miRNAs are major regulators that can lead to disease when dysregulated. Study 
1 established the miRNA profile of BAT in human newborns. Recent studies 
have shown that human adult BAT can vary depending on age, sex and 
adiposity. BAT presence, volume and activity measurement are based on the 
detection of glucose uptake using 18F-FDG PET under cold exposure. Glucose 
uptake is detected in active human adult BAT in the supraclavicular and 
paraspinal regions under cold exposure. Hence the terminology BAT-positive 
and BAT-negative subjects has been used in clinical trials. This capacity to 
respond to cold exposure reflects BAT activity in human adults. A positive 
correlation between an increased BAT activity and an enhanced thermogenesis, 
as well as an inversed correlation between BAT activity and body fat content 
have been observed in human adults. These findings suggest that variation in 
BAT activity in human adults can be altered or might cause alterations in 
metabolism. Whether BAT-positive and BAT-negative human adults 
demonstrate variations in miRNA expression is not known. 
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Aims 
To establish the miRNA profiles of BAT-positive and BAT-negative human adults 
and compare these profiles with the active newborn BAT profile in order to 
identify potential miRNA dysregulation. 
Key methods 
Human adults undergoing routine neck surgery would be recruited for this 
clinical trial. 18F-FDG PET would be used to determine their glucose uptake into 
BAT under cold exposure and separate them between BAT-positive and BAT-
negative groups. Biopsies would be taken near the longus colli region of the 
neck, closest to a classical BAT phenotype. Subcutaneous fat biopsies would be 
taken for each subject as a control. Total mRNA and miRNA would be extracted 
from the fat samples. Reverse transcription and RT-PCR would measure brown 
fat markers (UCP1, LHX8 and CIDEA) and white fat markers (LEP and HOXC9) 
to ensure the phenotype of the samples. Megaplex™ Primer Pools and TaqMan® 
miRNA Array Cards (Life Technologies, CA, USA) and analysis would be 
performed as described in Chapter 2. Comparison would be made with human 
newborn miRNA arrays dataset obtained in Chapter 2. 
Significance 
Establishing the BAT miRNA profiles of BAT-positive and BAT-negative human 
adults might identify dysregulated miRNAs involved in BAT activation, as well 
as thermogenesis and energy balance. Furthermore, comparing these profiles to 
a newborn miRNA profile might help to understand the miRNAs regulated 
during growth and development of this tissue. These findings may lead to the 
identification of potential therapeutic targets to increase BAT growth and 
activity in human adults and increase EE in obese populations.  
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V.2.2. Uncoupled respiration in response to a β-adrenergic 
stimulation in CD34+ cell population 
Rationale 
In Chapter 3, CD34+/31- cells were identified as a brown fat progenitor cell 
population inside human skeletal muscle. Morphological and mRNA studies 
established their brown fat phenotype with multilocular lipid droplets and 
expressing UCP1, LHX8 and CIDEA. Furthermore, function and metabolic 
pathway analyses based on the mRNA profile of these CD34+ brown adipocytes 
were performed. An enrichment of the up-regulated mRNAs in lipid metabolism, 
energy production pathways and more specifically in fatty acid β-oxidation was 
identified, suggesting an active role in EE. Classical brown adipocytes respond 
to a β-adrenergic stimulation by increasing their uncoupled respiration. 
However measurement of oxygen consumption in these CD34+ brown 
adipocytes has not been investigated.  
Aims 
To confirm that CD34+ brown adipocytes are metabolically active and are able 
of uncoupled respiration in response to a β-adrenergic stimulation.  
Key methods 
Experiments would be completed using the Seahorse XF24 Bioanalyzer 
(Seahorse Biosciences, MA, USA). CD34+ cells would be seeded in multiple 
Seahorse 24well plates for measurements during proliferation and 
differentiation. For each condition, one plate would be used for the 
measurement of mitochondrial function (including uncoupled respiration) and 
the other for substrate oxidation (glucose and FA oxidations). For the CD34+ 
proliferating cells, experiments would be started one day after plating. 
Differentiation would start on the same day in alternate plates using the 
adipogenic media as described in Chapter 3. Experiments on the CD34+ brown 
adipocytes would be conducted 9-11 days after differentiation. Cells would be 
starved for 24hrs in specific running media used for mitochondrial functions 
and glucose and FA oxidation, according to the manufacturer’s protocol. Basal 
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measurements would be taken before and after an injection of noradrenaline (1-
10μM) per well. For mitochondrial functions, measurement would be taken 
after an initial oligomycin injection, followed by a trifluorocarbonylcyanide 
phenylhydrazone (FCCP) injection and finally an antimycin injection. For 
substrate oxidations, measurements would be taken after a palmitate or glucose 
injection, followed by an insulin injection in all wells. Normalisation would be 
done by cell counts using CyQuant® cell proliferation assays. 
Significance 
These results would confirm that these CD34+ brown adipocytes are 
metabolically active and can be activated by a β-adrenergic stimulation as 
observed in classical BAT. If the proliferation, differentiation and activation of 
these cells can be manipulated inside of muscle, it might increase EE and 
lipolysis. Therefore these cells could become potential targets to decrease lipid 
accumulation and restore the signal to insulin in obese and T2D subjects. 
V.2.3. Over-expression and knock-down of specific miRNAs 
in CD34+ proliferating cells and mouse brown pre-adipocytes 
Rationale 
In Chapters 2, 3 and 4, specific miRNAs were identified as potential molecular 
regulators of brown adipogenesis. miR-20a was highly expressed in mouse and 
human BAT and predicted to target MYF5 and PPARγ, two important brown fat 
regulators. miR-15a expression was increased in CD34+ brown adipocytes and 
predicted to target a large number of mRNAs involved in cellular growth, 
proliferation and development. Furthermore, miR-15a was also expressed in 
mouse and human BAT, suggesting a conserved role in brown fat development. 
Finally miR-532-3p was one of four miRNAs increased by cold exposure in 
human skeletal muscle when compared to control. Additionally, miR-532-3p 
was expressed in human and mouse BAT, as well as being up-regulated in CD34+ 
brown adipocytes predicted to target mRNAs involved in growth, proliferation 
and development. miRNA studies in BAT have just started identifying specific 
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miRNAs regulating brown adipogenesis such as miR-133, -155, -193b-365 and -
196a.  
Aims 
To establish the role of miR-20a, -15a and -532-3p in CD34+ cells and mouse 
brown pre-adipocyte differentiation in mature brown adipocytes. 
Key methods 
CD34+ cells would be cultured as described in Chapter 3. Primary mouse pre-
adipocytes would be extracted and cultured as described in [147]. Ambion® 
Pre-miR™ miRNA precursors and Ambion® Anti-miR™ miRNA inhibitors would 
be used to over-express or knock-down the specific endogenous miRNAs. Cells 
would be transfected during proliferation with miRNA precursors and 
inhibitors using siPORT™ NeoFX™ Transfection Agent. To assess the transfection 
efficiency, cell controls would also be transfected with an Anti-miR Negative 
Control (Cy™3 dye-labelled Ambion® Anti-miR™ Negative Control #1) and Pre-
miR Precursor Negative Control (Cy™3 dye-labelled Ambion® Pre-miR™ 
Negative Control #1). Differentiation would be induced 24-48hrs after 
transfection using adipogenic media. Photos would be taken every 2 days. Total 
mRNA and miRNA would be extracted. Reverse transcription and RT-PCR would 
measure brown fat markers (Ucp1, Lhx8 and Cidea), white fat markers (Lep and 
Hoxc9) and myogenic markers (myogenic, MyoD and Srf) to ensure the 
phenotype of the differentiated cells. miRNAs would be specifically reversed 
transcripted using TaqMan® MicroRNA RT Kit and specific TaqMan® 
MicroRNA Assays to confirm the over-expression and knock-down of the 
miRNAs transfected.  
Significance 
These results would identify specific brown fat regulators and therefore open a 
new avenue to develop therapeutic strategies manipulating these miRNAs. If 
successful, this could lead to an increase in skeletal muscle derived-brown fat 
progenitor proliferation and BAT development, as well as an enhancement of 
their activity thereby restoring energy balance in obese and T2D populations. 
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Appendices 
 
Appendix 1: Muscle-enriched and WAT-enriched miRNAs, and miRNAs commonly enriched in 
mouse muscle and WAT.  
Mouse tissues 
Muscle-enriched 
miRNA ID 
WAT-enriched 
miRNA ID (1/2) 
WAT-enriched 
miRNA ID (2/2) 
Muscle & WAT-
enriched miRNA ID 
miR-1193 let-7a# miR-297a# miR-136# 
miR-1943 let-7d# miR-299 miR-143 
miR-206 let-7g# miR-29a# miR-196a 
miR-211 miR-10b# miR-30b# miR-213 
miR-466b miR-1186 miR-30c-2# miR-214# 
miR-489 miR-1188 miR-31# miR-299-5p 
miR-493 miR-1191 miR-326 miR-340 
miR-493-3p miR-1195 miR-327 miR-421 
miR-673-3p miR-125b# miR-33a# miR-10b 
miR-675-3p miR-1306 miR-344 miR-1198 
miR-704 miR-144 miR-345 miR-1839-5p 
 miR-147 miR-347 miR-186# 
 miR-148a# miR-34b-5p miR-1897-5p 
 miR-15a# miR-362-5p miR-1905 
 miR-15b# miR-376a# miR-1954 
 miR-17# miR-376a# miR-196b 
 miR-1894-3p miR-377 miR-2182 
 miR-1896 miR-465a-3p miR-2183 
 miR-1940 miR-465b-5p miR-337 
 miR-1957 miR-466a-3p miR-369-3p 
 miR-1961 miR-466g miR-376b# 
 miR-1981 miR-466J miR-504 
 miR-200a# miR-467a miR-539 
 miR-200b miR-467b miR-590-5p 
 miR-200c miR-485-3p miR-615-5p 
 miR-20a# miR-632 miR-665 
 miR-216b miR-669n miR-696 
 miR-217 miR-676# miR-29c# 
 miR-27a# miR-712 miR-350 
 miR-28-3p miR-743a 
 miR-292-3p miR-744# 
 miR-293 miR-878-3p 
 miR-295 miR-99a# 
 miR-296-3p  
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Appendix 2: Flow chart of the miRNA array analysis in mouse tissues.  
 
To define miRNAs enriched in mouse BAT, comparisons were made between 
BAT, muscle and WAT as described in the flowchart. From the 750 miRNAs 
measured 433 miRNAs were expressed at least in one tissue. The Venn diagram 
represents the tissue distribution of these 433 miRNAs. Six miRNAs were 
exclusively expressed in BAT. Nineteen miRNAs (circled) were expressed only 
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in BAT and WAT, with 4 of these significantly higher in BAT tissue. Three 
miRNAs were expressed only in BAT and muscle, but none were significantly 
elevated in BAT. There were 298 miRNAs (circled) commonly expressed in the 3 
tissues, of which 223 were differentially expressed. Post-hoc analyses identified 
that 57 miRNAs were differentially expressed between the 3 tissues (p<0.05 in 
3 combinations, i.e. BAT vs WAT, WAT vs muscle and muscle vs BAT). As shown 
in the heat map, an additional 19 miRNAs (framed in red) had a higher 
expression level in BAT in comparison to muscle and WAT. Post-hoc analyses 
also identified 166 miRNAs (table on the right of the heat map) that were 
specifically expressed in 1 or 2 tissues (p<0.05 in one or two of the 
combinations mentioned above). Another 35 miRNAs had higher expression 
levels in BAT vs muscle and WAT. So when adding all the significant highly 
expressed miRNAs found in BAT (6+4+19+35), a list of 64 BAT-enriched 
miRNAs was obtained. 
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Appendix 3: Table of the 35 mouse BAT-enriched miRNAs and their predicted gene targets 
involved in cellular growth, proliferation and differentiation. 
(1/7)  
miRNA ID Gene Symbol 
let-7g 
ABL2, ACP1, ACTA1, ACVR1B, ACVR1C, ACVR2A, ACVR2B, ADCY9, ADRB1, 
ADRB2, ADRB3, AGO1, AGO3, AGO4, AKT2, APC2, ARHGEF7, BCL2L1, CALM1 
(includes others), CAPN3, CASP3, CBL, CCND1, CCNF, CD86, CDC34, 
CDC42SE1, CDK6, CDKN1A, CHUK, CLDN12, CLDN16, CPSF4, CSNK1D, 
DOCK3, DPYSL3, DSP, DVL3, EEF2K, EIF2S2, EIF3J, EIF4G2, ELF4, EPB41, F2, 
FAM208A, FAS, FASLG, FGF11, FGF5, FRS2, FZD3, FZD4, GAB2, GHR, GLRX, 
GNAL, GNAT1, GNG5, GRIK2, GYS1, HAND1, HMOX1, HRAS, IGF1, IGF1R, 
IGF2BP1, IKBKAP, IKBKE, IL10, IL6, INSR, IRS2, ITGA11, ITGB3, ITGB8, 
KPNA1, KPNA4, KRAS, LIMK2, MAP3K1, MAP3K2, MAP3K3, MAPK11, 
MAPK9, MEF2C, MEF2D, MLLT4, MYC, NAPEPLD, NEDD4, NGF, NOS1, NRAS, 
NTRK3, NXN, OSMR, PAK1, PDGFB, PHC3, PLA2G3, PLD3, POLR2C, POLR2D, 
POLR3D, PPP2R2A, PRKAA2, PRKAB2, PTGS2, RAB8B, RAG1, RALB, RANBP2, 
Ras, RB1, RHOB, RHOG, RICTOR, RPL36A/RPL36A-HNRNPH2, RPS6KA3, 
SMAD2, SMARCAD1, SOCS4, SOCS7, TAB2, TGFBR1, TGFBR3, TP53, TSC1, 
TSPAN2, VIM, WASL, WNT1 
miR-107 
ABL2, ACTG1, ACTR2, ACVR2B, AGO1, AGO2, AGO3, AGO4, AK2, ARHGAP5, 
ARNT, BDNF, CAB39, CAMK2G, CASP3, CCNE1, CD80, CDK6, CLIP1, CREB5, 
CRKL, CSNK1G2, CTNND1, DLL1, DPYSL3, EIF1AX, EIF4B, EIF4EBP2, EIF5, 
EOMES, EXOC5, FASN, FERMT2, FGF18, FGF2, FGF5, FGF7, FGFRL1, FIGF, 
FNBP1L, FZD4, GIT2, GNAI3, GRIA4, IRS2, ITGA2, JAK1, KPNA1, KPNA3, 
KPNA4, MAP3K3, MEF2D, MYH9, NEDD9, NOS1, NOTCH2, NRP2, PHC1, 
PIK3R1, PLA2G2F, PLCB1, PPP2R5C, PPP3R1, PRKAB2, PRKCE, PRKCI, 
PRKG1, PVRL1, REST, RIF1, RPL34, RPS6KA3, S1PR3, SALL4, SH2D2A, 
SLC23A1, SLC2A3, SOCS7, SOS1, SYNJ1, TGFBR2, TGFBR3, TJP1, TNPO1, 
TRAF3, TSPAN5, VCL, WNT16, WNT3A, WNT4, YWHAH, ZYX 
miR-351 
ABL1, ABL2, ACACB, ACVR1C, ADCY1, AGGF1, AGO2, AKT1S1, ANGPT2, APC, 
ARF3, BCL2, BMPR1B, BMPR2, CASP6, CASP7, CBLL1, CDC42SE1, CDK6, 
CDKN2A, CGN, CLDN12, CPSF6, CREB1, CSNK1G1, CSNK2A1, DOCK3, 
DPYSL4, DVL3, EIF2B5, EIF4EBP1, ELAVL1, EPO, ETS1, FGF14, FGF9, FGFR1, 
FGFR2, GAB2, GDNF, GRB10, GRIN2A, ID1, ID2, ID3, IGFBP3, ITGA9, ITGB3, 
JARID2, KPNA6, LIF, LIFR, LIMK1, MAP2K7, MAP3K1, MAP3K10, MAP3K11, 
MAP3K13, MAP3K3, MAPK12, MAPK14, MAPKAPK2, MAPRE2, MCL1, 
MEF2D, MYO7A, NEDD9, PAPOLA, PCGF6, PIK3C2B, PIK3CD, PIK3R5, 
PLXNA1, PPAT, PPM1A, PPP1CA, PPP2CA, PPP2R4, PPP2R5C, PRKAA2, 
PVRL2, RAB8B, RAF1, REST, RHOQ, RHOT2, RND2, RPS6KA1, SEMA4D, 
SLC23A2, SMAD2, SMAD4, SMARCD2, SMO, SMURF1, SOCS4, SP1, SPTB, SRF, 
STAT3, TP53, TRAF6, TXNRD1, TXNRD3, VDR, VEGFA, YES1, YWHAG 
miR-126-3p CRK, CRKL, GNA13, IRS1, PIK3R2, VEGFA 
miR-129-3p ACACA, EIF2AK3, EIF3J, FRS2, KPNA4, MAP3K1, PARP1, RHOU, TNFRSF11A 
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Appendix 3: (2/7) 
miRNA ID Gene Symbol 
miR-132 
ACVR1, ACVR2B, ADCY1, ADCY3, AGO1, ARHGAP5, BMP3, BRCA1, CAPN8, 
CBLL1, CDC42BPA, CDKN1A, CFL2, CHRNA5, CPSF6, CREB5, CRK, CTGF, 
DIAPH1, DPYSL3, EIF2S3, EIF4A2, EP300, EPB41, FGF7, FGFR3, FOXA1, 
FOXO1, FOXO3, FRS2, GAB1, GNA12, GNB1, GRM3, GSK3B, ISL1, KDM5B, 
KITLG, KPNA1, MAP3K3, MAPK1, MAPK3, MAPKAP1, MAPT, MEF2A, MEIS1, 
MITF, MMP9, NFAT5, PAIP2, PAPOLA, PIK3R3, PPP2CB, PPP2R5C, PPP2R5E, 
PPP3CA, PRKD1, PTCH1, PXN, RAP2B, RASA1, RB1, RHOQ, RPL13A, SLC23A2, 
SLC2A1, SMAD2, SMAD5, SOD2, TCF7L1, TCF7L2, TJAP1, TJP1, TLN2, 
YWHAG 
miR-140 
ACACA, ADCY6, BCL2L1, BMP2, CAPN1, CDYL, CREB1, DNM3, DPYSL2, 
EIF4G2, FGF9, GIT1, GLI3, GNA13, GNG12, GYS1, IGF1R, IGF2BP1, IGFBP5, 
KAT2B, LIFR, LMO7, MAGI2, MAPK1, MEF2D, MYH9, NFAT5, PAX6, PDGFRA, 
PITX2, PPP1CC, PPP1R12A, PPP2R3A, RALA, RAP1B, RHOU, RPS6KA3, 
RPS6KA6, SLC2A1, SMAD3, SMURF1, SOCS7, SYNJ1, TGFBR1, VEGFA, WASF1, 
WNT1, YES1 
miR-142-3p 
ABL2, ACVR2A, ADCY9, AKT1S1, APC, ARHGEF12, BCL2L1, CD8A, CFL2, 
CHRNE, CLDN12, CRK, CTNND1, CTTN, EPN1, FGF9, FKBP1A, FOXO1, GAB1, 
GHR, GNAQ, GNB2, HGS, IL6ST, INPP5F, ITGAV, ITGB8, ITPR3, KAT2B, LIFR, 
MAP3K11, MYH10, MYH9, MYLK, NR2F6, PIK3CG, PIK3R6, PLCB1, PPP3CA, 
PPP3R1, RAC1, RHEB, RICTOR, ROCK2, S1PR3, SH3GLB1, SOCS6, TAB2, 
TGFB2, TGFBR1, TNFRSF13C, WASL, XIAP, XPO1, ZEB1 
miR-150 
ACVR1B, AKT3, APC, CAMK2G, CAPN6, CAST, CBL, CDKN1B, CNGB1, CSF3, 
EIF4B, EIF4E, ELK1, EP300, FOXD3, FZD4, GAB1, GRB7, GSK3B, HOXC9, 
IGF2BP1, IL7, IPO5, ITGAX, ITGB3, MAP2K4, MAP3K12, MAPK13, NOTCH3, 
NTRK2, PARVA, PDGFB, PIM1, PRKAR1A, PRKCA, PVRL2, SLC2A1, SLC2A4, 
SOCS7, SP1, TEK, TP53, UBTF, VEGFA, ZEB1 
miR-155 
ABL2, ACTA1, ACVR2A, ACVR2B, AGO4, AGTR1, APC, BDNF, CAB39, CBL, 
CCND1, CLDN1, CREB1, CSF2RB, CSNK1G2, CTNNB1, CYR61, EPAS1, ETS1, 
F2, FGF7, FGF9, FOS, FOXO3, FZD5, GNA13, GNAS, GSK3B, IKBKE, IL6ST, 
INPP5D, ITK, JARID2, KDM5B, KPNA1, KPNA4, KRAS, MAP3K10, MAP3K13, 
MAP3K14, MEF2A, MEIS1, MET, MYLK, NFAT5, PAK2, PHC3, PIK3R1, 
PRKAR1A, PRKCI, RAB5C, RAP1B, RELA, RHEB, RHOA, RHOQ, RICTOR, 
RPS6KA3, RPS6KA6, RPTOR, S1PR1, SKI, SMAD1, SMAD2, SMARCA4, 
SMARCAD1, SOCS1, SOCS6, SOS1, SOX10, SP1, SP3, TAB2, TCF4, TCF7L2, 
TGFBR2, TRAF3, TXNRD1, TYRP1, YWHAE, YWHAZ, ZIC3 
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Appendix 3: (3/7) 
miRNA ID Gene Symbol 
miR-15a 
ABL2, ACACA, ACTR2, ACVR2A, ACVR2B, AGO1, AGO4, AK4, AKT3, 
ARHGAP26, ARHGAP5, ATG13, BAIAP2, BCL2, BDNF, BMI1, BMPR1A, CAB39, 
CALM1 (includes others), CAPN6, CCND1, CCNE1, CD80, CDC42, CDC42EP2, 
CDK6, CFL2, CHP1, CHRNE, CLDN12, CLDN2, CREB5, CRKL, DIAPH1, DLL1, 
DRD1, EGFR, EIF2B5, EIF3A, EIF4B, EIF4E, EIF4G2, EXOC5, F2, FASN, 
FERMT2, FGF1, FGF18, FGF2, FGF7, FGF9, FGFR1, FIGF, FKBP1A, FOXO1, 
FRS2, FZD10, FZD4, FZD6, GHR, GIT1, GLRX, GNA12, GNA13, GNAI3, GNAT1, 
GRB10, GRIN1, GRM7, HMOX1, HSP90B1, HTR2A, HTR2C, IGF1, IGF1R, 
IKBKB, IL15, INSR, IRS1, IRS2, ITGA10, ITGA2, JARID2, JUN, KDR, KPNA1, 
KPNA3, KPNA4, KRAS, LIMS1, LIPE, MAP2K1, MAP2K4, MAP3K13, MAP3K4, 
MAP3K9, MAPK9, MAPRE1, MCL1, MKNK1, MRAS, MYLK, MYLK3, NAPEPLD, 
NFATC3, NOS1, NOTCH2, NRP2, OCRL, OTX1, PAK2, PAK7, PFKFB4, PHC3, 
PIK3C2A, PIK3R1, PIM1, PLCD1, PLXNB1, PPAP2B, PPM1A, PPM1D, 
PPP2R1A, PPP2R5C, PRKAB2, PRKAR2A, PRKCD, PRKG1, PTCH1, PTCH2, 
PTGS2, PTPRM, PVRL1, PVRL2, RAB8B, RAD9A, RAF1, RAPGEF1, RHOT1, 
RICTOR, RIF1, RPS6KA3, RPS6KA6, SALL4, SEMA3A, SH2D2A, SKI, SKIL, 
SLC2A3, SMAD3, SMAD5, SMAD7, SMURF1, SMURF2, SOCS6, SOS1, SOS2, 
SPTBN2, SYNJ1, TBP, TCF3, TGFBR3, TNFSF13B, TNPO1, TRAF3, TRAF6, 
TSC1, TSPAN5, TUBA1A, TXNRD3, VAV2, VEGFA, WASL, WIPF1, WNT3A, 
WNT4, WNT5B, WNT7A, YWHAH, YWHAQ, ZAK, ZFHX3, ZNF423, ZYX 
miR-20a 
ABL2, ACVR1B, ADRA1B, AGO1, AK4, AKT3, ARHGAP1, ARHGAP26, 
ARHGEF7, BCL2, BMP2, BMPR2, CASP7, CCND1, CDK6, CDKN1A, CFL2, 
CNGB3, CREB1, CREB5, CRK, CSNK1G1, DNM2, DPYSL2, DPYSL5, DRD1, 
E2F1, EIF4G2, ELK3, EPB41, F2R, FGD1, FGF12, FGF4, FGF5, FLT1, FNBP1L, 
FOXA1, FRS2, FZD3, FZD4, FZD7, GAB1, GIT2, GNB5, GUCY1A3, HIF1A, 
IGF2BP1, IL6ST, IL8, ITGA4, ITGB8, ITPR2, JAK1, KAT2B, KPNA2, KPNA3, 
KPNA4, LIF, LIMK1, MAP3K1, MAP3K11, MAP3K12, MAP3K13, MAP3K14, 
MAP3K2, MAP3K3, MAP3K5, MAP3K8, MAP3K9, MAPK1, MAPK9, MAPRE1, 
MAPRE3, MCL1, MEF2D, MTMR2, MYF5, NAPEPLD, NEUROG1, NFAT5, 
NRP2, NTRK3, OCRL, OSM, PAK7, PAPOLA, PDGFRA, PFKFB3, PFKP, PHC3, 
PIK3R1, PLA2G6, PLCB1, PLS1, PLXNA1, PPARG, PPM1A, PPP2CA, PPP2R2A, 
PPP2R3A, PPP3R1, PRKACB, PTEN, RAB5B, RAB8B, RAPGEF1, RB1, REST, 
RHOC, RND3, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6KA5, RPS6KA6, 
RUNX1, RUNX3, S1PR1, SEMA7A, SKI, SLC2A4, SMAD4, SMAD5, SMAD6, 
SMAD7, SMURF1, SOCS6, SOCS7, SOS1, SSX2IP, STAT3, STK11, TCF4, TCF7L1, 
TGFB1I1, TGFBR2, TNFSF11, TNS1, ULK1, VASP, VAV2, VCL, VEGFA, VIM, 
XIAP, YES1, ZFYVE9 
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Appendix 3: (4/7) 
miRNA ID Gene Symbol 
miR-182 
ABL2, ACTR2, ACVR1, ACVR1B, ACVR2B, ADCY2, ADCY6, ADRA2C, AGO1, 
ANGPTL1, APC, ARF4, ARHGEF12, ARHGEF7, ASAP1, BCL2, BDNF, BMPR1B, 
CAPN5, CASP9, CDC37, CDC42BPA, CDK6, CEBPA, CFL1, CNGA3, CREB1, 
CRKL, CSNK1E, CTTN, EIF2S1, EIF3J, EIF4EBP2, EIF5, ELAVL1, EOMES, 
EPAS1, EXOC4, FGF9, FIGF, FLNB, FLT1, FN1, FNBP1L, FOXO1, FOXO3, FRS2, 
FZD3, FZD5, GDNF, GIT2, GNA13, GNAI3, GNAQ, GRB2, GRIA1, GRIA3, GRID1, 
GRIK3, GRM5, HTR2C, IGF1R, IGF2BP1, INSR, ISL1, ITGB8, KPNA1, KPNA3, 
KPNB1, L1CAM, LIMS1, MAGI1, MAP3K3, MAPRE1, MAPRE2, MEF2C, MEF2D, 
MET, MITF, MRAS, NPM1, NUDT21, OCRL, PAIP1, PAIP2, PAX6, PDGFRA, 
PIK3R1, PLCB4, PLCG1, PLD1, PPM1A, PPP1R12A, PPP2R3A, PPP3CA, 
PPP3R1, PRKAA2, PRKACB, PRKAR1A, PRKCE, PRKD1, RAB8B, RAC1, RALB, 
RASA1, RHOJ, RHOQ, RICTOR, ROCK1, RPS6KA6, RSU1, S1PR2, SLC23A2, 
SMAD1, SMAD7, SOCS7, SOS1, SOX2, SP3, TCF7L1, TCF7L2, TNFSF11, TNPO1, 
TNS1, TOB1, TSPAN4, VAV2, VCL, WASF2, WIPF1, WNT5A, YES1, YWHAG, 
ZAK, ZIC3 
miR-18a 
ATM, CDK2, CDKN1A, CTGF, E2F1, FGF1, FGFR3, FNBP1, FOXH1, FRS2, 
HIF1A, IGF1, INPPL1, KDM5B, KIT, KPNA6, LIF, MAP3K1, MEF2D, MYLK, 
NEDD4, NEDD9, NFAT5, NOS1, NOTCH2, OCRL, OTX1, PHC3, PIAS3, RAB5A, 
RAB5C, RUNX1, SIX3, SMAD2, YBX3, YWHAB, ZAK 
miR-193 
ADCY9, ARHGEF12, ARNT, ATM, CALM1 (includes others), CCND1, CHRNB1, 
DVL3, EIF2AK1, EIF4B, ETS1, FGF1, GNAO1, GRB7, HOXC9, IGF2BP1, IGFBP5, 
ITPR2, KIT, KRAS, LIMS1, MAP3K3, MAPK10, MCL1, NFKBIE, OSMR, PLAU, 
POLR2J2/POLR2J3, PPP2R5C, PTK2, SF3A1, SLC23A2, SOS2, TCF4, TGFB2, 
TGFBR3, TSC1, UBA52, YWHAZ 
miR-19a 
ACTN1, ADCY1, ADCY7, ADCY9, ADRB1, AGO1, AK3, AK4, ARHGAP1, 
ARHGAP5, ARHGEF12, BCAR3, BMP3, BMPR2, CAB39, CALM1 (includes 
others), CAST, CCND1, CDC42BPA, CGN, CLIP1, CNGA3, CNR1, CNTFR, 
CREB5, CRMP1, CSF2RB, CSNK1G1, CTGF, DBN1, DOCK3, DPYSL5, EIF4A2, 
EIF4G2, ELAVL1, ELK3, EPN2, EXOC5, FGF6, FLNC, FRS2, FZD3, FZD6, GIT2, 
GRB10, GRIN2A, GSC, GSK3B, ID2, IGF1, IGFBP3, IL6ST, INHBB, ITGA11, 
ITGA2, ITGA6, ITGB3, ITGB8, JARID2, KIT, KPNA3, KPNA4, KPNA6, KRAS, LIF, 
MAGI2, MAP2K3, MAP3K12, MAP3K14, MAP3K2, MAPK1, MAPK14, MEF2A, 
MEF2C, MEF2D, MPRIP, NEUROG1, NRP2, OCRL, PAK6, PAX6, PFKFB3, 
PIK3C2A, PIK3CA, PIK3R3, PLA2G10, PLCL1, PLCL2, PPM1A, PPP1R12A, 
PPP2R4, PPP2R5A, PPP2R5E, PRKAA1, PRKAA2, PRKACB, PRR5L, PTEN, 
PTK2B, RAB5B, RAB8B, RAF1, RAP1A, RAP1B, RAP2B, REST, RFX4, RHOB, 
RICTOR, RPS6KA2, RPS6KA5, RUNX3, S1PR1, S1PR2, SLC2A1, SMAD4, 
SMAD5, SMARCA2, SMARCD2, SMURF1, SOCS1, SOCS3, SOCS5, SOCS6, 
SPHK2, STAT2, TGFBR2, TGIF1, TLN2, TNF, TNIP1, TSC1, VAV2, WNT1, 
WNT10A, WNT3, WNT7B, XIAP, YES1, ZAK, ZFYVE9 
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Appendix 3: (5/7) 
miRNA ID Gene Symbol 
miR-203 
ABL1, ACVR2A, ACVR2B, ADCY9, AK4, AKT2, ANGPTL1, APC, ARHGAP1, ATM, 
BIRC5, BMI1, CAB39, CAV1, CBL, CLDN1, CNTFR, CREB1, CREB3, CRK, CUL1, 
DGKZ, DNM1L, EIF4E, ETS2, FAM208A, FGF2, FGF5, GLI3, GNG2, GNG4, 
GYS1, HLA-DOA, HTR2A, HTR2C, ID4, IGFBP5, IL15, IRS2, ITGA2, ITGAV, 
ITPR2, KAT6A, KPNB1, KRT1, LIFR, MAGI1, MAP3K1, MAP3K13, MAP3K2, 
MAPK10, MAPK9, MAPRE1, MEF2C, MLLT4, NEDD9, NR5A2, NUDT21, OCLN, 
PDGFD, PDGFRA, PHC3, PIK3CA, PIK3CD, PLD1, PLD2, PPAP2B, PPM1A, 
PPM1D, PPP1CB, PPP1R12A, PRKAB1, PRKAB2, PRKAG2, PRKCA, PRKCB, 
PRKCI, PTCH1, PTPN1, PXN, RALB, RAP1A, RAP2A, RAPGEF1, RHOQ, 
RPL23A, RUNX2, SEMA3A, SIX3, SLC2A3, SMAD3, SMAD9, SMURF1, SNAI2, 
SOCS3, SOCS6, SOCS7, SP1, SP4, SPTBN1, SRC, SYNJ1, TCF12, TCF4, TESK1, 
TGFB2, TNPO1, VEGFA, YWHAQ, ZAK, ZEB1, ZFHX3 
miR-26b 
ABL2, ACVR1C, ACVR2B, AGO1, ARHGAP26, ARHGEF12, ATF2, CBLL1, CDH2, 
CDK6, CNR1, CPSF2, CREB1, CREBBP, CSNK1G1, CTGF, EIF2S1, EIF3A, 
EIF4G2, EIF5, FAM208A, FGD1, FGF9, GATA4, GNA13, GRB10, GSK3B, HGF, 
HNF1B, HOXC9, HTR2C, IGF1, INHBB, ITGA4, ITGA5, ITGA6, ITGB8, ITPR1, 
JARID2, KPNA2, KPNA3, KPNA6, LEF1, LIF, LIFR, LIMS1, MAP3K1, MAP3K2, 
MAP3K9, MCL1, MEF2C, MITF, MRAS, MYH10, MYLK3, NRAS, OCLN, PAK2, 
PFKFB2, PFKFB3, PIK3C2A, PIK3R3, PIM1, PLCB1, PLCL1, PPM1B, PPP2R3A, 
PPP2R5A, PPP3CB, PPP3R1, PRKAA2, PRKAG2, PRKCD, PRKCQ, PRR5L, 
PTEN, PTGS2, RAP1A, RB1, REST, RHOQ, RHOU, RPS6KA2, RPS6KA6, SLC2A3, 
SMAD1, SMAD2, SMAD4, SOCS6, SOCS7, SPTBN1, SSX2IP, TCF12, TCF7L2, 
TGFBR2, TNPO1, TOB1, TRAF3, TXNRD3, UBTF, ULK1, WDR33, WNT5A, 
WWP2, YWHAE, ZFHX3 
miR-30b 
ABL1, ABL2, ACTC1, ACTN1, ACVR1, ADRA1D, ADRA2A, ADRA2B, ADRB1, 
AGO1, AGO3, ARHGAP26, ARHGEF6, ARPC5, BCL2, BDNF, BMP7, CAMK2D, 
CAMK4, CAPN5, CCNE2, CFL2, CNGB3, CPSF6, CRKL, CSNK1A1, CSNK1G1, 
CTGF, DDIT4, DGKZ, DPYSL2, EPB41, EPN2, F2, FOXA1, FOXO3, FRS2, FZD2, 
FZD3, GDNF, GLI2, GNA13, GNAI2, GNAO1, GNG10, GRB10, GRIA2, GRIN2A, 
GRM3, GRM5, GUCY2C, IGF1, IGF1R, IL1A, IRS1, IRS2, ITGA2, ITGA4, ITGA5, 
ITGA6, ITGB3, JAK1, JARID2, JUN, KPNA3, KPNA6, KRAS, LIFR, LYN, MAGI2, 
MAP3K1, MAP3K12, MAP3K13, MAP3K2, MAP3K5, MEF2D, MET, MPL, 
MYH10, MYH11, NEDD4, NFAT5, NFATC3, NOTCH1, NR2F2, NR5A2, NRP2, 
PAPOLA, PAX3, PDGFRB, PHC3, PIK3CD, PIK3R2, PLCB4, PLCG1, PLS1, 
PLXNA1, PPP1R12A, PPP2R4, PPP3CA, PPP3CB, PPP3R1, PRKAR1A, RAB7A, 
RAP1B, RAP2B, RASA1, RHOB, RPS6KA2, RUNX1, RUNX2, SEMA3A, 
SERPINE1, SMAD1, SMAD2, SMARCD2, SNAI1, SNAI2, SOCS1, SOCS3, SOCS6, 
SOS1, SP4, SSX2IP, TCF7, THEM4, TIMP3, TNIP1, TNPO1, TP53, TRAF3, TSC1, 
TSPAN2, VAV2, WIPF1, WNT5A, WNT7B, XPO1, YWHAZ 
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miRNA ID Gene Symbol 
miR-320 
ACVR2B, AK4, AKT3, ANGPTL1, ARF1, ARHGAP26, ARHGAP5, ARPC5, ASH2L, 
BMI1, BMP3, BMP6, BMPR1A, CALM1 (includes others), CBL, CBLL1, CDH2, 
CDK6, CREB5, CRK, CRKL, CSNK1E, CSNK1G3, DBN1, DPYSL3, E2F1, EIF2B1, 
EIF4B, EPN2, EPO, ETS2, FAM208A, FGF9, FLNC, FOXO3, FZD3, GNAI1, GNAZ, 
GRB2, HLTF, ID4, IGF1, IGF1R, IPO5, ITGB3, KITLG, MAGI1, MAPK1, MAPK9, 
MCL1, MYH10, MYL12A, NFATC3, NRP1, ONECUT1, PAK7, PFKFB2, PFKM, 
PHC1, PIK3R1, PLCG1, PPP1CB, PPP2R2C, PPP2R5B, PRKAG2, PRKAR1A, 
PRKG1, PTEN, RAC1, RAD9A, RANBP2, RAP1A, RAP2B, RASA1, RPL15, RSU1, 
RUNX1, S1PR1, SEMA3A, SMAD4, SMARCD2, SMURF1, SP1, TGFBR1, 
TGFBR2, TNPO1, TSC1, TUBA8, ULK1, VIM, XIAP, XPO1, YES1, YWHAG, 
YWHAQ, YWHAZ, ZIC3 
miR-328 
ADCY1, ARPC4, CLDN19, CNR1, CPT1A, EIF4EBP1, ELF1, EPO, FGD1, FGF11, 
FOXA2, FZD3, FZD7, GLRX, IGF1R, IL5, IL8, ITGA5, MAGI1, MAP2K7, MAP3K9, 
MAPK14, NFATC4, PAK6, PHC3, PIM1, PLA2G4C, PLCE1, PNPLA2, PPP2R5D, 
SLC2A1, TCF7L2, TGFB2, TNS1, TSC1, TYR, WASF2, YWHAZ, ZAK 
miR-338-5P PHC3 
miR-345-3p CSNK2A1, TRAF5 
miR-365 
ACVR1, ACVR2B, ADCY6, AGO4, AKT3, BCL2, BDNF, CCND1, CHP1, CLDN11, 
CPT1A, CREB5, CSF2RB, CSK, CSTF1, EPAS1, ETS1, FGF1, FRS2, FZD3, FZD5, 
GNAT1, IL1A, ITGA10, MAP3K13, MAPK1, MEF2D, MEIS1, MTMR2, MYLK, 
PAX6, PIK3R3, PLCB4, PPM1D, PRKAR2A, PRKG1, RHEB, RICTOR, RPS6KA6, 
SEMA3A, SET, SKI, SMAD2, SOCS5, SOCS7, SOS1, SYNJ1, WNT5A, YWHAH 
miR-374-5p 
ACTN1, ACTN4, ACVR2B, ADCY1, ADRB1, AKT1, APC, ARHGAP5, ATF2, BMP2, 
CBL, CCND1, CEBPA, CLDN14, CNTFR, CREB1, CREB5, CSNK1G1, EIF2AK4, 
EIF2S2, EIF4G1, EIF4G2, EPAS1, EXOC5, FGF18, FGF5, FGF9, FGFR2, FLT1, 
FOXD3, FOXO1, FRS2, FZD5, GBX2, GNB2, ID4, IGFBP3, IL10, INHBB, ISL1, 
KAT6A, L1CAM, LPAR1, MAP2K4, MAP2K6, MAP3K2, MEF2D, MEIS1, MYLK, 
NCK1, NOG, NOTCH2, NR2F2, NTF3, OCRL, PABPC1, PAX6, PDPK1, PITX2, 
PPAP2B, PPP2R2A, PPP2R2C, PRKCA, PRKCD, PRKCE, PRKG2, PTEN, 
PTPN11, RAB5B, RFX4, RHOQ, RUNX1, SKI, SMAD5, SMAD6, SMARCAD1, 
SOCS4, SOS1, SP1, SP3, SP4, TCF4, VEGFA, WASL, WNT16, WNT5A, WNT5B, 
XIAP, ZNF423 
miR-423-5p 
ACACA, ACVR1B, AK1, BAIAP2, BMP8B, CALM1 (includes others), CALML5, 
CAPN5, CCNF, CD8A, CDC42SE1, CDKN1A, CLDN19, CLDN23, CRHR2, CSF1, 
DOCK1, DPYSL4, DVL1, EIF4EBP1, ELF4, EPN2, EXOC3, FGFR3, GNAI2, 
GRIK3, GRIN1, GRM2, GYS1, INPPL1, ITGA5, KEAP1, LIMK1, MAP3K14, 
MEF2D, MRAS, NFATC1, NFATC2, NOS1, NPM2, PAK6, PDGFRB, PDPK1, 
PLA2G2F, PLA2G6, PLCB1, PRKACA, RAC2, RCC1, RPS6KA4, S1PR3, SGSM3, 
SHC1, TGFBR3, TSPAN3, TUBB6, UBA52, WNT3A 
miR-450a-5p CREB1, GNA13, MEIS1 
miR-451 CAB39, CAV1, MEF2D, MYLK3, NEDD9, NR5A2, S1PR2, TSC1, TTN, YWHAZ 
miR-455 
ARHGEF12, ARNT, BMP8A, BMPR2, CAMK4, CAST, CDKN1B, CTNND1, EPN2, 
ETS1, FZD5, IGF1R, INPP5K, ITGB8, KDR, KPNA1, KPNA3, MKNK1, NCK2, 
PARD3, PARVA, PLD1, PPP1R12A, PRKCI, RAF1, RUNX2, S1PR1, SOCS3, 
SYNJ2, TJP1, TNPO1, TSPAN5, TUBB 
miR-484 
CSF1, F2RL3, FGF1, FLNB, HNF1A, MAGI1, MAPKAPK2, PDGFA, PIK3CD, 
TGFBR3, WNT2B 
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miRNA ID Gene Symbol 
miR-491 
ARF3, BCL2L1, CAMK2B, CAPN5, CSNK1G1, EXOC8, FGD1, GATA4, GIT1, 
GNAT1, IGF2, IGF2BP1, INPP5F, IQGAP3, ITGAX, KDM5B, LIMK1, MAP3K11, 
MAPKAP1, MPL, MYL9, PARVA, PDGFRA, PHC3, PTPN11, PVRL1, PXN, 
RAB7A, RND2, RPS24, RPTOR, SF3A1, SLC2A1, SNAI1, SPTB, TCF7, TNS1, 
TXNRD1 
miR-582-3p PHC3, SYK 
miR-542-3p 
ACVR1C, ANGPT2, BIRC5, BMP7, BMP8A, CBL, CDX2, CREB5, CSF3, EIF1, 
EIF5, ETS1, FIGF, FZD4, GDNF, GNB5, ILK, ITGB8, MAP3K11, MAPKAP1, 
MEIS1, MYH9, NRP2, PFKM, PIK3C2B, PIM1, PPP1CB, PPP2R1A, PRKAB1, 
PTEN, PTGS2, RPS6KA4, SIX3, SLC2A3, SPTBN1, SYNJ2, TLN2, TUBB2B, 
ZFHX3 
miR-671-3p CCNF, FGF11, GRB10 
miR-25 
ABL2, ACTC1, ADCY3, ADRB1, AGGF1, AGO3, ARF1, BMP7, BMPR2, CALM1 
(includes others), CAMK2A, CCNE2, CDC42, CDC42BPA, CDC42EP2, CDK6, 
CDKN1A, CEBPA, CFL2, CLDN11, CNR1, CREB1, DDIT4, EIF4G2, EOMES, 
EXOC5, FKBP1A, FRS2, FZD10, GATA6, GIT2, GRIA1, GRIA3, GRIA4, GRM2, 
HAND1, HNF1B, IL6ST, IQGAP2, IRS2, ITGA5, ITGA6, ITGAV, ITPR1, JARID2, 
KAT2B, MAP2K4, MAP3K13, MAP3K2, MCL1, MEF2D, MITF, MYH9, NFAT5, 
NOTCH1, PAIP1, PAX3, PFKFB4, PIK3R3, PPAP2B, PPP1R12A, PRKAB2, 
PRKAR1B, PRKAR2B, PRKCE, PTEN, PVRL1, RAB8B, RAG1, RAP1A, RAP1B, 
REST, RPL15, RPS6KA4, S1PR1, SEMA3A, SKI, SLC2A3, SMAD6, SMAD7, 
SMURF1, SNAI1, SOCS6, SP1, SPHK2, SYNJ1, TCF4, TGFB2, TGIF1, TNPO1, 
TOB1, TRAF3, TSC1, ULK1, VCL, WASL, WNT5A, WWP2, ZAK, ZFHX3 
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Appendix 4: Table of the 145 miRNAs commonly expressed in both human and mouse BAT.  
145 miRNAs commonly expressed in both human and mouse BAT 
let-7a miR-142-3p miR-19b miR-30d miR-433 
let-7b miR-143 miR-200c miR-30e-3p miR-451 
let-7c miR-145 miR-203 miR-320 miR-455-5p 
let-7d miR-146a miR-204 miR-323-3p miR-455-3p 
let-7e miR-146b miR-20a miR-324-3p miR-484 
let-7f miR-148a miR-20b miR-328 miR-486 
let-7g miR-149 miR-21 miR-331-3p miR-489 
miR-100 miR-150 miR-210 miR-335-5p miR-491 
miR-101a miR-151-3p miR-212 miR-337-5p miR-494 
miR-103 miR-151-5P miR-214 miR-338-5P miR-495 
miR-106a miR-152 miR-218 miR-339-3p miR-500 
miR-106b miR-155 miR-22 miR-339-5p miR-511 
miR-10a miR-15a miR-22# miR-340-5p miR-532-3p 
miR-10b miR-15b miR-222 miR-342-3p miR-532-5p 
miR-125a-5p miR-16 miR-223 miR-345-5p miR-574-3p 
miR-125b-5p miR-17 miR-224-5p miR-34a miR-598 
miR-126-3p miR-181a miR-24 miR-365 miR-652 
miR-127 miR-185 miR-25 miR-370 miR-664 
miR-130a miR-186 miR-26a miR-376a miR-7# 
miR-130b miR-18a miR-26b miR-376c miR-708 
miR-132 miR-191 miR-27a miR-378 miR-720 
miR-133a miR-192 miR-28 miR-379 miR-744 
miR-133b miR-193 miR-29a miR-382 miR-9 
miR-134 miR-193b miR-29c miR-409-3p miR-92a 
miR-138 miR-194 miR-301a miR-410 miR-93 
miR-139-3p miR-195 miR-30a miR-411 miR-93# 
miR-139-5p miR-197 miR-30a-3p miR-423-5p miR-99a 
miR-140 miR-199a-3p miR-30b miR-425 miR-99b 
miR-140-3p miR-19a miR-30c miR-431 miR-99b# 
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Appendix 5: Table of the 25 mouse BAT-enriched miRNAs in human BAT and their predicted 
gene targets involved in cellular growth, proliferation and differentiation. 
(1/5) 
miRNA ID Gene Symbol 
let-7g 
ABL2, ACP1, ACTA1, ACVR1B, ACVR1C, ACVR2A, ACVR2B, ADCY9, ADRB1, 
ADRB2, ADRB3, AGO1, AGO3, AGO4, AKT2, APC2, ARHGEF7, BCL2L1, CALM1 
(includes others), CAPN3, CASP3, CBL, CCND1, CCNF, CD86, CDC34, 
CDC42SE1, CDK6, CDKN1A, CHUK, CLDN12, CLDN16, CPSF4, CSNK1D, 
DOCK3, DPYSL3, DSP, DVL3, EEF2K, EIF2S2, EIF3J, EIF4G2, ELF4, EPB41, F2, 
FAM208A, FAS, FASLG, FGF11, FGF5, FRS2, FZD3, FZD4, GAB2, GHR, GLRX, 
GNAL, GNAT1, GNG5, GRIK2, GYS1, HAND1, HMOX1, HRAS, IGF1, IGF1R, 
IGF2BP1, IKBKAP, IKBKE, IL10, IL6, INSR, IRS2, ITGA11, ITGB3, ITGB8, 
KPNA1, KPNA4, KRAS, LIMK2, MAP3K1, MAP3K2, MAP3K3, MAPK11, 
MAPK9, MEF2C, MEF2D, MLLT4, MYC, NAPEPLD, NEDD4, NGF, NOS1, NRAS, 
NTRK3, NXN, OSMR, PAK1, PDGFB, PHC3, PLA2G3, PLD3, POLR2C, POLR2D, 
POLR3D, PPP2R2A, PRKAA2, PRKAB2, PTGS2, RAB8B, RAG1, RALB, RANBP2, 
Ras, RB1, RHOB, RHOG, RICTOR, RPL36A/RPL36A-HNRNPH2, RPS6KA3, 
SMAD2, SMARCAD1, SOCS4, SOCS7, TAB2, TGFBR1, TGFBR3, TP53, TSC1, 
TSPAN2, VIM, WASL, WNT1 
miR-126-3p CRK, CRKL, GNA13, IRS1, PIK3R2, VEGFA 
miR-132 
ACVR1, ACVR2B, ADCY1, ADCY3, AGO1, ARHGAP5, BMP3, BRCA1, CAPN8, 
CBLL1, CDC42BPA, CDKN1A, CFL2, CHRNA5, CPSF6, CREB5, CRK, CTGF, 
DIAPH1, DPYSL3, EIF2S3, EIF4A2, EP300, EPB41, FGF7, FGFR3, FOXA1, 
FOXO1, FOXO3, FRS2, GAB1, GNA12, GNB1, GRM3, GSK3B, ISL1, KDM5B, 
KITLG, KPNA1, MAP3K3, MAPK1, MAPK3, MAPKAP1, MAPT, MEF2A, MEIS1, 
MITF, MMP9, NFAT5, PAIP2, PAPOLA, PIK3R3, PPP2CB, PPP2R5C, PPP2R5E, 
PPP3CA, PRKD1, PTCH1, PXN, RAP2B, RASA1, RB1, RHOQ, RPL13A, SLC23A2, 
SLC2A1, SMAD2, SMAD5, SOD2, TCF7L1, TCF7L2, TJAP1, TJP1, TLN2, 
YWHAG 
miR-140 
ACACA, ADCY6, BCL2L1, BMP2, CAPN1, CDYL, CREB1, DNM3, DPYSL2, 
EIF4G2, FGF9, GIT1, GLI3, GNA13, GNG12, GYS1, IGF1R, IGF2BP1, IGFBP5, 
KAT2B, LIFR, LMO7, MAGI2, MAPK1, MEF2D, MYH9, NFAT5, PAX6, PDGFRA, 
PITX2, PPP1CC, PPP1R12A, PPP2R3A, RALA, RAP1B, RHOU, RPS6KA3, 
RPS6KA6, SLC2A1, SMAD3, SMURF1, SOCS7, SYNJ1, TGFBR1, VEGFA, WASF1, 
WNT1, YES1 
miR-142-3p 
ABL2, ACVR2A, ADCY9, AKT1S1, APC, ARHGEF12, BCL2L1, CD8A, CFL2, 
CHRNE, CLDN12, CRK, CTNND1, CTTN, EPN1, FGF9, FKBP1A, FOXO1, GAB1, 
GHR, GNAQ, GNB2, HGS, IL6ST, INPP5F, ITGAV, ITGB8, ITPR3, KAT2B, LIFR, 
MAP3K11, MYH10, MYH9, MYLK, NR2F6, PIK3CG, PIK3R6, PLCB1, PPP3CA, 
PPP3R1, RAC1, RHEB, RICTOR, ROCK2, S1PR3, SH3GLB1, SOCS6, TAB2, 
TGFB2, TGFBR1, TNFRSF13C, WASL, XIAP, XPO1, ZEB1 
miR-150 
ACVR1B, AKT3, APC, CAMK2G, CAPN6, CAST, CBL, CDKN1B, CNGB1, CSF3, 
EIF4B, EIF4E, ELK1, EP300, FOXD3, FZD4, GAB1, GRB7, GSK3B, HOXC9, 
IGF2BP1, IL7, IPO5, ITGAX, ITGB3, MAP2K4, MAP3K12, MAPK13, NOTCH3, 
NTRK2, PARVA, PDGFB, PIM1, PRKAR1A, PRKCA, PVRL2, SLC2A1, SLC2A4, 
SOCS7, SP1, TEK, TP53, UBTF, VEGFA, ZEB1 
miR-155 
ABL2, ACTA1, ACVR2A, ACVR2B, AGO4, AGTR1, APC, BDNF, CAB39, CBL, 
CCND1, CLDN1, CREB1, CSF2RB, CSNK1G2, CTNNB1, CYR61, EPAS1, ETS1, 
F2, FGF7, FGF9, FOS, FOXO3, FZD5, GNA13, GNAS, GSK3B, IKBKE, IL6ST, 
INPP5D, ITK, JARID2, KDM5B, KPNA1, KPNA4, KRAS, MAP3K10, MAP3K13, 
MAP3K14, MEF2A, MEIS1, MET, MYLK, NFAT5, PAK2, PHC3, PIK3R1, 
PRKAR1A, PRKCI, RAB5C, RAP1B, RELA, RHEB, RHOA, RHOQ, RICTOR, 
RPS6KA3, RPS6KA6, RPTOR, S1PR1, SKI, SMAD1, SMAD2, SMARCA4, 
SMARCAD1, SOCS1, SOCS6, SOS1, SOX10, SP1, SP3, TAB2, TCF4, TCF7L2, 
TGFBR2, TRAF3, TXNRD1, TYRP1, YWHAE, YWHAZ, ZIC3 
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miRNA ID Gene Symbol 
miR-15a 
ABL2, ACACA, ACTR2, ACVR2A, ACVR2B, AGO1, AGO4, AK4, AKT3, 
ARHGAP26, ARHGAP5, ATG13, BAIAP2, BCL2, BDNF, BMI1, BMPR1A, CAB39, 
CALM1 (includes others), CAPN6, CCND1, CCNE1, CD80, CDC42, CDC42EP2, 
CDK6, CFL2, CHP1, CHRNE, CLDN12, CLDN2, CREB5, CRKL, DIAPH1, DLL1, 
DRD1, EGFR, EIF2B5, EIF3A, EIF4B, EIF4E, EIF4G2, EXOC5, F2, FASN, 
FERMT2, FGF1, FGF18, FGF2, FGF7, FGF9, FGFR1, FIGF, FKBP1A, FOXO1, 
FRS2, FZD10, FZD4, FZD6, GHR, GIT1, GLRX, GNA12, GNA13, GNAI3, GNAT1, 
GRB10, GRIN1, GRM7, HMOX1, HSP90B1, HTR2A, HTR2C, IGF1, IGF1R, 
IKBKB, IL15, INSR, IRS1, IRS2, ITGA10, ITGA2, JARID2, JUN, KDR, KPNA1, 
KPNA3, KPNA4, KRAS, LIMS1, LIPE, MAP2K1, MAP2K4, MAP3K13, MAP3K4, 
MAP3K9, MAPK9, MAPRE1, MCL1, MKNK1, MRAS, MYLK, MYLK3, NAPEPLD, 
NFATC3, NOS1, NOTCH2, NRP2, OCRL, OTX1, PAK2, PAK7, PFKFB4, PHC3, 
PIK3C2A, PIK3R1, PIM1, PLCD1, PLXNB1, PPAP2B, PPM1A, PPM1D, 
PPP2R1A, PPP2R5C, PRKAB2, PRKAR2A, PRKCD, PRKG1, PTCH1, PTCH2, 
PTGS2, PTPRM, PVRL1, PVRL2, RAB8B, RAD9A, RAF1, RAPGEF1, RHOT1, 
RICTOR, RIF1, RPS6KA3, RPS6KA6, SALL4, SEMA3A, SH2D2A, SKI, SKIL, 
SLC2A3, SMAD3, SMAD5, SMAD7, SMURF1, SMURF2, SOCS6, SOS1, SOS2, 
SPTBN2, SYNJ1, TBP, TCF3, TGFBR3, TNFSF13B, TNPO1, TRAF3, TRAF6, 
TSC1, TSPAN5, TUBA1A, TXNRD3, VAV2, VEGFA, WASL, WIPF1, WNT3A, 
WNT4, WNT5B, WNT7A, YWHAH, YWHAQ, ZAK, ZFHX3, ZNF423, ZYX 
miR-18a 
ATM, CDK2, CDKN1A, CTGF, E2F1, FGF1, FGFR3, FNBP1, FOXH1, FRS2, 
HIF1A, IGF1, INPPL1, KDM5B, KIT, KPNA6, LIF, MAP3K1, MEF2D, MYLK, 
NEDD4, NEDD9, NFAT5, NOS1, NOTCH2, OCRL, OTX1, PHC3, PIAS3, RAB5A, 
RAB5C, RUNX1, SIX3, SMAD2, YBX3, YWHAB, ZAK 
miR-193 
ADCY9, ARHGEF12, ARNT, ATM, CALM1 (includes others), CCND1, CHRNB1, 
DVL3, EIF2AK1, EIF4B, ETS1, FGF1, GNAO1, GRB7, HOXC9, IGF2BP1, IGFBP5, 
ITPR2, KIT, KRAS, LIMS1, MAP3K3, MAPK10, MCL1, NFKBIE, OSMR, PLAU, 
POLR2J2/POLR2J3, PPP2R5C, PTK2, SF3A1, SLC23A2, SOS2, TCF4, TGFB2, 
TGFBR3, TSC1, UBA52, YWHAZ 
miR-19a 
ACTN1, ADCY1, ADCY7, ADCY9, ADRB1, AGO1, AK3, AK4, ARHGAP1, 
ARHGAP5, ARHGEF12, BCAR3, BMP3, BMPR2, CAB39, CALM1 (includes 
others), CAST, CCND1, CDC42BPA, CGN, CLIP1, CNGA3, CNR1, CNTFR, 
CREB5, CRMP1, CSF2RB, CSNK1G1, CTGF, DBN1, DOCK3, DPYSL5, EIF4A2, 
EIF4G2, ELAVL1, ELK3, EPN2, EXOC5, FGF6, FLNC, FRS2, FZD3, FZD6, GIT2, 
GRB10, GRIN2A, GSC, GSK3B, ID2, IGF1, IGFBP3, IL6ST, INHBB, ITGA11, 
ITGA2, ITGA6, ITGB3, ITGB8, JARID2, KIT, KPNA3, KPNA4, KPNA6, KRAS, LIF, 
MAGI2, MAP2K3, MAP3K12, MAP3K14, MAP3K2, MAPK1, MAPK14, MEF2A, 
MEF2C, MEF2D, MPRIP, NEUROG1, NRP2, OCRL, PAK6, PAX6, PFKFB3, 
PIK3C2A, PIK3CA, PIK3R3, PLA2G10, PLCL1, PLCL2, PPM1A, PPP1R12A, 
PPP2R4, PPP2R5A, PPP2R5E, PRKAA1, PRKAA2, PRKACB, PRR5L, PTEN, 
PTK2B, RAB5B, RAB8B, RAF1, RAP1A, RAP1B, RAP2B, REST, RFX4, RHOB, 
RICTOR, RPS6KA2, RPS6KA5, RUNX3, S1PR1, S1PR2, SLC2A1, SMAD4, 
SMAD5, SMARCA2, SMARCD2, SMURF1, SOCS1, SOCS3, SOCS5, SOCS6, 
SPHK2, STAT2, TGFBR2, TGIF1, TLN2, TNF, TNIP1, TSC1, VAV2, WNT1, 
WNT10A, WNT3, WNT7B, XIAP, YES1, ZAK, ZFYVE9 
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miRNA ID Gene Symbol 
miR-203 
ABL1, ACVR2A, ACVR2B, ADCY9, AK4, AKT2, ANGPTL1, APC, ARHGAP1, ATM, 
BIRC5, BMI1, CAB39, CAV1, CBL, CLDN1, CNTFR, CREB1, CREB3, CRK, CUL1, 
DGKZ, DNM1L, EIF4E, ETS2, FAM208A, FGF2, FGF5, GLI3, GNG2, GNG4, 
GYS1, HLA-DOA, HTR2A, HTR2C, ID4, IGFBP5, IL15, IRS2, ITGA2, ITGAV, 
ITPR2, KAT6A, KPNB1, KRT1, LIFR, MAGI1, MAP3K1, MAP3K13, MAP3K2, 
MAPK10, MAPK9, MAPRE1, MEF2C, MLLT4, NEDD9, NR5A2, NUDT21, OCLN, 
PDGFD, PDGFRA, PHC3, PIK3CA, PIK3CD, PLD1, PLD2, PPAP2B, PPM1A, 
PPM1D, PPP1CB, PPP1R12A, PRKAB1, PRKAB2, PRKAG2, PRKCA, PRKCB, 
PRKCI, PTCH1, PTPN1, PXN, RALB, RAP1A, RAP2A, RAPGEF1, RHOQ, 
RPL23A, RUNX2, SEMA3A, SIX3, SLC2A3, SMAD3, SMAD9, SMURF1, SNAI2, 
SOCS3, SOCS6, SOCS7, SP1, SP4, SPTBN1, SRC, SYNJ1, TCF12, TCF4, TESK1, 
TGFB2, TNPO1, VEGFA, YWHAQ, ZAK, ZEB1, ZFHX3 
miR-20a 
ABL2, ACVR1B, ADRA1B, AGO1, AK4, AKT3, ARHGAP1, ARHGAP26, 
ARHGEF7, BCL2, BMP2, BMPR2, CASP7, CCND1, CDK6, CDKN1A, CFL2, 
CNGB3, CREB1, CREB5, CRK, CSNK1G1, DNM2, DPYSL2, DPYSL5, DRD1, 
E2F1, EIF4G2, ELK3, EPB41, F2R, FGD1, FGF12, FGF4, FGF5, FLT1, FNBP1L, 
FOXA1, FRS2, FZD3, FZD4, FZD7, GAB1, GIT2, GNB5, GUCY1A3, HIF1A, 
IGF2BP1, IL6ST, IL8, ITGA4, ITGB8, ITPR2, JAK1, KAT2B, KPNA2, KPNA3, 
KPNA4, LIF, LIMK1, MAP3K1, MAP3K11, MAP3K12, MAP3K13, MAP3K14, 
MAP3K2, MAP3K3, MAP3K5, MAP3K8, MAP3K9, MAPK1, MAPK9, MAPRE1, 
MAPRE3, MCL1, MEF2D, MTMR2, MYF5, NAPEPLD, NEUROG1, NFAT5, 
NRP2, NTRK3, OCRL, OSM, PAK7, PAPOLA, PDGFRA, PFKFB3, PFKP, PHC3, 
PIK3R1, PLA2G6, PLCB1, PLS1, PLXNA1, PPARG, PPM1A, PPP2CA, PPP2R2A, 
PPP2R3A, PPP3R1, PRKACB, PTEN, RAB5B, RAB8B, RAPGEF1, RB1, REST, 
RHOC, RND3, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6KA5, RPS6KA6, 
RUNX1, RUNX3, S1PR1, SEMA7A, SKI, SLC2A4, SMAD4, SMAD5, SMAD6, 
SMAD7, SMURF1, SOCS6, SOCS7, SOS1, SSX2IP, STAT3, STK11, TCF4, TCF7L1, 
TGFB1I1, TGFBR2, TNFSF11, TNS1, ULK1, VASP, VAV2, VCL, VEGFA, VIM, 
XIAP, YES1, ZFYVE9 
miR-25 
ABL2, ACTC1, ADCY3, ADRB1, AGGF1, AGO3, ARF1, BMP7, BMPR2, CALM1 
(includes others), CAMK2A, CCNE2, CDC42, CDC42BPA, CDC42EP2, CDK6, 
CDKN1A, CEBPA, CFL2, CLDN11, CNR1, CREB1, DDIT4, EIF4G2, EOMES, 
EXOC5, FKBP1A, FRS2, FZD10, GATA6, GIT2, GRIA1, GRIA3, GRIA4, GRM2, 
HAND1, HNF1B, IL6ST, IQGAP2, IRS2, ITGA5, ITGA6, ITGAV, ITPR1, JARID2, 
KAT2B, MAP2K4, MAP3K13, MAP3K2, MCL1, MEF2D, MITF, MYH9, NFAT5, 
NOTCH1, PAIP1, PAX3, PFKFB4, PIK3R3, PPAP2B, PPP1R12A, PRKAB2, 
PRKAR1B, PRKAR2B, PRKCE, PTEN, PVRL1, RAB8B, RAG1, RAP1A, RAP1B, 
REST, RPL15, RPS6KA4, S1PR1, SEMA3A, SKI, SLC2A3, SMAD6, SMAD7, 
SMURF1, SNAI1, SOCS6, SP1, SPHK2, SYNJ1, TCF4, TGFB2, TGIF1, TNPO1, 
TOB1, TRAF3, TSC1, ULK1, VCL, WASL, WNT5A, WWP2, ZAK, ZFHX3 
miR-26b 
ABL2, ACVR1C, ACVR2B, AGO1, ARHGAP26, ARHGEF12, ATF2, CBLL1, CDH2, 
CDK6, CNR1, CPSF2, CREB1, CREBBP, CSNK1G1, CTGF, EIF2S1, EIF3A, 
EIF4G2, EIF5, FAM208A, FGD1, FGF9, GATA4, GNA13, GRB10, GSK3B, HGF, 
HNF1B, HOXC9, HTR2C, IGF1, INHBB, ITGA4, ITGA5, ITGA6, ITGB8, ITPR1, 
JARID2, KPNA2, KPNA3, KPNA6, LEF1, LIF, LIFR, LIMS1, MAP3K1, MAP3K2, 
MAP3K9, MCL1, MEF2C, MITF, MRAS, MYH10, MYLK3, NRAS, OCLN, PAK2, 
PFKFB2, PFKFB3, PIK3C2A, PIK3R3, PIM1, PLCB1, PLCL1, PPM1B, PPP2R3A, 
PPP2R5A, PPP3CB, PPP3R1, PRKAA2, PRKAG2, PRKCD, PRKCQ, PRR5L, 
PTEN, PTGS2, RAP1A, RB1, REST, RHOQ, RHOU, RPS6KA2, RPS6KA6, SLC2A3, 
SMAD1, SMAD2, SMAD4, SOCS6, SOCS7, SPTBN1, SSX2IP, TCF12, TCF7L2, 
TGFBR2, TNPO1, TOB1, TRAF3, TXNRD3, UBTF, ULK1, WDR33, WNT5A, 
WWP2, YWHAE, ZFHX3 
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miRNA ID Gene Symbol 
miR-30b 
ABL1, ABL2, ACTC1, ACTN1, ACVR1, ADRA1D, ADRA2A, ADRA2B, ADRB1, 
AGO1, AGO3, ARHGAP26, ARHGEF6, ARPC5, BCL2, BDNF, BMP7, CAMK2D, 
CAMK4, CAPN5, CCNE2, CFL2, CNGB3, CPSF6, CRKL, CSNK1A1, CSNK1G1, 
CTGF, DDIT4, DGKZ, DPYSL2, EPB41, EPN2, F2, FOXA1, FOXO3, FRS2, FZD2, 
FZD3, GDNF, GLI2, GNA13, GNAI2, GNAO1, GNG10, GRB10, GRIA2, GRIN2A, 
GRM3, GRM5, GUCY2C, IGF1, IGF1R, IL1A, IRS1, IRS2, ITGA2, ITGA4, ITGA5, 
ITGA6, ITGB3, JAK1, JARID2, JUN, KPNA3, KPNA6, KRAS, LIFR, LYN, MAGI2, 
MAP3K1, MAP3K12, MAP3K13, MAP3K2, MAP3K5, MEF2D, MET, MPL, 
MYH10, MYH11, NEDD4, NFAT5, NFATC3, NOTCH1, NR2F2, NR5A2, NRP2, 
PAPOLA, PAX3, PDGFRB, PHC3, PIK3CD, PIK3R2, PLCB4, PLCG1, PLS1, 
PLXNA1, PPP1R12A, PPP2R4, PPP3CA, PPP3CB, PPP3R1, PRKAR1A, RAB7A, 
RAP1B, RAP2B, RASA1, RHOB, RPS6KA2, RUNX1, RUNX2, SEMA3A, 
SERPINE1, SMAD1, SMAD2, SMARCD2, SNAI1, SNAI2, SOCS1, SOCS3, SOCS6, 
SOS1, SP4, SSX2IP, TCF7, THEM4, TIMP3, TNIP1, TNPO1, TP53, TRAF3, TSC1, 
TSPAN2, VAV2, WIPF1, WNT5A, WNT7B, XPO1, YWHAZ 
miR-320 
ACVR2B, AK4, AKT3, ANGPTL1, ARF1, ARHGAP26, ARHGAP5, ARPC5, ASH2L, 
BMI1, BMP3, BMP6, BMPR1A, CALM1 (includes others), CBL, CBLL1, CDH2, 
CDK6, CREB5, CRK, CRKL, CSNK1E, CSNK1G3, DBN1, DPYSL3, E2F1, EIF2B1, 
EIF4B, EPN2, EPO, ETS2, FAM208A, FGF9, FLNC, FOXO3, FZD3, GNAI1, GNAZ, 
GRB2, HLTF, ID4, IGF1, IGF1R, IPO5, ITGB3, KITLG, MAGI1, MAPK1, MAPK9, 
MCL1, MYH10, MYL12A, NFATC3, NRP1, ONECUT1, PAK7, PFKFB2, PFKM, 
PHC1, PIK3R1, PLCG1, PPP1CB, PPP2R2C, PPP2R5B, PRKAG2, PRKAR1A, 
PRKG1, PTEN, RAC1, RAD9A, RANBP2, RAP1A, RAP2B, RASA1, RPL15, RSU1, 
RUNX1, S1PR1, SEMA3A, SMAD4, SMARCD2, SMURF1, SP1, TGFBR1, 
TGFBR2, TNPO1, TSC1, TUBA8, ULK1, VIM, XIAP, XPO1, YES1, YWHAG, 
YWHAQ, YWHAZ, ZIC3 
miR-328 
ADCY1, ARPC4, CLDN19, CNR1, CPT1A, EIF4EBP1, ELF1, EPO, FGD1, FGF11, 
FOXA2, FZD3, FZD7, GLRX, IGF1R, IL5, IL8, ITGA5, MAGI1, MAP2K7, MAP3K9, 
MAPK14, NFATC4, PAK6, PHC3, PIM1, PLA2G4C, PLCE1, PNPLA2, PPP2R5D, 
SLC2A1, TCF7L2, TGFB2, TNS1, TSC1, TYR, WASF2, YWHAZ, ZAK 
miR-338-5P PHC3 
miR-365 
ACVR1, ACVR2B, ADCY6, AGO4, AKT3, BCL2, BDNF, CCND1, CHP1, CLDN11, 
CPT1A, CREB5, CSF2RB, CSK, CSTF1, EPAS1, ETS1, FGF1, FRS2, FZD3, FZD5, 
GNAT1, IL1A, ITGA10, MAP3K13, MAPK1, MEF2D, MEIS1, MTMR2, MYLK, 
PAX6, PIK3R3, PLCB4, PPM1D, PRKAR2A, PRKG1, RHEB, RICTOR, RPS6KA6, 
SEMA3A, SET, SKI, SMAD2, SOCS5, SOCS7, SOS1, SYNJ1, WNT5A, YWHAH 
miR-423-5p 
ACACA, ACVR1B, AK1, BAIAP2, BMP8B, CALM1 (includes others), CALML5, 
CAPN5, CCNF, CD8A, CDC42SE1, CDKN1A, CLDN19, CLDN23, CRHR2, CSF1, 
DOCK1, DPYSL4, DVL1, EIF4EBP1, ELF4, EPN2, EXOC3, FGFR3, GNAI2, 
GRIK3, GRIN1, GRM2, GYS1, INPPL1, ITGA5, KEAP1, LIMK1, MAP3K14, 
MEF2D, MRAS, NFATC1, NFATC2, NOS1, NPM2, PAK6, PDGFRB, PDPK1, 
PLA2G2F, PLA2G6, PLCB1, PRKACA, RAC2, RCC1, RPS6KA4, S1PR3, SGSM3, 
SHC1, TGFBR3, TSPAN3, TUBB6, UBA52, WNT3A 
miR-451 CAB39, CAV1, MEF2D, MYLK3, NEDD9, NR5A2, S1PR2, TSC1, TTN, YWHAZ 
miR-455 
ARHGEF12, ARNT, BMP8A, BMPR2, CAMK4, CAST, CDKN1B, CTNND1, EPN2, 
ETS1, FZD5, IGF1R, INPP5K, ITGB8, KDR, KPNA1, KPNA3, MKNK1, NCK2, 
PARD3, PARVA, PLD1, PPP1R12A, PRKCI, RAF1, RUNX2, S1PR1, SOCS3, 
SYNJ2, TJP1, TNPO1, TSPAN5, TUBB 
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miRNA ID Gene Symbol 
miR-484 
CSF1, F2RL3, FGF1, FLNB, HNF1A, MAGI1, MAPKAPK2, PDGFA, PIK3CD, 
TGFBR3, WNT2B 
miR-491 
ARF3, BCL2L1, CAMK2B, CAPN5, CSNK1G1, EXOC8, FGD1, GATA4, GIT1, 
GNAT1, IGF2, IGF2BP1, INPP5F, IQGAP3, ITGAX, KDM5B, LIMK1, MAP3K11, 
MAPKAP1, MPL, MYL9, PARVA, PDGFRA, PHC3, PTPN11, PVRL1, PXN, 
RAB7A, RND2, RPS24, RPTOR, SF3A1, SLC2A1, SNAI1, SPTB, TCF7, TNS1, 
TXNRD1 
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Appendix 6: Biological function pathways involving our 2375 genes regulated in CD34+ brown 
adipocytes vs CD34+ proliferating cells.  
Threshold set at p<0.05.  
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Appendix 7: Significant metabolic pathways involving the 2375 genes regulated in CD34+ 
brown adipocytes vs CD34+ proliferating cells. 
Y axis represents the percentage of genes from the dataset involved in a particular pathway. 
Bold number on the right of each bar represents the number of genes involved in this particular 
pathway based on Ingenuity database. (p<0.05). 
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Appendix 8: Table of the 108 miRNAs differentially regulated during CD34+ cell differentiation. 
108 miRNAs differentially regulated during CD34+ cell differentiation 
let-7b miR-145# miR-301a miR-422a 
let-7c miR-148a miR-30a-3p miR-425 
let-7d miR-148b# miR-30a-5p miR-425# 
let-7e miR-151-5P miR-30b miR-431 
let-7f miR-152 miR-30c miR-432 
let-7g miR-155 miR-30d miR-452 
miR-100# miR-15a miR-30e-3p miR-455-3p 
miR-101 miR-15b# miR-320 miR-455-5p 
miR-103 miR-16 miR-320B miR-484 
miR-106b# miR-186 miR-324-3p miR-485-3p 
miR-10b miR-191 miR-324-5p miR-491-5p 
miR-10b# miR-192 miR-328 miR-493 
miR-1247 miR-193a-3p miR-335 miR-500 
miR-125a-5p miR-193a-5p miR-335# miR-532-3p 
miR-126 miR-193b miR-339-3p miR-532-5p 
miR-126# miR-195 miR-340 miR-543 
miR-1260 miR-196b miR-340# miR-574-3p 
miR-1274A miR-19b-1# miR-342-3p miR-598 
miR-1274B miR-204 miR-345 miR-625# 
miR-1275 miR-21 miR-361-5p miR-628-5p 
miR-1290 miR-22 miR-362-5p miR-642 
miR-130a miR-22# miR-365 miR-652 
miR-136# miR-222# miR-374a miR-660 
miR-140-3p miR-224 miR-374b miR-664 
miR-140-5p miR-26a miR-376a miR-708 
miR-143 miR-26b miR-378 miR-769-5p 
miR-145 miR-27a# miR-378 miR-885-5p 
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Appendix 9: Table of the 48 miRNAs differentially regulated during CD34+ cell differentiation 
and their predicted gene targets involved in cellular growth, proliferation and development. 
(1/2) 
miRNA ID Gene Symbol 
let-7g BCL2L1, CALM1 (includes others), CCND1, CCNF, CSNK1D, DPYSL3, EIF2S2, 
ELF4, MYC, PAK1, RPL36A/RPL36A-HNRNPH2 
miR-101 CLDN11, FN1, KITLG, SOCS2, SOCS5, SSX2IP, TGIF1, TSPAN5 
miR-103 ACTG1, BDNF, DPYSL3, ITGA2, MYH9, RPL34, SLC2A3, TGFBR2, TSPAN5, 
YWHAH, ZYX 
miR-10b ACTG1, BDNF, SSX2IP 
miR-1247 NRP1 
miR-125a-5p ID1, ID3, PPP2R4 
miR-1260 IGFBP4, SEMA3A, WNT5A 
miR-1275 ADRB2, IGF1, IGF2 
miR-140-5p BCL2L1, MYH9, SMAD3 
miR-143 CALM1 (includes others), PLAU, SMAD3, WNT5B 
miR-145 ACTG1, ARPC5, CCNA2, CDH2, MYC, RPL36A/RPL36A-HNRNPH2, SEMA3A, 
SMAD3, TGFBR2 
miR-148a ACVR1, CDK1, ITGA5, NRP1, RPL36A/RPL36A-HNRNPH2, SLC2A3, SOCS3, 
TEK 
miR-15a 
BDNF, CALM1 (includes others), CCND1, DIAPH1, ITGA10, ITGA2, JUN, 
PFKFB4, SEMA3A, SLC2A3, SMAD3, TSPAN5, TUBA1A, WNT5B, YWHAH, ZYX 
miR-186 ACVR1, CDK2, EIF2S2, NRP1, PFKFB4, TGFBR2, WNT5A 
miR-191 BDNF 
miR-193a-5p EIF2S2 
miR-193b CALM1 (includes others), CCND1, PLAU 
miR-196b CALM1 (includes others), EIF2S2, ELF4, SEMA3A 
miR-204 BDNF, CCND1, CDH2, DPYSL3, NRP1, RUNX2, TGFBR2 
miR-21 PFKM, SOCS5, TGFBR2 
miR-22 ARPC5, CALM1 (includes others), DPYSL3, ITGA10, ITGA5, SOCS2 
miR-224 BCL2, FZD5, IRS2, PFKFB3, PPP2R1B, ZNF423 
miR-26a CDH2, HGF, ITGA4, ITGA5, KPNA2, SLC2A3, SSX2IP, TGFBR2, WNT5A 
miR-301a ACVR1, CALM1 (includes others), DIAPH3, ITGA4, NRP1, RPL36A/RPL36A-
HNRNPH2, SOCS5, TGFBR2 
miR-30d ACVR1, ARPC5, BDNF, ITGA2, ITGA4, ITGA5, JUN, PPP2R4, RUNX2, SEMA3A, 
SOCS3, SSX2IP, WNT5A 
miR-30e-3p TUBA1A 
miR-320 ARPC5, CALM1 (includes others), CDH2, DBN1, DPYSL3, FLNC, KITLG, NRP1, 
PFKM, SEMA3A, TGFBR2 
miR-324-3p DPYSL3, RPS24 
miR-324-5p PFKFB4, RAN, ZYX 
miR-328 ITGA5 
miR-335 ADCY3, CCNF, LPAR1, SSX2IP 
miR-339-3p TUBB, BCL2L1, FLNC, BDNF, CALM1 (includes others), NRP1 
miR-342-3p BCL2L1, FLNC 
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miRNA ID Gene Symbol 
miR-361-5p BDNF, CALM1 (includes others), NRP1 
miR-365 ACVR1, BDNF, CCND1, CLDN11, ITGA10, SEMA3A, SOCS5, WNT5A, YWHAH 
miR-374a CCND1, EIF2S2, LPAR1, WNT5A, WNT5B 
miR-376a FERMT2, PIK3R1 
miR-431 IRS2, PARVA, TCF7L1 
miR-455-3p IGFBP4, PLAU 
miR-455-5p RUNX2, SOCS3, SYNJ2, TSPAN5, TUBB 
miR-485-3p PPM1B 
miR-491-5p BCL2L1, RPS24 
miR-532-3p IGFBP4 
miR-532-5p CDC2 
miR-543 ADCY6, AK3, ARHGEF7, FZD4, IGFBP3, IRS2, SH3GLB1, SPTBN1 
miR-660 YWHAH 
miR-708 PFKM, SMAD3 
miR-769-5p CDK1, TGFBR2 
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Appendix 10: Table of the 4 miRNAs up-regulated in human skeletal muscle following cold 
exposure and their predicted gene targets. 
(1/2) 
miRNA ID Gene Symbol 
hsa-miR-1208 
ADH6, AKIRIN1, C6orf223, DR1, EIF2S2, ELTD1, EPHA7, FGFR1, FNDC3A, 
GRIP1, NEMF, PABPC3, PEG3, PLCXD3, PPP2R2A, PTGER2, RAVER2, RGMB, 
SCFD1, ST8SIA2, TCEAL7, UTP23, ZFR, ZNF280D, ZNF33B 
hsa-miR-517c 
ADAM9, ALCAM, ALPK3, ANKRD29, APBB2, AREG/AREGB, C10orf54, 
C1orf173, C5orf63, CACNG4, CLIC4, DBN1, DGKH, ENPP6, EPM2A, FFAR2, 
GNG7, HOXA5, HPGDS, ISL1, KRTAP2-3 (includes others), LDLR, MYH4, NFIA, 
NPHS2, NR1D2, NUGGC, NUPL2, OLFM3, PHF13, PRTG, PTGES, RNF111, 
RPRD1B, SDR16C5, SEMA3A, SEMA5B, SH3TC2, SLC46A2, SLITRK1, SMG7, 
SNX18, TARSL2, TMCC1, TNIP1, TRPA1, VSTM2B, WDR45B, ZNF521, ZYG11B 
hsa-miR-532-3p 
AADACL3, ADAM8, ADCYAP1R1, ADIPOR2, ADORA1, ALCAM, ALKBH4, 
ANKRD12, ANKRD33B, APOBEC3D, ARFIP2, ARL6IP1, ARPC3, ATP1A2, 
ATP2B1, ATP6V1H, BORA, BPHL, BRF2, BTG2, BZRAP1, C10orf95, C1orf172, 
C1orf177, C22orf46, C2orf68, C2orf72, C6orf132, C6orf141, C9orf152, 
C9orf47, CACNG8, CALB1, CARHSP1, CBL, CBX1, CCDC170, CCDC47, CCDC68, 
CD84, CELSR3, CHD3, CLEC10A, CLSPN, CMKLR1, CMTM6, CNOT7, CNPPD1, 
CNTD2, CSF3, CSGALNACT1, CTXN2, CXCL3, CYTH1, DCAF6, DDOST, DDTL, 
DMP1, DNAL4, DOCK2, DRAXIN, DRP2, DTX3L, DTX4, ENSA, ETNK2, EXOSC3, 
EZH1, FAM49A, FANCC, FNDC5, FRAT2, GALNT10, GALNT6, GDAP2, GDF6, 
GLB1L2, GLP1R, GNL1, GPLD1, GRK6, GSG1L, GSTCD, GUCY1A3, HCN3, 
HECTD1, HHIPL2, HLA-DOA, HMGA2, HNRNPH3, HS3ST5, IBA57, ID4, 
IGFBP4, IL15RA, IRAK2, IST1, ITGB3, KATNAL2, KCNE3, KCTD7, KIF1C, 
KLHL12, LBH, LEPR, LIMK2, LMO7, LOC554223, LRRC27, MAPT, MARK2, 
MBLAC1, MEOX1, MEPCE, METTL14, METTL7A, MGAT3, MLPH, MRPL49, 
MRPS18A, MRPS25, MRVI1, MTMR12, MYB, MYOM3, NABP1, NFASC, ODF2L, 
ORAI2, P2RX6, PAFAH1B2, PEA15, PEG10, PHC1, PHF19, PID1, PISD, 
PLEKHG2, PNPLA4, PPP1R1A, PRDM7, PRKAR2B, PRR3, PSAPL1, PTK6, 
PTPRT, R3HCC1L, RAB11FIP4, RASSF8, RCAN1, RIMKLB, RNF122, RNF145, 
RPRML, RPS6KA2, RSU1, RTP1, SAE1, SAMD12, SH3RF2, SLC33A1, SLC39A7, 
SLC7A6OS, SLC9B2, SNX30, SPTLC1, SREBF1, ST6GALNAC2, ST7L, STAC2, 
SYNCRIP, TADA1, TARS, TEAD3, TLDC2, TLE3, TM2D3, TMEM100, 
TMEM101, TMEM127, TMEM81, TRAF2, TRAPPC4, TRIL, TRIM11, TRIM27, 
TRIM9, TRPV3, UCP3, VAMP4, VRTN, WDR36, WDR66, ZBTB42, ZNF229, 
ZNF48, ZNF514, ZNF554, ZNF605, ZNF707, ZNF74, ZNF775, ZNF829 
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miRNA ID Gene Symbol 
hsa-miR-28-5p 
AAK1, ADCY2, AGPAT3, AGTR2, ALG9, AMIGO1, AMOTL2, ANK1, ANKRD52, 
ARAF, ARIH1, ARL17A, AS3MT, ASB5, ASPA, ATP6V1A, ATPAF1, ATRNL1, 
ATXN1, BAG1, BAZ1B, BCAM, BRD3, BSN, BTRC, C12orf29, C16orf52, 
C20orf112, CANT1, CAPN6, CAPRIN1, CASC3, CASP2, CBFB, CBL, CBX5, 
CCDC113, CCDC6, CCND3, CCNL2, CD276, CD34, CD3G, CDC42SE1, CDKN1A, 
CDPF1, CHL1, CHRM2, CHTF8, CLNS1A, CNEP1R1, CNTFR, CREB1, CRIM1, 
CSF1, CSNK1G1, CTNNBIP1, CWF19L1, CYTH2, DCAF10, DCC, DCUN1D5, 
DDTL, DKK3, DNAJA4, DNAJC18, DRAM1, DSEL, DUSP4, DYNC1LI2, DYSF, 
E2F6, EFNB3, EFR3B, EIF2B3, EN2, EPB41L4A, EPDR1, ERF, ETF1, EYA3, 
FAM107A, FAM126A, FAM135B, FAM217B, FAM228A, FBXO40, FGF23, 
FKTN, FOXJ3, FOXN3, FOXO1, FOXO3, FRA10AC1, FRMPD4, FTSJ2, GAPVD1, 
GIT2, GLG1, GLRX, GNG12, GOLT1A, GON4L, GPM6A, GPR107, GPR26, GPR64, 
GPR88, GRIP2, GSK3B, GSTT2/GSTT2B, HEPH, HNRNPC, HOXA1, HOXB3, 
HS2ST1, HTRA2, IFFO2, IGF2BP1, IKBKB, IKZF4, IMPDH1, INTS7, IQGAP1, 
IQSEC2, ITGB8, ITPKB, ITSN1, JAGN1, JAK1, JMJD6, KCNH1, KCNJ1, KCNN3, 
KIAA0355, KIAA1009, KIAA1211, KIAA1430, KIF6, KLHL18, KPNA4, 
LDLRAD3, LIF, LPHN1, LPPR5, LSMEM1, LURAP1L, LUZP1, LYPD3, 
MAP3K13, MAP3K3, MARCH5, MARCH9, MASP1, MCM9, MDGA1, MED12L, 
METTL12, METTL21A, MPL, MRE11A, MTCP1, MTMR3, MTSS1, MYCBP, 
N4BP1, NAA60, NANOS1, NAV1, NDOR1, NFE2L2, NLGN2, NNAT, NOS1, 
NPY2R, NRAS, NT5E, NTM, NXF1, OSBPL10, OSBPL3, OTUB1, PAFAH1B2, 
PAFAH2, PAPPA, PARVA, PATE4, PDK4, PDZD4, PFKM, PHF21A, PIANP, 
PITPNM3, POM121/POM121C, POU6F1, PPIE, PPP1R18, PPP2R3A, PREPL, 
PRTG, PRUNE2, PSAP, PSMA5, PSMF1, PTGER3, PTPN21, PTPRF, QKI, 
RAB14, RAB8B, RAP1B, RARG, RBBP5, RC3H1, RCVRN, RFT1, RGL1, RGS16, 
RHO, RNF150, RNF165, RORA, RPGRIP1L, RPRD1A, RPTN, S1PR1, SBNO1, 
SCAF4, SDC1, SEMA4C, SEMA4G, SEMA7A, SETDB1, SF3A1, SFXN2, SHANK2, 
SIK2, SIRT3, SKA1, SLAMF6, SLC13A3, SLC31A1, SLC35C1, SLC37A4, 
SLC39A14, SLC44A5, SLC4A11, SLC7A14, SMAD3, SMAD4, SMARCC2, SNUPN, 
SORT1, SPARC, SPATA8, SPRY3, SRCRB4D, SRPRB, SRRM4, SRSF1, SRSF6, 
SSH2, SSRP1, STK24, STK4, STRN, SYT11, SZRD1, TAGAP, TEX261, THRB, 
THTPA, TIMELESS, TLN2, TMEM127, TMEM132B, TMEM167B, TMEM170A, 
TMEM200B, TMEM260, TMEM92, TNS3, TNS4, TRIM23, TRIM67, TRNP1, 
TRPS1, TTBK1, TTC39A, TUBB4A, TXNL1, UNK, UPB1, VAMP2, VAT1L, 
VPS13A, WIPF2, YWHAZ, ZBED4, ZC3H11A, ZC3H7B, ZKSCAN8 
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MicroRNAs in skeletal muscle: their role and regulation
in development, disease and function
Isabelle Gu¨ller and Aaron P. Russell
Centre for Physical Activity and Nutrition Research, School of Exercise and Nutrition Sciences, Deakin University, Burwood 3125, Australia
Maintaining skeletal muscle function throughout the lifespan is a prerequisite for good health
and independent living. For skeletal muscle to consistently function at optimal levels, the
efﬁcient activation of processes that regulate muscle development, growth, regeneration and
metabolism is required. Numerous conditions including neuromuscular disorders, physical
inactivity, chronic disease and ageing are associated with perturbations in skeletal muscle
function. A loss or reduction in skeletal muscle function often leads to increased morbidity and
mortality eitherdirectly, or indirectly, via thedevelopmentof secondarydiseases suchasdiabetes,
obesity, cardiovascular and respiratory disease. Identifying mechanisms which inﬂuence the
processes regulating skeletal muscle function is a key priority. The discovery of microRNAs
(miRNAs) provides a new avenue that will extend our knowledge of factors controlling skeletal
muscle function. miRNAs may also improve our understanding and application of current
therapeutic approaches as well as enable the identiﬁcation of new therapeutic strategies and
targets aimed at maintaining and/or improving skeletal muscle health. This review brings
together the latest developments in skeletal muscle miRNA biology and focuses on their role and
regulation under physiological and patho-physiological conditions with an emphasis on: myo-
genesis, hypertrophy, atrophy and regeneration; exercise and nutrition; muscle disease, ageing,
diabetes and obesity.
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myogenic regulatory factors; MyoD, myogenic differentiation 1; SRF, serum response factor; T2D, type 2 diabetes;
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Introduction
Skeletal muscle makes up approximately 40% of the
body’s mass. The principal function of skeletal muscle
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degree in Metabolic Regulation, Nutrition and Endocrinology (2008) from the University of Lyon,
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microRNA regulation of skeletal muscle-derived brown adipocyte precursor cells, supported by
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Switzerland (2002) investigating the role and regulation of skeletal muscle uncoupling proteins.
Then developed a molecular physiology research laboratory at the Clinic Romande de Re´adaptation
in Sion, Switzerland, focusing on the regulation of the Akt/Forkhead/atrogene pathway in human
skeletal muscle under anabolic and catabolic conditions. Since 2006 he has been leading a research
teamwithin the Centre of Physical Activity andNutrition Research at DeakinUniversity, focusing on
understanding the molecular mechanisms regulating skeletal muscle growth, atrophy and function in chronic disease, ageing and following exercise,
supported by the NH&MRC.
is contraction-related in order to control movement and
posture, a process generally requiring the oxidation of
nutrients delivered to the body through the diet. Skeletal
muscle has a unique ability to adapt to changes in
C© 2010 The Authors. Journal compilation C© 2010 The Physiological Society DOI: 10.1113/jphysiol.2010.194175
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its environment. In response to increased use through
regular exercise training, skeletal muscle can increase its
size and capacity to produce force (Fry, 2004), improve
its resistance to fatigue and enhance its oxidation of
carbohydrates and fats (Coyle, 2000). In contrast, ageing,
sedentary lifestyles and immobilization, as well as neuro-
muscular disorders (Lynch, 2001) and chronic disease
conditions (Jagoe & Goldberg, 2001; Di Giovanni et al.
2004; Tisdale, 2004; Doucet et al. 2007) are associated with
the loss of skeletal muscle mass and function. Reduced
muscle size and contraction have negative consequences
for skeletalmuscle carbohydrate and fatmetabolism (Stein
& Wade, 2005) which increases the risk of metabolic
disorders (Corpeleijn et al. 2009). The important role of
musclemass and function in numerous disease conditions
underpins the necessity of understanding the molecular
factors which control skeletal muscle development over
the entire lifespan, from embryonic, postnatal and adult
development, through to the changes which occur in the
elderly. The recent identiﬁcation ofmicroRNAs (miRNAs)
has opened up a new ﬁeld of investigation to under-
stand the molecular processes which control numerous
disease states (Croce & Calin, 2005; Pandey et al. 2009;
Pauley et al. 2009; Saal & Harvey, 2009). This review will
highlight our present understanding of skeletal muscle
miRNA regulation and how miRNAs may control skeletal
muscle development, function and adaptation.
What are miRNAs?
miRNAs are small (∼20–30 nucleotides (nt)) non-coding
ribonucleic acids (RNAs)which are highly conserved from
plants to mammals (reviewed previously in Bartel, 2004).
Presently their known functions are to inhibit protein
translation or enhance messenger RNA degradation
(Hamilton & Baulcombe, 1999; Reinhart et al. 2000).
miRNAs are initially transcribed in the nucleus as
long primary transcripts up to several kilobases long
which are known as primary miRNA (pri-miRNA)
(Bartel, 2004). The ribonuclease (RNase) III endonuclease
Drosha associated with Pasha (also known as DGCR8)
cleaves the pri-miRNA into a ∼60–70 nt intermediate
referred to as the miRNA precursor, or pre-miRNA
(Lee et al. 2003). Exportin-5 (XPO5) transports the
pre-miRNA from the nucleus to the cytoplasm (Lund
et al. 2004) where a second RNase III endonuclease,
Dicer1, cuts the pre-miRNA into a ∼22 nt miRNA duplex
(Lee et al. 2003). One strand is degraded while the
other confers the mature miRNA. The latter is then
incorporated into a ribonucleoprotein complex known
as the RNA-induced silencing complex (RISC) (Schwarz
et al. 2002). This complex enables the identiﬁcation and
binding to the target mRNA resulting in its degradation
or repression of protein translation (Bartel, 2004). TRBP
(human immunodeﬁciency virus transactivating response
RNA-binding protein) forms part of the RISC complex
(Chendrimada et al. 2005). Phosphorylation of TRBP
by the mitogen-activated protein kinase Erk increases
the stability of the RISC complex and enhances miRNA
production (Paroo et al. 2009). Individual miRNAs do
not act alone nor do they target only a unique gene.
Indeed, miRNAs have multiple gene targets and each
target may be regulated by multiple miRNAs (Lewis et al.
2003).
As most of this review paper discusses the roles and
regulation of thematuremiRNA transcripts, ‘miRNA’ will
always refer to the mature form. When referring to the
primary miRNA transcript ‘pri-miRNA’ will be written,
while ‘pre-miRNA’ will be used when discussing amiRNA
precursor.
miRNAs highly enriched in muscle
A suite of miRNAs, highly enriched in cardiac and/or
skeletal muscle (referred to as myomiRs), has recently
been identiﬁed and include miR-1, miR-133a, miR-133b,
miR-206, miR-208, miR-208b, miR-486 and miR-499
(McCarthy & Esser, 2007; Callis et al. 2008; van Rooij
et al. 2008, 2009; Small et al. 2010). Several of these
miRNAs are organized under bicistronic clusters on the
same chromosome (i.e. miR-1-1/133a-2, miR-1-2/133a-1
and miR-206/133b) and are transcribed together (Chen
et al. 2009; Liu & Olson, 2010). Regulation of these myo-
miRs is controlled by key myogenic regulatory factors
(MRFs), including myogenic differentiation 1 (MyoD)
and myogenin (Rao et al. 2006; Rosenberg et al. 2006)
as well as myocyte enhancer factor 2 (MEF2) (Liu et al.
2007), serum response factor (SRF) (Chen et al. 2006)
and myocardin-related transcription factor-A (MRTF-A)
(Small et al. 2010). MyomiRs inﬂuence multiple facets
of muscle development and function through their
regulation of key genes controlling myogenesis (Chen
et al. 2006; Kim et al. 2006; Rao et al. 2006). miR-1 and
miR-133a also regulate SRF and MEF2 demonstrating the
existence of negative feedback loops (Chen et al. 2006).
Aberrant regulation of some of these muscle-enriched
miRNAs can disrupt intracellular signalling networks
(Elia et al. 2009; Small et al. 2010) which may result in
pathological conditions (Eisenberg et al.2009). Identifying
the role and regulation of skeletal muscle miRNAs during
various phases of muscle development, as well as in
healthy and diseased conditions, will signiﬁcantly enhance
our understanding of skeletal muscle biology and may
result in new therapies to target muscle diseases or
chronic diseases associated with impaired muscle growth,
regeneration or function. Additionally, understanding
miRNA biology and function will enhance our under-
standing and application of current therapies.
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miRNAs and myocyte proliferation and differentiation
Skeletal muscle development is a complex process
requiring coordination of multiple factors which govern
the proliferation of myoblasts, their exit from the cell
cycle and subsequent differentiation into multinucleated
myotubes (Buckingham, 2006). Myogenesis is mainly
controlled by several key transcription factors, including
the basic helix–loop–helix MRFs, myogenic factor 5
(Myf5), MyoD, myogenin and MRF4 (Berkes & Tapscott,
2005), as well MEF2 and SRF (Duprey & Lesens, 1994).
miRNAs have been shown to be involved in myo-
genesis (Zhao&Srivastava, 2007) through their regulatory
relationship with MRFs (Fig. 1).
miR-133a increases myoblast proliferation, via its
repression of SRF (Chen et al. 2006), while
miR-1 stimulates myoblast differentiation via its
inhibition of histone deacetylase 4 (HDAC4) (Chen
et al. 2006). Along similar lines, miR-206 further
inﬂuences the differentiation programme via an indirect
down-regulation of the helix–loop–helix protein Id, a
repressor of MyoD (Kim et al. 2006). miR-24 induces
cardiomyocyte hypertrophy in vitro and is up-regulated
during cardiac hypertrophy (van Rooij et al. 2006).
While miR-24 levels are maintained in adult terminally
differentiated cardiac and skeletal muscle, its precise
functional role in these tissues is unknown (Sun et al.
2008). The early stages of differentiation show an
up-regulation of miR-24 and its regulatory pattern
mimics that of differentiation-speciﬁc markers, such
as myosin heavy chain (MHC). Transforming growth
factor β (TGF-β)/Smad3 signalling inhibits miR-24,
resulting in the inhibition of differentiation (Sun et al.
2008). miR-181 is up-regulated at the onset of myo-
blast terminal differentiation with expression proﬁles
mimicking differentiation-speciﬁc genes such as creatine
kinase (Naguibneva et al. 2006). It was observed that
miR-181 may exert its pro-differentiation effects via its
inhibition of the homeobox protein Hox-A1; the latter a
protein which can inhibit MyoD expression (Yamamoto
& Kuroiwa, 2003). miR-27b targets the 3′-UTR of Pax3
leading to its down-regulation and early differentiation
(Crist et al. 2009). The inhibition of miR-27b maintains
Figure 1. microRNA regulation of muscle proliferation and differentiation
This ﬁgure shows the miRNAs and their targets regulated during proliferation (rectangle) and differentiation
(circles). miR-133a is increased during proliferation. It reduces serum response factor (SRF), which is known to
inhibit proliferation. miR-24 is up-regulated during early differentiation, and maintained during the latter stages of
differentiation. Its regulated targets are presently unknown. miR-27b enhances differentiation by targeting Pax3
which is known to stimulate muscle proliferation. miR-1 stimulates differentiation through its direct inhibition of
HDAC4, an inhibitor of differentiation, while miR-206 indirectly inhibits helix–loop–helix, the latter, a repressor
of MyoD. At the late stage of differentiation, miR-181a is increased and targets Hox-A11, a known inhibitor of
MyoD. miR-221/222 are decreased in differentiated myotubes. This removes its repression of p27 which is required
to inhibit proliferation. Outside symbols: → activates; —| inhibits; ? unknown target. Within symbols: ↑ increased;
↓ decreased.
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Pax3 levels, leads tomoreproliferationanddelays theonset
of differentiation. While some miRNAs are up-regulated
during the transition from proliferation to differentiation,
others, such asmiR-221 andmiR-222, are down-regulated
(Cardinali et al. 2009). Decreases inmiR-221 andmiR-222
are associated with increased expression of the cell cycle
inhibitor p27; the latter a direct target of both miR-221
and miR-222. Overexpression of miR-221 and miR-222 in
differentiating myotubes delays cell cycle withdrawal and
differentiation, a response associated with a reduction in
sarcomeric proteins (Cardinali et al. 2009).
The regulation between myogenic transcription factors
and various miRNAs is complex and appears to depend
on the cell cycle and fusion stages. Establishing the role
and regulation ofmusclemiRNAswill enhance our under-
standing of embryonic and adultmuscle development and
regeneration.
miRNAs and muscle ﬁbre type
Human skeletal muscle consists of predominantly three
muscle ﬁbre types: I, IIa and IIx (also known as IIb). The
ﬁbre types are generally classiﬁedas slowor fast, depending
on their contractile characteristics, a reﬂection of the
expression of either the slow or fast contractile protein
isoforms of MHC (Schiafﬁno & Reggiani, 1996), and
metabolic characteristics, a reﬂection of mitochondrial
enzyme activities (Essen et al. 1975). Type I ﬁbres (slow)
are recruited at low stimulation frequencies and function
oxidatively. In contrast, type IIx ﬁbres (fast) require high
stimulation frequencies and function glycolytically, while
type IIa ﬁbres (fast) possess intermediate characteristics
between type I and IIx ﬁbres. miR-208b and miR-499
are a part of a myomiR network that regulates MHC
expression, ﬁbre type and muscle performance (van
Rooij et al. 2007, 2009). miR-208b and miR-499 are
encoded in the introns of the mouse slow type I β-MHC
(Myh7) gene on chromosome 14 and mouse slow type
I MHC7b (My7b) gene positioned on chromosome 2.
As such these miRNA/myosin networks share a positive
regulatory circuit which promotes a slow skeletal muscle
gene programme. This occurs, in part, through the
miR-208b andmiR-499 targetingof several transcriptional
repressors known to regulate muscle gene expression and
function including Sox6, Pur β, Sp3 (repressors of slow
muscle genes), HP-1 β and Thrap1 (McCarthy et al. 2009;
van Rooij et al. 2009; Bell et al. 2010).
miRNAs and skeletal muscle hypertrophy and atrophy
Synergistic ablation, an intervention which increases
functional overload (FO), is often used to develop
hypertrophy of the plantaris muscle. Following 7 days
of FO, mouse plantaris muscle mass increased by
45% with an associated change in several primary
miRNAs (pri-miR) and their corresponding mature
miRNA transcripts (McCarthy & Esser, 2007). While
pri-miR-1-2 and pri-miR-133a2 were increased 2-fold,
their mature transcripts, miR-1 and miR-133a, were
decreased by 50%. pri-miR-206 was increased 18.3-fold;
however, its mature transcript did not change (Fig. 2A).
The reason for this discordant regulation between the
pri-miRNAs and their mature miRNA transcripts is
not clear. However, these observations may have been
inﬂuenced by the time of muscle sampling and future
time course experiments are required to determine
this. Alternatively, the functional-overload model may
have inﬂuenced mechanisms that control pri-mRNA
processing, such as RNA editing by ADAR (adenosine
deaminase, RNA speciﬁc) enzymes; a reaction known to
suppress pri-mRNA processing by Drosha, resulting in a
loss of the mature miRNA transcript (Yang et al. 2006).
The decrease in mature miR-1 and mature miR-133a
expression with FO may contribute to muscle hyper-
trophy. This suggests an additional function to their
previously identiﬁed roles in muscle differentiation and
proliferation, respectively (Chen et al. 2006). The potential
of miR-1 and miR-133a to regulate multiple facets of
muscle biologymay depend upon the stimulus controlling
their activation. miR-1 and mature miR-133a may play
a role in muscle hypertrophy by the removal of their
transcriptional inhibition of growth factor gene targets,
including hepatocyte growth factor receptor (c-MET),
hepatocyte growth factor (HGF), leukaemia inhibitor
factor (LIF), insulin-like growth factor 1 (IGF-1) and
SRF (McCarthy & Esser, 2007) (Fig. 2A). Indeed, IGF-1
levels are increased in rat plantaris following overload
(Adams et al. 1999) while work from our laboratory
has shown that SRF levels are increased in human
skeletalmuscle followinghypertrophy-inducing resistance
exercise (Lamon et al. 2009). Further evidence that a
regulatory loop between miR-1 and IGF-1 may regulate
muscle growth comes from recent observations made in
C2C12 myotubes and cardiomyocytes (Elia et al. 2009).
Increased levels of endogenous miR-1 in differentiating
C2C12 myotubes resulted in a reduction in the activation
of an IGF-1 luciferase reporter construct and a decrease in
IGF-1 protein levels. Conversely, IGF-1 treatment reduced
miR-1 levels in C2C12myotubes. IGF-1 stimulates C2C12
myotube hypertrophy via the activation of Akt signalling
and the inhibition of Forkhead (FoXO) transcription
factors (Rommel et al. 2001). Hypertrophied human
skeletal muscle also presents an increase in active Akt and
a reduction in FoXO levels (Leger et al. 2006a). miR-1
levels are reduced by active Akt and increased by active
FoXO3a (Elia et al. 2009) demonstrating a regulatory
loop whereby IGF-1 regulates miR-1 via an Akt/FoXO3a
pathway (Fig. 2B); a pathway known to increase muscle
cell size (Latres et al. 2005). Furthermore, miR-1 levels
can be increased via FoXO3a which results in reduced
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IGF-1 protein levels and reduced Akt activity; a response
seen during myotube atrophy (Sandri et al. 2004; Latres
et al. 2005).
A direct genetic link has been observed between
miRNAs and muscle hypertrophy (Clop et al. 2006). The
enhanced muscular development of the Texel sheep has
been mapped to a single G-A mutation in the 3′-UTR of
the myostatin gene, a gene involved in the repression of
muscle growth (Thomas et al. 2000;McFarlane et al. 2006).
The mutation provides a novel binding site for miR-1 and
miR-206 which inhibits the translation of the myostatin
protein. The existence of polymorphic miRNA–target
interactions is of considerable interest and may help to
underpinmechanisms involved in congenital andacquired
myopathies.
Unloading of skeletal muscle, as caused by the micro-
gravity during spaceﬂight or via hind limb suspension
(HS), decreases muscle mass and force production
and shifts the muscle towards a glycolytic phenotype.
Following 11 days of spaceﬂight,miR-206was signiﬁcantly
decreased (Fig. 3A) while miR-1 and miR-133a showed
a trend towards a reduction in mouse gastrocnemius
muscle (Allen et al. 2009). This was paralleled by an
increase in themuscle atrophy F-box (MAFbx; also known
as atrogin-1) and myostatin, genes that are involved in
muscle atrophy (Bodine et al. 2001) and inhibition of
muscle growth (Morissette et al. 2009), respectively, and
increased in numerous models of muscle wasting (Glass,
2005; Leger et al. 2006b; Doucet et al. 2007; Leger et al.
2008). Whether miR-206 plays a direct or indirect role
in repressing these atrophy genes is unknown. miR-206
is up-regulated via MyoD (Chen et al. 2006), a protein
which can be degraded by MAFbx/atrogin-1 (Tintignac
et al. 2005). The possibility that a miR-206/MyoD/MAFbx
regulatory loop exists which inﬂuences skeletal muscle
growth requires investigation.
miR-107, miR-208b, miR-221 and miR-499 were
signiﬁcantly down-regulated in rat soleus muscle
following 7 days of HS-induced muscle atrophy; miR-23b
showed a tendency to be reduced (P = 0.054) (McCarthy
et al. 2009) (Fig. 3B). Unlike the space ﬂight model of
muscle atrophy, miR-206 was not decreased following HS
whichmay be due tomethodological differences including
species, muscle analysed and/or experimental duration.
Cytokines are known to increase protein degradation
and reduce protein synthesis (Menconi et al. 2007;
Tisdale, 2007). The pro-inﬂammatory cytokine TNF-like
weak inducer of apoptosis (TWEAK) has been
shown to cause muscle atrophy (Dogra et al. 2007).
TWEAK down-regulated several growth-related myo-
miRs, includingmiR-1, miR-23, miR-133a, miR-133b and
miR-206 in C2C12 myotubes; however, it only reduced
miR-1, miR-133a and miR-133b in mouse skeletal muscle
in vivo (Panguluri et al. 2010) (Fig. 3C). There was also an
increase inmiR-455which is also elevated in severalmuscle
dystrophies (Eisenberg et al. 2007). While treatment with
TWEAK regulates several muscle miRNAs involved in
muscle growth, it is not known whether their regulation is
a cause of muscle wasting or a response to prevent further
muscle wasting.
Figure 2. microRNA regulation of skeletal muscle hypertrophy
A, following functional overload-induced hypertrophy in mice, primary miR-1-2, -133a-2 and -206 are increased.
In contrast, the mature forms of miR-1 and miR-133a are decreased while miR-206 is unchanged. There is
also an increase in several growth-related genes that are predicted targets of these miRNAs; a cause and effect
relationship has not been conﬁrmed. ↑ increased; ↓ decreased; → unchanged; ← ·· → cause and effect unknown.
B, a regulatory loop exists in which Akt activation inhibits the FoXO3a transcriptional activation of miR-1. This could
remove the miR-1 repression of IGF-1 and potentially assist with muscle hypertrophy. → activates; —| inhibits.
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miRNAs and muscle regeneration
Skeletal muscle regeneration is a vital process required
to maintain healthy muscle mass, structure and function
throughout the adult life. While few studies have
investigated the miRNAs involved in regeneration,
miR-27, miR-1, miR-133, miR-206 and miR-188 are
potential regulators. In regenerating adult muscle, miR-27
is required to down-regulate Pax3 in order to promote
myogenesis, while its inhibition in injured muscle in
vivo delays muscle regeneration (Crist et al. 2009).
Following the laceration of rat tibialis anterior, an
injection of a cocktail of miRNAs including miR-1, -133
and -206 into the injured site enhanced regeneration
and prevented ﬁbrosis (Nakasa et al. 2009). This was
also associated with increases in the myogenic markers
MyoD, myogenin and Pax7; however, no cause and effect
relationship between these miRNAs, target genes and
muscle regeneration was determined. miR-181 increases
during muscle cell differentiation; however, it is expressed
at low levels in adult tissue except under conditions of
regeneration (Naguibneva et al. 2006). Presently the role
of miR-181 during regeneration has yet to be determined.
Identifying the miRNAs which enhance and/or inhibit
muscle regeneration has implications for the development
of potential therapeutic strategies for conditions with
compromised regeneration as seen in various muscle
dystrophies and in sarcopenia.
Inﬂuence of exercise on miRNAs
Exercise can reduce morbidity associated with chronic
disease, such as type 2 diabetes (T2D) (Lanza et al. 2008),
cancer (Newton & Galvao, 2008) and cardiovascular
disease (Wisloff et al. 2005). At one end of the exercise
continuum is endurance exercise, commonly performed
at a moderate intensity with continuous or interval-based
repetitions. Repeated bouts of endurance exercise results
in increased mitochondrial content, capillary density and
enhanced capacity of the oxidation of carbohydrates and
lipids (Fluck, 2006; Joseph et al. 2006; Coffey & Hawley,
Figure 3. microRNAs and skeletal muscle atrophy
A, following spaceﬂight-induced atrophy in mice, a decrease in miR-206 has been observed as well as an increase in
myostatin and atrogin-1. A cause and effect relation between miR-206 and these targets has not been determined.
B, hind limb suspension decreases miR-107, -208b, -221, -499 and -23b in rat skeletal muscle; for miR-23,
P = 0.054. C, TWEAK increases protein degradation with an associated decrease in miR-23, miR-206, miR-1 and
miR-133a/b in C2C12 myotubes. TWEAK also reduces miR-1 and miR-133a/b and increases miR-455 in mouse
muscle in vivo. ↑ increased; ↓ decreased; ← ·· → cause and effect unknown.
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2007). Following 90min of exhaustive endurance exercise
(forced treadmill running) in mice, miR-1 and miR-181,
both thought to increase muscle differentiation and
development, as well as miR-107, were increased (Safdar
et al. 2009). miR-23 was decreased which correlated
with an increase in peroxisome proliferator-activated
receptor-γ coactivator-1α (PGC-1α) (Safdar et al.
2009) (Fig. 4A), the latter a predicted target of this
miRNA (Wilfred et al. 2007). PGC-1α, a transcriptional
co-activator, regulates numerous skeletalmuscle functions
including mitochondrial biogenesis, substrate oxidation,
muscle ﬁbre type (Russell, 2005) and recently, the
protection against muscle wasting (Sandri et al. 2006).
Four weeks of treadmill running endurance training
in mice resulted in an increase in miR-21 and a
decrease in miR-696, -709 and -720 (Aoi et al. 2010).
The decrease in miR-696 was negatively correlated with
PGC-1α protein levels. The transient elevation ofmiR-696
in C2C12 myotubes did not inﬂuence PGC-1α mRNA
levels but did result in the suppression of PGC-1α
protein levels. Conversely, transfection of the myotubes
with a miR-696 inhibitor elevated PGC-1α protein
levels, without changing PGC-1α mRNA. While these
observations suggest that miR-696 may regulate PGC-1α
translation, no cause and effect has been established. To
datemiR-696 and -709 have not been identiﬁed in humans
so the relevance of these observations to human skeletal
muscle development and function is unknown.
At the other end of the continuum is resistance exercise
which is commonly performed at high intensities for
shorter durations of time. This type of exercise has
an anabolic stimulus and it enhances muscle size by
increasing the synthesis of contractile and structural
proteins; as a result the muscle is often larger and also
more powerful (Fry, 2004; Leger et al. 2006a). Following
an acute bout of resistance exercise, performed by both
young and older men, pri-miR-1-2 and pri-miR-133a-1
were reduced in muscle biopsy samples taken from the
young subjects 6 h post exercise (Drummond et al. 2008).
Pri-miR-133a-2 was reduced at 3 and 6 h post exercise
in the older and young subjects, respectively. In contrast,
pri-miR-206 was increased at 3 and 6 h post exercise in the
older and young subjects, respectively (Drummond et al.
2008). Of the mature miRNAs, only miR-1 was reduced
at 3 and 6 h post exercise in the older and young subjects,
respectively; no changes in miR-133a or miR-206 were
observed (Fig. 4B).
These studies show that exercise is capable of regulating
miRNA levels. It will be important to identify which
exercise-induced pathways alter miRNA expression and
how miRNA regulation contributes to the physiological
adaptations to exercise. Investigations that identify the
miRNAs responsible for exercise-induced adaptations, or
which can mimic some exercise-induced adaptations, will
signiﬁcantly advance the miRNA–muscle ﬁeld.
Inﬂuence of nutrition on miRNAs
The impact of ingesting essential amino acids (EAAs)
on skeletal muscle miRNA expression has also been
Figure 4. Inﬂuence of exercise on microRNAs
A, a single bout of endurance exercise in mice reduces miR-23a and increases miR-1, -181, -107. Endurance training
increases miR-21 expression and decreases miR-696, -709, -720 expression in mice. A commonality between acute
endurance exercise and endurance exercise training is an increase in PGC-1α. PGC-1α is a predicted target for
miR-23a and miR-696. B, following a single bout of resistance exercise in men, miR-1 decreases with no changes
observed in miR-133a or miR-206. ↑ increased; ↓ decreased; → unchanged; ·· → cause and effect unknown.
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investigated (Drummond et al. 2009). Healthy males
ingested 10 g of EAAs with muscle biopsies taken
before and 3 h following. Analyses of microRNAs and
muscle-growth-related genes in the skeletal muscle
biopsies revealed an increase in miR-499, -208b, -23a, -1
and pri-miR-206, as well as MyoD1 and follistatin-like 1
(FSTL1) mRNA, and a decrease in myostatin and MEF2C
expression (Fig. 5). While EAAs can regulate muscle
miRNA and mRNA, no causal observations have been
determined.
The inﬂuence of elevated glucose levels on skeletal
muscle miR-1 and miR-133a was investigated in humans
following a 3 h hyperglycaemic–euinsulinaemic clamp
(Granjon et al. 2009). Hyperglycaemia alone, in the
absence of hyperinsulinaemia, did not have an impact
on the expression levels of these two myomiRs. While no
study has investigated the effect of oral glucose ingestion
on skeletal musclemiRNA levels, the results fromGranjon
et al. (2009) suggest that any consequence of glucose
ingestion would be via an indirect effect of insulin.
miRNAs and skeletal muscle disease and dysfunction
Primary skeletal muscle disorders involve several groups
of diseases including muscular dystrophies, inﬂammatory
myopathies and congenital myopathies. While these
diseases can be deﬁned by their clinical and pathological
traits the molecular pathways involved in these conditions
are not well understood. With the evolution of miRNA
biology, studies have now begun to identify miRNA
signatures which are dysregulated in patient muscle
biopsies. Eisenberg and colleagues identiﬁed altered
Figure 5. Inﬂuence of EAAs on microRNAs
Essential amino acids increased miR-499, -208b, -23a, -1 and
pri-miR-206 levels in healthy males. This is associated with an increase
in MyoD1 and FSLT1 and a decrease in myostatin and MEF2C. A causal
link between these miRNAs and mRNAs has not been determined.
↑ increased; ↓ decreased; ← ·· → cause and effect unknown.
regulation of 185 miRNAs from 10 different muscle
disorders (Eisenberg et al. 2007). Of special interest were
miR-146b, miR-155, miR-214, miR-221 and miR-222,
which were increased in almost all of the samples
analysed. Of further interest will be identifying if, and
how, the regulation of these miRNAs contributes to the
pathophysiology of these muscle diseases.
Several studies have investigated the regulation of
miRNAs in patients with Duchene muscular dystrophy
(DMD), in the mdx mouse and the CXMDJ dog, two
animal models of muscular dystrophy, as well as in myo-
tonic dystrophy type 1 (MD1) and type 2 (MD2). Greco
et al. observed signiﬁcant increases in miR-31, -34c, -206,
-222, -223, -335, -449 and -494 and decreases in miR-1,
-29c and miR-135a in the quadriceps femoris muscles of
DMD patients and adductor muscles of mdx mice (Greco
et al. 2002). Similarly, Yuasa et al. observed that, miR-206,
but not miR-1, was increased in the tibialis anterior (TA)
muscle of mdx mice; however, both were reduced in the
TA muscle of the CXMDJ dog (Yuasa et al. 2008). In
vastus lateralismuscle biopsies frompatients withMD1 an
increase in miR-206, but not miR-1, -133a/b or -181a/b/c,
has been observed (Gambardella et al. 2010). However, the
suite of miRNAs measured by Greco et al., which included
miR-206, were unchanged in biceps brachii biopsies from
patients with MD2 (Greco et al. 2002). The increase in
miR-206 inMD1, butnotMD2,maybedue to thedifferent
muscles analysed ormay be a characteristic of the diseases.
In the mdx mouse there is muscle-speciﬁc regulation of
various miRNAs. When compared with control animals,
miR-206 expression is dramatically increased 4.5-fold in
the mdx diaphragm, decreased by 29% in the plantaris
muscle but unchanged in the soleus muscle (McCarthy
et al. 2007). miR-133a is modestly decreased by 23% in
the soleus muscle, but not in the plantaris, diaphragm
(McCarthy et al. 2007) or TA muscles (Yuasa et al. 2008).
The dramatic increase in miR-206 in mdx diaphragm is
of interest as this is the only muscle in the mdx mouse
which exhibits extensive and progressive degeneration,
ﬁbrosis and functional deﬁcits comparable to the limb
muscles of boys with DMD (Stedman et al. 1991; Lynch
et al. 1997). The reason for the different regulatory pattern
of these miRNAs from one muscle group to another is
unclear; however, dystrophin deﬁciency is known to cause
muscle-speciﬁc responses in mice (Moens et al. 1993)
and humans (Webster et al. 1988; Khurana et al. 1995).
Differences inmiRNA regulation across species may relate
to the severity of their respective dystrophic phenotypes
and relevance to the human DMD. For example, it is
generally agreed that the dystrophic phenotype of limb
muscles fromtheCXMDJ dog is a very good representation
of human DMD, while the mdx mouse presents a
much milder phenotype (Shimatsu et al. 2005; Banks &
Chamberlain, 2008). However, within the mdx mouse,
the diaphragm muscle does have an evolving dystrophic
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phenotype similar to humanDMD limbmuscle (Stedman
et al. 1991).
miRNAs and age-related muscle wasting
The age-related loss of skeletal mass and function,
known as sarcopenia, is a key factor increasing falls
and fractures and reducing independent living. Elevated
levels of pri-miRNA-1-1, -1-2, -133a-1 and -133a-2, with
no change in pri-miR206, were observed in skeletal
muscle biopsies taken from six elderly (70 ± 2 years)
when compared with six younger (29 ± 2 years) men
(Drummond et al. 2008). However, there were no
differences in the mature miR-1 or miR-133a species.
Whether age-related alterations in miRNAs are a cause
or effect in humans in vivo is unclear. More studies
are required with larger sample sizes to establish if the
age-related changes in skeletal muscle are inﬂuenced by
aberrant miRNA expression and activity. Additionally, it
will be important to consider the potential inﬂuence of
physical activity levels andnutritional status, factorswhich
can inﬂuence muscle miRNA levels, when comparing
young and older subjects.
miRNA and diabetes
Obesity and the metabolic syndrome are serious public
health problems, generating life-threatening diseases such
as atherosclerosis, cancer and type 2 diabetes (T2D).
The involvement of microRNAs in obesity and T2D
has recently been reviewed with a focus on non-muscle
tissues such as pancreas, adipose tissue and liver (Lynn,
2009; Pandey et al. 2009; Heneghan et al. 2010). While
microRNAs play important roles in the regulation of
glucose and lipid metabolisms through the control of
pancreatic islet cell function, adipocyte proliferation and
differentiation and cholesterol biosynthesis, their role in
skeletal muscle function in diabetes and obesity is not
well established. To date only four papers have looked
at the consequences of insulin resistance on miRNA
expression in skeletal muscle of Goto-Kakizaki (GK) rats
(a rodent model of diabetes) (He et al. 2007; Huang
et al. 2009) as well as in T2D patients (Granjon et al.
2009; Gallagher et al. 2010). miRNA expression proﬁles,
analysed and compared from skeletal muscle of GK and
control rats, revealed the differential expression of 15
microRNAs (4 up- and 11 down-regulated; fold change
≥1.5). Interestingly, three out of the four up-regulated
miRNAs were paralogues of the miR-29 family. Northern
blot analyses conﬁrmed the increase in their expression in
three insulin-dependent tissues (i.e. skeletal muscle, liver
and fat) from diabetic GK rats, suggesting an association
between this microRNA family and insulin sensitivity (He
et al. 2007). A similar study determined the regulation
of miRNA expression in GK rats but observed slightly
different results (Huang et al. 2009). In this study nine
microRNAs were differentially expressed (2 up- and 7
down-regulated; fold change ≥2.0), with only miR-24
and miR-126 down-regulation conﬁrmed by Northern
blot analysis. Disparity in these results may have been
due to different microRNA extraction methods, probe
preparation and software used to identify the regulated
miRNAs in the microarrays. It should also be noted that
Huang et al. (2009) also observed a 3-fold increase in
p38 mitogen-activated protein kinase (MAPK) protein
levels. p38 MAPK is known to be a direct target of miR-24
(Kiriakidou et al. 2004). Further studies are necessary to
analyse the regulation of the insulin-responsive miR-29
family, the relationship between miR-24 and p38 MAPK
in diabetic skeletal muscle, as well as deﬁne their precise
role in the insulin signalling pathway.
To observe the impact of insulin on skeletal muscle
microRNA levels, vastus lateralis muscle biopsies were
taken from healthy subjects before and after a 3 h
euglycaemic–hyperinsulinaemic clamp (Granjon et al.
2009). microRNA expression proﬁling showed that 39
microRNAs were down-regulated by insulin, including
the traditional myomiRs miR-1, miR-133a and miR-206.
Additionally, miR-29a andmiR-29c, microRNAs enriched
to insulin-sensitive tissues, such as muscle, liver and
adipose tissue, were also down-regulated. In contrast,
Drosha and Dicer1 as well as the several Argonaute
proteins were increased. The increase in these components
of themiRNA synthesis andRISCpathwaysmay be a failed
attempt tomaintainmiRNA levels. Insulindown-regulates
miR-1 andmiR-133a, via the activationof sterol regulatory
element binding protein 1c (SREBP-1c) and its inhibition
of MEF2C, in human muscle cells in vitro (Granjon et al.
2009). Furthermore, the expression levels of miR-1 and
miR-133a are increased in an insulin-deﬁcient mouse
model induced by streptozotocin injection (Granjon et al.
2009). In human skeletalmuscle the basal expression levels
ofmiR-1 andmiR-133awere not differentwhen compared
between ﬁve healthy controls and ﬁve insulin-resistant
type 2 diabetics (T2D) (Granjon et al. 2009). However,
insulin reduced miR-1 and miR-133a expression in the
healthy, but not in the T2D subjects. This response was
also associated with the inability of insulin to reduce
MEF2C expression in the diabetic patients. Along similar
lines, the expression levels of miR-1 were not different
when compared between 10 T2D patients, 10 impaired
glucose-tolerant patients (IGT) and 10 healthy controls
(Gallagher et al. 2010). However, this study did observe
a decrease in miR-133a and miR-206 in the T2D patients
when compared with the IGT and healthy subjects. Of
clinical interest was the signiﬁcant positive correlation
between miR-133a and fasting glucose levels and 2 h
glucose tolerance, when all 30 subjects were analysed.
While a discrepancy with respect to the regulation of
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miR-133a between these studies is evident, the reason for
this is not clear andhighlights the need for further research
in this area.
The role of miRNAs in obesity and diabetes has only
started to be explored and future investigationwill unravel
their roles in metabolism and energy expenditure. Based
on recent observations the role and regulation of miRNAs
in rodent models of diabetes and obesity should be
considered with caution when potentially extrapolating
to human obesity and diabetes.
Conclusion
The emergence of the miRNA ﬁeld provides an exciting
opportunity to further understand the molecular factors
which control skeletal muscle development, regeneration
and function. miRNA biology also provides an avenue to
dissect the mechanisms which may contribute to genetic
and acquired muscle disorders and related complications.
The impact of behavioural choices inﬂuencing physical
activity and nutrition has an import role in determining
our longevity and quality of life. The observations
that exercise and nutrition may inﬂuence miRNA levels
has important implications for understanding how to
maintain health throughout the lifespan; an issue of
great relevance considering our ageing and sedentary
communities. Future studies will focus more on the
possibility of using miRNA as a therapeutic tool via gain
of function and loss of function experiments in muscle
cell models and in rodents. As with all models of genetic
manipulation issues such as target and tissue speciﬁcity
will be of major importance. Nevertheless, the potential
of miRNA-based therapies offers an exciting and powerful
alternative to attenuate and hopefully cure debilitating
muscle diseases.
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